var title_f42_19_43312="Neurologic disorders brain PI";
var content_f42_19_43312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Dementia caused by changes in the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Different forms of dementia are linked to changes in the brain. Alzheimer disease causes many parts of the brain to shrink. Parkinson disease damages parts of the brain involved in movement. Vascular dementia happens when the blood vessels that supply the brain are diseased.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43312=[""].join("\n");
var outline_f42_19_43312=null;
var title_f42_19_43313="Racemic epinephrine and aluminum potassium sulfate: Drug information";
var content_f42_19_43313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Racemic epinephrine and aluminum potassium sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Van R Gingibraid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Astringent;",
"     </li>",
"     <li>",
"      Vasoconstrictor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gingival retraction: Pass the impregnated yarn around the neck of the tooth and place into gingival sulcus; normal tissue moisture, water, or gingival retraction solutions activate impregnated yarn. Limit use to one quadrant of the mouth at a time; recommended use is for 3-8 minutes in the mouth.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yarn, saturated in solution of racemic epinephrine 8% and aluminum potassium sulfate 7% (Van R Gingibraid&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Type &ldquo;0e&rdquo;: 0.20 &plusmn; 0.10 mg epinephrine/inch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Type &ldquo;1e&rdquo;: 0.40 &plusmn; 0.20 mg epinephrine/inch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Type &ldquo;2e&rdquo;: 0.60 &plusmn; 0.20 mg epinephrine/inch",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gingival retraction",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epinephrine or any component of the formulation; cardiovascular disease, hyperthyroidism, or diabetes; do not apply to areas of heavy or deep bleeding or over exposed bone",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Caution should be exercised whenever using gingival retraction cords with epinephrine since it delivers vasoconstrictor doses of racemic epinephrine to patients; the general medical history should be thoroughly evaluated before using in any patient.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epinephrine stimulates alpha",
"     <sub>",
"      1",
"     </sub>",
"     adrenergic receptors to cause vasoconstriction in blood vessels in gingiva; aluminum potassium sulfate, precipitates tissue and blood proteins",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data reported.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10137 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43313=[""].join("\n");
var outline_f42_19_43313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165551\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165552\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165553\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165546\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165536\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165556\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165549\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165540\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165544\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165539\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165548\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43314="Uterus didelphys normal vagina";
var content_f42_19_43314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77029%7EOBGYN%2F55525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77029%7EOBGYN%2F55525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys, bicollis, with normal vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys, bicollis, with complete vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43314=[""].join("\n");
var outline_f42_19_43314=null;
var title_f42_19_43315="Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)";
var content_f42_19_43315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43315/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43315/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"mobipreview.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"mobipreview.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen serves as the primary source of energy for high-intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lysosome-associated membrane protein 2 (LAMP2) deficiency (GSD IIB, OMIM #300257) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/1\">",
"     1",
"    </a>",
"    ] is known as Danon disease and predominantly affects cardiac and skeletal muscle. It has also been called lysosomal GSD with normal acid maltase (acid maltase deficiency is GSD II).",
"   </p>",
"   <p>",
"    This topic will review lysosomal-associated membrane 2 deficiency (GSD IIb). An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSD IIB is a semidominant X-linked disorder. It is due to mutations in the gene encoding lysosome-associated membrane protein 2 (LAMP2), located at Xq24. The specific function of LAMP2 is unknown. However, the glycoprotein may be involved in lysosomal enzyme targeting, autophagy, and lysosomal biogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of point mutations or small deletions or insertions within the LAMP2 gene and also splicing mutations have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Females are affected less than males.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Danon disease is characterized by severe cardiomyopathy, mild skeletal myopathy, ophthalmic abnormalities, and variable intellectual disability (mental retardation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The age of onset ranges from infancy to adulthood. Female carriers have a later onset of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. The cardiomyopathy may be the presenting manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of Danon disease were described in 38 affected patients in 13 families with genetically confirmed disease. All had cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10\">",
"     10",
"    </a>",
"    ]. Skeletal myopathy occurred in 18 of 20 males and 6 of 18 females. Intellectual disability was present in 14 males and one female. Late-onset disease with onset in the fifth decade or later, characterized by mild cardiac phenotype with progressive generalized severe skeletal muscle weakness without mental retardation, has been described in male members of a family with a novel missense mutation in the LAMP2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/13\">",
"     13",
"    </a>",
"    ]. LAMP2 protein staining in the skeletal muscle was normal.",
"   </p>",
"   <p>",
"    Ophthalmic manifestations were described in another series of six patients, including four females and two males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/14\">",
"     14",
"    </a>",
"    ]. All of the females had peripheral retinal pigmentary changes (\"peppered\" or \"mottled\"), whereas the males had near complete loss of retinal pigment. Additional findings included lens changes, myopia, and abnormal electroretinogram and visual fields.",
"   </p>",
"   <p>",
"    Danon disease may be an underrecognized cause of hypertrophic cardiomyopathy in childhood. The cardiomyopathy usually develops before age 20 in males and in adulthood in females. Cardiomyopathy in patients with Danon disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link&amp;anchor=H19#H19\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'LAMP2 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatine kinase (CPK) typically is moderately elevated. The diagnosis is suggested by muscle biopsy. The characteristic pathologic feature is intracytoplasmic vacuoles that contain autophagic material and glycogen in skeletal muscle cells, although in young children, the vacuoles may not yet be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/15\">",
"     15",
"    </a>",
"    ]. The vacuoles are also present in cardiac tissue. Acid phosphatase-positive material is present within membranes that lack LAMP2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10\">",
"     10",
"    </a>",
"    ]. Acid alpha glucosidase activity is normal. LAMP2 staining is sometimes absent in skeletal muscle, but not always [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/13\">",
"     13",
"    </a>",
"    ]. The detection of a mutation in the LAMP2 gene confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment is available for the disorder. Cardiac transplantation is the most effective treatment for the cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lysosome-associated membrane protein 2 (LAMP2) deficiency (glycogen storage disease IIb, Danon disease) is an X-linked disorder due to mutations in the gene encoding LAMP2. The specific function of LAMP2 is unknown. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LAMP2 deficiency is usually characterized by severe cardiomyopathy, mild skeletal myopathy, ophthalmologic abnormalities, and variable intellectual disability. The age of onset ranges from infancy to adulthood. Female carriers have a later onset of disease. Males with severe skeletal myopathy and rather mild cardiac involvement also have been described. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory features of LAMP2 deficiency include moderately elevated creatine kinase. The diagnosis is supported by muscle biopsy demonstrating intracytoplasmic vacuoles that contain autophagic material and glycogen. DNA testing is commercially available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific treatment is available, but early consideration of heart transplantation may be life saving. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/1\">",
"      Vi&eacute;itez I, Teijeira S, Miranda S, et al. Gene symbol: LAMP2. Disease: Glycogen storage disease 2b. Hum Genet 2008; 123:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/2\">",
"      Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/3\">",
"      Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/4\">",
"      Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009; 301:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/5\">",
"      Di Blasi C, Jarre L, Blasevich F, et al. Danon disease: a novel LAMP2 mutation affecting the pre-mRNA splicing and causing aberrant transcripts and partial protein expression. Neuromuscul Disord 2008; 18:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/6\">",
"      Bui YK, Renella P, Martinez-Agosto JA, et al. Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. Pediatr Transplant 2008; 12:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/7\">",
"      Regelsberger G, H&ouml;ftberger R, Pickl WF, et al. Danon disease: case report and detection of new mutation. J Inherit Metab Dis 2009; 32 Suppl 1:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/8\">",
"      Yang Z, Funke BH, Cripe LH, et al. LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet 2010; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/9\">",
"      Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981; 31:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/10\">",
"      Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002; 58:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/11\">",
"      Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/12\">",
"      Dworzak F, Casazza F, Mora M, et al. Lysosomal glycogen storage with normal acid maltase: a familial study with successful heart transplant. Neuromuscul Disord 1994; 4:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/13\">",
"      van der Kooi AJ, van Langen IM, Aronica E, et al. Extension of the clinical spectrum of Danon disease. Neurology 2008; 70:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/14\">",
"      Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology 2006; 113:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43315/abstract/15\">",
"      Taylor MR, Ku L, Slavov D, et al. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet 2007; 52:830.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2916 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43315=[""].join("\n");
var outline_f42_19_43315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43316="Gynecologic examination of the newborn and child";
var content_f42_19_43316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gynecologic examination of the newborn and child",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     S Jean Emans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43316/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43316/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecological evaluation of the prepubertal child is approached by directing attention to the specific complaint or question to be answered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43316/abstract/1\">",
"     1",
"    </a>",
"    ]. Educating the child and her family prior to this examination is important both for their reassurance and for gaining their trust. Inspection of the genital region should follow a focused general examination. Knowledge of normal prepubertal anatomy and use of accurate nomenclature are essential for describing and documenting anatomic findings (",
"    <a class=\"graphic graphic_figure graphicRef50025 \" href=\"mobipreview.htm?33/57/34706\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Gynecological examination of newborns and children will be reviewed here. Evaluation of common vulvovaginal complaints in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of external genitalia is a normal part of the routine physical examination. This examination is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=see_link&amp;anchor=H2#H2\">",
"     \"The pediatric physical examination: The perineum\", section on 'Genitourinary system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal examination in children is restricted to those with genitourinary complaints that cannot be addressed with external evaluation or in situations of suspected genitourinary pathology. These include vaginal bleeding, persistent discharge, trauma, cystic or solid masses, ulcerative or inflammatory lesions, suspected congenital anomalies, or sexual abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history is obtained from both the child, if possible, and her parent(s) or legal guardian. Prior to the examination, she should be told the reason for the office evaluation. A prior traumatic incident or examination can cause girls to become apprehensive and uncooperative. The provider should explain why examination of this area is needed and how the examination will be performed, including what instruments, if any, will be used. Allowing her to maintain some control of the environment is also important. As an example, she can be offered the opportunity to select the gown that she will wear and to view the light source (otoscope, magnifying glass, or direct light).",
"   </p>",
"   <p>",
"    The goal of the examination is to obtain information without traumatizing the child. The patient can be asked to climb onto the examining table; alternatively, younger patients may be examined while sitting in a parent's or guardian's lap. Evaluation of the vulva can be done with the child lying supine with the legs in a \"frog-leg\" or \"butterfly\" position and, if needed, for complaints requiring visualization of the vagina, in a \"knee-chest\" position (",
"    <a class=\"graphic graphic_figure graphicRef55157 \" href=\"mobipreview.htm?33/5/33887\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rarely, an adequate examination cannot be performed in the office setting, and so an examination under anesthesia may be required. This can be done in an outpatient ambulatory surgical unit with mask general anesthesia or intravenous conscious sedation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When performing an anesthesia examination, a lighted Killian nasal speculum (",
"    <a class=\"graphic graphic_figure graphicRef76609 \" href=\"mobipreview.htm?5/55/6001\">",
"     figure 3",
"    </a>",
"    ) and a fiberoptic scope (cystoscope, flexible hysteroscope) are useful for examining the prepubertal vagina. A liquid distention media can be used for vaginoscopy once vaginal cultures have been obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22147?source=see_link\">",
"     \"Vaginoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HOW TO OBTAIN CULTURES FROM CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some special issues to consider in obtaining cultures from children. If the child is awake, Calgiswabs moistened with sterile saline can be used to obtain the specimen by gently inserting the swab through the hymenal ring without touching the edges of the hymen. Alternatively, a soft sterile eyedropper or a small feeding tube or urethral catheter with a syringe can be gently inserted through the hymenal opening to aspirate secretions or to obtain a vaginal wash sample. Another method uses saline squirted into the vagina while three swabs are held near the hymenal ring with the labia manually closed over them. The child is then asked to cough to expel the saline from the vagina onto the swabs. The swab should be transported to the laboratory using Culturette II and plated by the laboratory on genitourinary media (eg, blood, MacConkey, chocolate). Cultures are more useful and more likely to be positive in girls who have discharge evident at the time of the examination.",
"   </p>",
"   <p>",
"    If gonorrhea infection is possible, a test for",
"    <em>",
"     Neisseria gonorrhoeae",
"    </em>",
"    is done by plating the swab obtained on modified Thayer-Martin-Jembec medium at the time of the examination or by sending the appropriate swab or urine sample for nucleic acid amplification test (NAAT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43316/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Culture is preferred for sexual abuse evaluations, but urine NAATs are more practical for the evaluation of routine vulvovaginitis. The laboratory should be informed that the specimen was obtained from a prepubertal child so that identification of",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    is precise. Similarly, a positive NAAT must be confirmed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Prepubertal victims'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures for",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    are performed using a saline moistened male urethral swab specifically designed for this purpose. Although cultures do not require confirmation, they are much less sensitive than NAATs. For most patients, specimens for NAAT testing are obtained from urine or occasionally a vaginal sample; a positive test needs to be confirmed because of the medical legal implications. Treatment should be delayed prior to a confirmatory test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital cultures are transported using a Calgiswab or Culturette II and plated by the laboratory on genitourinary media (eg, blood, MacConkey's, chocolate). A Nickerson Biggy agar can be used for detection of",
"    <em>",
"     Candida",
"    </em>",
"    spp if the child has itching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microscopy of vaginal secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopy is less useful diagnostically for evaluating vaginitis in prepubertal girls than adolescents. Saline microscopy can be performed to look for",
"    <em>",
"     Trichomonas",
"    </em>",
"    . Signs of bacterial vaginosis include positive whiff (amine) test, defined as the presence of a fishy odor when 10 percent potassium hydroxide (KOH) is added to vaginal discharge samples; clue cells (&gt;20 percent) on saline wet mount; or a homogeneous, grayish-white discharge (not present before puberty), but are rare in prepubertal girls. The addition of 10 percent KOH is helpful for diagnosing",
"    <em>",
"     Candida",
"    </em>",
"    vaginitis. Culture for",
"    <em>",
"     Candida",
"    </em>",
"    may be useful if microscopy is negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maturation index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls with precocious pubertal development may rarely (and only if atraumatic) have a vaginal smear obtained as part of their evaluation to determine degree of estrogenization using the maturation index. Vaginal smears for maturation index are used more commonly to evaluate adolescents with amenorrhea if visual inspection does not confirm estrogen effect on the vaginal mucosa. In the Meisel system, 100 cells are counted and scored 0 points for parabasal cells,",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    point for intermediate cells, and 1 point for superficial cells.",
"   </p>",
"   <p>",
"    The sum of points is interpreted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      60 to 70 points - newborns",
"     </li>",
"     <li>",
"      0 to 30 points - prepubertal girl",
"     </li>",
"     <li>",
"      31 to 45 points - hypoestrogenic female",
"     </li>",
"     <li>",
"      45 to 60 points - pubertal female",
"     </li>",
"     <li>",
"      90 to 100 points - hyperestrogenic female",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vaginal pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal pH in prepubertal and pubertal girls is 6.5 to 7.5 and 3.5 to 4.5, respectively. Therefore, vaginal pH is not useful for diagnosis of bacterial vaginosis and vaginal trichomonas infection in prepubertal girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION OF PELVIC ORGANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     cervix/uterus",
"    </span>",
"    and adnexa in the child can be evaluated through examination using a finger placed rectally and the other hand abdominally with the patient lying supine. If a mass is suspected or cannot be excluded, then an abdominal pelvic ultrasound is indicated.",
"   </p>",
"   <p>",
"    Examination of the vulva in the child may be facilitated by using a colposcope, especially in cases of sexual abuse. The colposcope magnifies the area being examined and allows photography of areas of interest. However, magnification with an otoscope, hand lens, or 35 mm camera with macro-lens can also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE HYMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the hymen is an important part of the evaluation of girls who may have been sexually abused. The examiner must be able to distinguish the normal hymen and its normal variants from abnormal hymens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43316/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, 80 to 90 percent of girls who are known victims of sexual abuse have a normal genital examination. Anatomic variants sometimes mistaken for signs of sexual abuse include midline sparing (linea vestibularis), lichen sclerosus, failure of midline fusion, urethral prolapse, labial adhesions, pemphigoid, and other dermatologic conditions. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Congenital abnormalities of the hymen'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link&amp;anchor=H23#H23\">",
"     \"Vulvovaginal complaints in the prepubertal child\", section on 'Labial adhesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hymens change with age. Newborns have redundant, estrogenized, thick, elastic hymens, often with a prominent ridge at six o'clock. White discharge due to maternal and",
"    <span class=\"nowrap\">",
"     fetal/newborn",
"    </span>",
"    estradiol-stimulated mucus production may appear at the hymenal orifice.",
"   </p>",
"   <p>",
"    The hymen of prepubertal girls is unestrogenized, thin, and easy to assess. It may appear as a posterior rim, annular, redundant, and sleeve-like configuration (",
"    <a class=\"graphic graphic_figure graphicRef61605 \" href=\"mobipreview.htm?3/46/3808\">",
"     figure 4",
"    </a>",
"    ). In contrast, pubertal girls have thick, estrogenized, elastic hymens with white discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Descriptions of hymenal tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be cautious about making judgments about abnormalities of the hymen in children being evaluated for sexual abuse. Several texts have provided atlases and descriptions of abnormal findings. In prepubertal girls, a complete transection of hymenal tissue between three and nine o'clock (lower half) is highly suspicious for trauma. Accidental trauma usually spares the hymen, whereas sexual abuse may cause this type of injury in a small number of girls. The transverse width of the hymenal opening in millimeters can be measured but is not diagnostic of sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43316/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bumps refer to elevations of hymenal tissue that are usually attached to longitudinal intravaginal rugae. They are a normal variant. A hymenal fold at six o'clock may appear as a bump but disappears in the knee-chest position. Rarely, a bump may occur between three and nine o'clock adjacent to a partial transection.",
"   </p>",
"   <p>",
"    Thickening of the hymen occurs upon estrogenization but may also develop after trauma. Folding of the hymen may give a false appearance of thickening. This finding should be confirmed in a knee-chest position.",
"   </p>",
"   <p>",
"    Midline sparing (linea vestibularis) refers to a symmetric, flat avascular area of the posterior vestibule observed in 10 percent of normal newborns. It can sometimes be confused with scarring, which usually occurs on the hymen and posterior fourchette.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Congenital abnormalities of the hymen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital abnormalities of hymens occur in approximately 3 to 4 percent of the female population. These anomalies are comprised of imperforate, microperforate, cribiform, and septate hymens (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"mobipreview.htm?8/20/8514\">",
"     figure 5",
"    </a>",
"    ). Of note, a study of 1131 female newborns did not find any cases of congenital absence of the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43316/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of external genitalia is a normal part of the routine physical examination of children, while internal examination is restricted to those with genitourinary complaints or suspected of genitourinary pathology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of the examination is to obtain information without traumatizing the child. The child can be asked to climb onto the examining table; alternatively, younger patients may be examined while sitting in a parent's or guardian's lap. Evaluation of the vulva can be done with the child lying supine, with the legs in a \"frog-leg\" or \"butterfly\" position or, if needed to visualize the vagina, in a \"knee-chest\" position (",
"      <a class=\"graphic graphic_figure graphicRef55157 \" href=\"mobipreview.htm?33/5/33887\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Internal organs can be evaluated abdominally with a rectal examination, but ultrasound imaging is more commonly employed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation of pelvic organs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining vaginal cultures in children is done without a speculum and requires special techniques. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'How to obtain cultures from children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examiner must be able to distinguish a normal hymen (",
"      <a class=\"graphic graphic_figure graphicRef61605 \" href=\"mobipreview.htm?3/46/3808\">",
"       figure 4",
"      </a>",
"      ) and normal variants (",
"      <a class=\"graphic graphic_figure graphicRef57977 \" href=\"mobipreview.htm?8/20/8514\">",
"       figure 5",
"      </a>",
"      ) from abnormal hymens. However, a normal hymen does not exclude the possibility of sexual abuse. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation of the hymen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Emans SJ. Office evaluation of the child and adolescent. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/2\">",
"      Girardet RG, Lahoti S, Howard LA, et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics 2009; 124:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/3\">",
"      Black CM, Driebe EM, Howard LA, et al. Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J 2009; 28:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/4\">",
"      Berenson A, Heger A, Andrews S. Appearance of the hymen in newborns. Pediatrics 1991; 87:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/5\">",
"      Berenson AB, Heger AH, Hayes JM, et al. Appearance of the hymen in prepubertal girls. Pediatrics 1992; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/6\">",
"      McCann J, Voris J, Simon M, Wells R. Perianal findings in prepubertal children selected for nonabuse: a descriptive study. Child Abuse Negl 1989; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/7\">",
"      McCann J, Wells R, Simon M, Voris J. Genital findings in prepubertal girls selected for nonabuse: a descriptive study. Pediatrics 1990; 86:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43316/abstract/8\">",
"      Jenny C, Kuhns ML, Arakawa F. Hymens in newborn female infants. Pediatrics 1987; 80:399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5908 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43316=[""].join("\n");
var outline_f42_19_43316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HOW TO OBTAIN CULTURES FROM CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microscopy of vaginal secretions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maturation index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vaginal pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION OF PELVIC ORGANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION OF THE HYMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Descriptions of hymenal tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Congenital abnormalities of the hymen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5908|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/57/34706\" title=\"figure 1\">",
"      Prepubertal perineal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/5/33887\" title=\"figure 2\">",
"      Knee chest examination position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/55/6001\" title=\"figure 3\">",
"      Prepubertal vaginal examination using a Killian nasal speculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/46/3808\" title=\"figure 4\">",
"      Normal hymens in prepubertal girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/20/8514\" title=\"figure 5\">",
"      Hymen anatomic variations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22147?source=related_link\">",
"      Vaginoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43317="Mallory-Weiss syndrome";
var content_f42_19_43317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mallory-Weiss syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43317/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43317/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallory-Weiss syndrome is characterized by longitudinal mucosal lacerations (intramural dissections) in the distal esophagus and proximal stomach, which are usually associated with forceful retching. The lacerations often lead to bleeding from submucosal arteries. Since the initial description in 1929 by Mallory and Weiss in 15 alcoholic subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/1\">",
"     1",
"    </a>",
"    ], gastroesophageal tears have been a recognized cause of upper gastrointestinal hemorrhage. The prevalence of such tears among patients presenting with upper gastrointestinal bleeding is approximately 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12664?source=see_link\">",
"     \"Major causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .) Rarely, perforation can occur with repeated, protracted vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=see_link\">",
"     \"Boerhaave's syndrome: Effort rupture of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    How frequently a Mallory-Weiss tear occurs without bleeding cannot be determined with any certainty. It is highly likely that the condition occurs in a less severe form more frequently than is recognized. As an example, the incidence of Mallory-Weiss tears in patients receiving colonoscopic preparation with polyethylene glycol electrolyte lavage solution has been reported at 0.06 percent (2 of 3172 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/5\">",
"     5",
"    </a>",
"    ]. In comparison, we found a higher rate when we studied 1248 consecutive patients receiving a standard preparation of polyethylene glycol electrolyte lavage solution with gastroscopy followed immediately by colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/6\">",
"     6",
"    </a>",
"    ]. A Mallory-Weiss tear was found in 13 patients (1 percent); four developed active bleeding and nine were asymptomatic tears incidentally diagnosed during endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of this syndrome is not completely understood. Mallory-Weiss tears are usually secondary to a sudden increase in intraabdominal pressure. Precipitating factors include vomiting, straining at stool or lifting, coughing, epileptic convulsions, hiccups under anesthesia, closed-chest massage, blunt abdominal injury, colonoscopic preparation with polyethylene glycol electrolyte lavage solution, and gastroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/2-5,7-9\">",
"     2-5,7-9",
"    </a>",
"    ]. A case report described fatal bleeding following transesophageal echocardiography and placement of a nasogastric tube during cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/10\">",
"     10",
"    </a>",
"    ]. The frequency of Mallory-Weiss tears following endoscopic examination appears to be low. In a national survey of the American Society for Gastrointestinal Endoscopy, a tear was found in 0.13 percent of 2320 patients undergoing gastroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/11\">",
"     11",
"    </a>",
"    ]. Predisposing conditions to Mallory-Weiss tears include hiatal hernia, chronic alcoholism, and perhaps increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/3,4,8,12-15\">",
"     3,4,8,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hiatal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiatal hernia has been found in 40 to 100 percent of patients with Mallory-Weiss tears and has been considered by some to be a necessary predisposing factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/12\">",
"     12",
"    </a>",
"    ]. It has been proposed that, in hiatus hernia, a higher pressure gradient develops in the hernia compared with that in the rest of the stomach during retching, thereby increasing the potential for mucosal laceration. Gastroesophageal tears may also be more likely to occur when the upper esophageal sphincter does not relax during vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=see_link\">",
"     \"Hiatus hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcoholism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of heavy alcohol use leading to vomiting has been noted in 40 to 80 percent of patients with Mallory-Weiss syndrome in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/4,12-15\">",
"     4,12-15",
"    </a>",
"    ]. The bleeding is usually more severe when Mallory-Weiss tears are associated with portal hypertension and esophageal varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Occasionally, patients give a history of ingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing age has been advocated as a predisposing factor of Mallory-Weiss tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/8\">",
"     8",
"    </a>",
"    ]. In a small series, six of seven patients with tears occurring during endoscopy were elderly, suggesting a possible increase in vulnerability of the atrophic gastric mucosa in these subjects. However, most tears occur in patients under the age of 40, suggesting that age does not play a major role. Tears have also occurred in children as young as three weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastrointestinal bleeding is the major clinical manifestation, which may be accompanied by epigastric pain or pain in the back. Bleeding occurs when the tear involves the underlying esophageal venous or arterial plexus. Patients usually, but not always, give a history of nonbloody vomiting or retching before the onset of hematemesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of blood loss is usually small and self-limited. However, massive hemorrhage requiring transfusions and even leading to death can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/19\">",
"     19",
"    </a>",
"    ]. Active bleeding at the time of initial endoscopy and a low initial hematocrit have a high association with a complicated course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/20\">",
"     20",
"    </a>",
"    ]. These data add further support to early endoscopy in patients with clinically significant upper GI hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is the diagnostic modality of choice to document the presence of a gastroesophageal tear, and it allows the possibility of therapeutic intervention. The tears are located in the esophagogastric junction, often within a hiatal hernia; they usually extend downward into the cardia and sometimes upward into the esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mallory-Weiss tears are usually single and longitudinal. However, multiple mucosal tears have been found in up to 27 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. On endoscopy, the tears typically appear as a red longitudinal crack in the mucosa (",
"    <a class=\"graphic graphic_picture graphicRef57049 \" href=\"mobipreview.htm?24/9/24720\">",
"     picture 1",
"    </a>",
"    ), sometimes extending through the muscularis mucosa (",
"    <a class=\"graphic graphic_picture graphicRef76980 \" href=\"mobipreview.htm?32/35/33342\">",
"     picture 2",
"    </a>",
"    ), and occasionally covered by a clot (",
"    <a class=\"graphic graphic_picture graphicRef68239 \" href=\"mobipreview.htm?24/12/24782\">",
"     picture 3",
"    </a>",
"    ). Active bleeding may also be noted (",
"    <a class=\"graphic graphic_picture graphicRef71690 \" href=\"mobipreview.htm?10/62/11247\">",
"     picture 4",
"    </a>",
"    ). In many instances, the lesions are recognized only after retroflexion of the tip of the gastroscope to view the cardia from below. Most tears heal uneventfully within 24 to 48 hours in patients without portal hypertension; as a result, they may not be seen if endoscopy is delayed.",
"   </p>",
"   <p>",
"    Mallory-Weiss tears must be distinguished from other ulcerative diseases of the esophagus, including ulcerative reflux esophagitis, infectious esophagitis, or pill-induced esophageal ulcers. Mallory-Weiss tears are usually focal lesions with normal appearing adjacent mucosa. In contrast, there is typically diffuse involvement of the distal esophagus with reflux or infectious esophagitis, while pill-induced ulcers are suspected by the history (eg, use of a drug such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ) and are located more proximally in the esophagus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although 40 to 70 percent of patients with bleeding Mallory-Weiss tear require blood transfusions, most tears heal spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. A classification scheme has been proposed to identify patients at risk for recurrent bleeding and mortality and those patients requiring only brief hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/22\">",
"     22",
"    </a>",
"    ]. Portal hypertension and coagulopathy were identified as the major risk factors for rebleeding. Rebleeding usually occurred within 24 hours and most often in patients with a coagulopathy. Clinical features which indicated a severe bleed were those of hematochezia and hemodynamic instability.",
"   </p>",
"   <p>",
"    Endoscopic therapy is the first-line treatment of actively bleeding lacerations. Several hemostatic methods have been used to control bleeding. The results obtained with any modality depend upon technique, experience, and practice.",
"   </p>",
"   <p>",
"    Injection therapy of various agents, including epinephrine&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/5,21,23\">",
"     5,21,23",
"    </a>",
"    ], ethanol&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/5,24\">",
"     5,24",
"    </a>",
"    ], and other sclerosants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/23\">",
"     23",
"    </a>",
"    ], has been used as monotherapy or in combination with thermal devices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injection of epinephrine (1:10,000 to 20,000) diminishes arterial blood flow by a combination of vasoconstriction and edema permitting more effective thermal therapy. Epinephrine has also been used successfully in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/6/110?source=see_link\">",
"       polidocanol",
"      </a>",
"      (a sclerosing agent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bipolar or multipolar electrocoagulation (eg, a bipolar probe at 15 watts, mild tamponade, and one second pulses) is the most popular thermal therapy. It is effective, safe, and inexpensive and most endoscopists have had experience with this technique. However, there are few prospective or controlled data on effectiveness. The technique for Mallory-Weiss syndrome is generally similar to that used for bleeding ulcers, but less tamponade force and lower total energy is usually recommended because of the smaller size of the underlying artery and a desire to avoid perforation. In one small study of patients with active arterial bleeding from a Mallory-Weiss tear, treatment with multipolar electrocoagulation significantly decreased the rate of continued bleeding, the number of transfusions required, and rate of emergency surgery when compared with medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thermal coagulation should not be performed in patients with portal hypertension and esophageal varices since it may precipitate or worsen bleeding; sclerotherapy or endoscopic variceal ligation is preferable in such cases. Another limiting factor is that the esophagus lacks a serosa and may be very thin at the tear site. Thus, repeated coagulation should be avoided because of the risk of transmural injury and perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach that has been described in case reports and small controlled trials is the use of endoscopic band ligation. Similar to variceal band ligation, the affected mucosa is suctioned into the ligating device after which the band is applied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful hemostasis using hemoclips has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/9,31,32\">",
"     9,31,32",
"    </a>",
"    ]. Hemoclips were as effective as epinephrine injection in patients with spurting vessels or oozing lesions in a small controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/33\">",
"     33",
"    </a>",
"    ]. A prospective study comparing band ligation to hemoclip placement in 41 patients found that both methods were equally effective and safe for management of actively bleeding Mallory-Weiss tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study comparing band ligation to hemoclips plus epinephrine injection in 56 patients found that endoscopic hemostasis was achieved in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/35\">",
"     35",
"    </a>",
"    ]. However, recurrent bleeding occurred in 0 percent in the banding group versus 18 percent in the hemoclip plus epinephrine group (p = 0.02). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost all patients will respond to endoscopic hemostatic therapy. Intravenous infusion of vasopressin, esophageal balloon tamponade, and angiographic arterial embolization have been used occasionally to control severe or refractory hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43317/abstract/2,4,36\">",
"     2,4,36",
"    </a>",
"    ]. Surgery, with oversewing of the bleeding vessel, may be necessary in those rare instances when bleeding cannot be controlled.",
"   </p>",
"   <p>",
"    We place all patients on a proton pump inhibitor, although the benefit for preventing rebleeding in Mallory-Weiss syndrome has not been well-studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mallory-Weiss syndrome is characterized by longitudinal mucosal lacerations (intramural dissections) in the distal esophagus and proximal stomach that are usually associated with forceful retching. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute gastrointestinal bleeding is the major clinical manifestation of Mallory-Weiss syndrome and may be accompanied by epigastric pain or pain in the back. Bleeding occurs when the tear involves the underlying esophageal venous or arterial plexus. Patients usually, but not always, give a history of nonbloody vomiting or retching before the onset of hematemesis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy is the diagnostic modality of choice to document the presence of a gastroesophageal tear, and it allows the possibility of therapeutic intervention. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients without risk factors for rebleeding (ie, portal hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coagulopathy), clinical features indicating severe bleeding (ie, hematochezia and hemodynamic instability), or active bleeding at endoscopy be managed medically with a brief hospitalization of 24 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Almost all such patients will heal spontaneously. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients not actively bleeding at endoscopy but with clinical risk factors for rebleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonbleeding endoscopic stigmata such as a protruding visible vessel, pigmented protuberance, or fresh adherent clot be observed for 48 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with active bleeding at endoscopy should be treated with endoscopic hemostasis. They should be hospitalized for at least 48 hours because rebleeding generally occurs within 24 hours of the initial therapeutic endoscopy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients with Mallory-Weiss syndrome be treated with a proton pump inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/1\">",
"      Mallory GK, Weiss S. Hemorrhages from lacerations of the cardiac orifice of the stomach due to vomiting. Am J Med Sci 1929; 178:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/2\">",
"      Weaver DH, Maxwell JG, Castleton KB. Mallory-Weiss syndrome. Am J Surg 1969; 118:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/3\">",
"      Watts HD, Admirand WH. Mallory-Weiss syndrome. A reappraisal. JAMA 1974; 230:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/4\">",
"      Michel L, Serrano A, Malt RA. Mallory-Weiss syndrome. Evolution of diagnostic and therapeutic patterns over two decades. Ann Surg 1980; 192:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/5\">",
"      Santoro MJ, Chen YK, Collen MJ. Polyethylene glycol electrolyte lavage solution-induced Mallory-Weiss tears. Am J Gastroenterol 1993; 88:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/6\">",
"      Guelrud M, Torres E, Vezga MA, et al. Miss rate of Mallory-Weiss tear after polyethylene glycol electrolyte lavage solution (abstract). Gastrointest Endosc 1998; 47:A51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/7\">",
"      Fishman ML, Thirlwell MP, Daly DS. Mallory-Weiss tear. A complication of cancer chemotherapy. Cancer 1983; 52:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/8\">",
"      Penston JG, Boyd EJ, Wormsley KG. Mallory-Weiss tears occurring during endoscopy: a report of seven cases. Endoscopy 1992; 24:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/9\">",
"      Shimoda R, Iwakiri R, Sakata H, et al. Endoscopic hemostasis with metallic hemoclips for iatrogenic Mallory-Weiss tear caused by endoscopic examination. Dig Endosc 2009; 21:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/10\">",
"      De Vries AJ, van der Maaten JM, Laurens RR. Mallory-Weiss tear following cardiac surgery: transoesophageal echoprobe or nasogastric tube? Br J Anaesth 2000; 84:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/11\">",
"      Gilbert DA, Silverstein FE, Tedesco FJ. National ASGE survey on upper gastrointestinal bleeding: complications of endoscopy. Dig Dis Sci 1981; 26:55S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/12\">",
"      Dagradi AE, Broderick JT, Juler G, et al. The Mallory-Weiss syndrome and lesion. A study of 30 cases. Am J Dig Dis 1966; 11:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/13\">",
"      Harris JM, DiPalma JA. Clinical significance of Mallory-Weiss tears. Am J Gastroenterol 1993; 88:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/14\">",
"      Knauer CM. Mallory-Weiss syndrome. Characterization of 75 Mallory-weiss lacerations in 528 patients with upper gastrointestinal hemorrhage. Gastroenterology 1976; 71:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/15\">",
"      Sugawa C, Benishek D, Walt AJ. Mallory-Weiss syndrome. A study of 224 patients. Am J Surg 1983; 145:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/16\">",
"      Paquet KJ, Mercado-Diaz M, Kalk JF. Frequency, significance and therapy of the Mallory-Weiss syndrome in patients with portal hypertension. Hepatology 1990; 11:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/17\">",
"      Schuman BM, Threadgill ST. The influence of liver disease and portal hypertension on bleeding in Mallory-Weiss syndrome. J Clin Gastroenterol 1994; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/18\">",
"      Cannon RA, Lee G, Cox KL. Gastrointestinal hemorrhage due to Mallory-Weiss syndrome in an infant. J Pediatr Gastroenterol Nutr 1985; 4:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/19\">",
"      Skok P. Fatal hemorrhage from a giant Mallory-Weiss tear. Endoscopy 2003; 35:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/20\">",
"      Kortas DY, Haas LS, Simpson WG, et al. Mallory-Weiss tear: predisposing factors and predictors of a complicated course. Am J Gastroenterol 2001; 96:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/21\">",
"      Kovacs TO, Jensen DM. Endoscopic diagnosis and treatment of bleeding Mallory-Weiss tears. Gastrointest Endosc Clin North Am 1991; 1:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/22\">",
"      Bharucha AE, Gostout CJ, Balm RK. Clinical and endoscopic risk factors in the Mallory-Weiss syndrome. Am J Gastroenterol 1997; 92:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/23\">",
"      Bataller R, Llach J, Salmer&oacute;n JM, et al. Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-Weiss syndrome. Am J Gastroenterol 1994; 89:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/24\">",
"      Sugawa C, Fujita Y, Ikeda T, Walt AJ. Endoscopic hemostasis of bleeding of the upper gastrointestinal tract by local injection of ninety-eight per cent dehydrated ethanol. Surg Gynecol Obstet 1986; 162:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/25\">",
"      Llach J, Elizalde JI, Guevara MC, et al. Endoscopic injection therapy in bleeding Mallory-Weiss syndrome: a randomized controlled trial. Gastrointest Endosc 2001; 54:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/26\">",
"      Laine L. Multipolar electrocoagulation in the treatment of active upper gastrointestinal tract hemorrhage. A prospective controlled trial. N Engl J Med 1987; 316:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/27\">",
"      Wong RM, Ota S, Katoh A, et al. Endoscopic ligation for non-esophageal variceal upper gastrointestinal hemorrhage. Endoscopy 1998; 30:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/28\">",
"      Abi-Hanna D, Williams SJ, Gillespie PE, Bourke MJ. Endoscopic band ligation for non-variceal non-ulcer gastrointestinal hemorrhage. Gastrointest Endosc 1998; 48:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/29\">",
"      Matsui S, Kamisako T, Kudo M, Inoue R. Endoscopic band ligation for control of nonvariceal upper GI hemorrhage: comparison with bipolar electrocoagulation. Gastrointest Endosc 2002; 55:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/30\">",
"      Park CH, Min SW, Sohn YH, et al. A prospective, randomized trial of endoscopic band ligation vs. epinephrine injection for actively bleeding Mallory-Weiss syndrome. Gastrointest Endosc 2004; 60:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/31\">",
"      Yamaguchi Y, Yamato T, Katsumi N, et al. Endoscopic hemoclipping for upper GI bleeding due to Mallory-Weiss syndrome. Gastrointest Endosc 2001; 53:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/32\">",
"      Yuan Y, Wang C, Hunt RH. Endoscopic clipping for acute nonvariceal upper-GI bleeding: a meta-analysis and critical appraisal of randomized controlled trials. Gastrointest Endosc 2008; 68:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/33\">",
"      Huang SP, Wang HP, Lee YC, et al. Endoscopic hemoclip placement and epinephrine injection for Mallory-Weiss syndrome with active bleeding. Gastrointest Endosc 2002; 55:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/34\">",
"      Cho YS, Chae HS, Kim HK, et al. Endoscopic band ligation and endoscopic hemoclip placement for patients with Mallory-Weiss syndrome and active bleeding. World J Gastroenterol 2008; 14:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/35\">",
"      Lecleire S, Antonietti M, Iwanicki-Caron I, et al. Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine. Aliment Pharmacol Ther 2009; 30:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43317/abstract/36\">",
"      Dill JE, Wells RF. Use of vasopressin in the Mallory-Weiss syndrome. N Engl J Med 1971; 284:852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2272 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43317=[""].join("\n");
var outline_f42_19_43317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hiatal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcoholism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2272|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/9/24720\" title=\"picture 1\">",
"      Mallory Weiss tear Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/35/33342\" title=\"picture 2\">",
"      Mallory Weiss muscularis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/12/24782\" title=\"picture 3\">",
"      Mallory Weiss clot Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/62/11247\" title=\"picture 4\">",
"      Bleeding Mallory Weiss Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=related_link\">",
"      Boerhaave's syndrome: Effort rupture of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12664?source=related_link\">",
"      Major causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43318="Hemoglobin SC disease";
var content_f42_19_43318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear in hemoglobin SC disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with hemoglobin SC disease shows numerous target cells (red arrows), partially sickled \"canoe\" shaped erythrocytes (black arrows), and folded (Pita bread) red cells (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43318=[""].join("\n");
var outline_f42_19_43318=null;
var title_f42_19_43319="Anticholinergic poisoning";
var content_f42_19_43319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticholinergic poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Mark Su, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Matthew Goldman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43319/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the American Association of Poison Control Centers (AAPCC), there were approximately 20,000 exposures to anticholinergic drugs and plants with 46 major outcomes, but no deaths recorded in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/1\">",
"     1",
"    </a>",
"    ]. This demonstrates a significant improvement in outcomes compared to previous data in which there were 51 deaths reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/2-9\">",
"     2-9",
"    </a>",
"    ]. Anticholinergic toxicity is commonly encountered, and familiarity with the management of this syndrome is essential for the emergency clinician.",
"   </p>",
"   <p>",
"    The basic mechanisms and management of anticholinergic poisoning is reviewed here. Discussions of specific agents that can cause an anticholinergic toxidrome and the general approach to the poisoned patient are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary table to facilitate emergent management of anticholinergic overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef74091 \" href=\"mobipreview.htm?40/43/41660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTICHOLINERGIC POISONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 600 compounds have anticholinergic properties, including prescription drugs, over-the-counter medications, and plants (",
"    <a class=\"graphic graphic_table graphicRef61270 \" href=\"mobipreview.htm?19/40/20107\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Examples of classes of medications with anticholinergic properties include: antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ), tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ), sleep aids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/52/17221?source=see_link\">",
"     doxylamine",
"    </a>",
"    ), cold preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    , and tainted illicit street drugs (eg, heroin \"cut\" with scopolamine).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    , a belladonna alkaloid, is a commonly used anticholinergic medication for the treatment of bradyarrhythmias.",
"   </p>",
"   <p>",
"    Many plants, such as jimson weed (Datura stramonium) and deadly nightshade (Atropa belladonna), may also produce anticholinergic toxicity. Jimson weed contains significant concentrations of belladonna alkaloids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"     hyoscyamine",
"    </a>",
"    , hyoscine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ). Parts of jimson weed may be ingested (or, less commonly, smoked) usually by adolescents, for their hallucinatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic drugs competitively inhibit binding of the neurotransmitter acetylcholine to muscarinic acetylcholine receptors, and are commonly called \"antimuscarinic agents\". Muscarinic receptors are found on peripheral postganglionic cholinergic nerves in smooth muscle (intestinal, bronchial, and cardiac), the secretory glands (salivary and sweat), the ciliary body of the eye, and the central nervous system (CNS). Anticholinergic agents do not antagonize the effects at nicotinic acetylcholine receptors, such as at the neuromuscular junction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of anticholinergic toxicity varies depending on the particular toxin, but usually occurs within one to two hours of oral ingestion.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is rapidly absorbed from the gastrointestinal tract, and achieves peak plasma concentrations within two hours.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9094?source=see_link\">",
"     Diphenoxylate-atropine",
"    </a>",
"    (eg, lomotil) is an antidiarrheal agent that may present with toxicity up to 12 hours after ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/11\">",
"     11",
"    </a>",
"    ]. Toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    may persist for over a day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic description of anticholinergic intoxication is well known:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Red as a beet\" &ndash; Cutaneous vasodilation occurs as a means to dissipate heat by shunting blood to the skin, in order to compensate for the loss of sweat production.",
"     </li>",
"     <li>",
"      \"Dry as a bone\" (anhidrosis) &ndash; Sweat glands are innervated by muscarinic receptors, so anticholinergic medications produce dry skin.",
"     </li>",
"     <li>",
"      \"Hot as a hare\" (anhydrotic hyperthermia) &ndash; Interference with normal heat dissipation mechanisms (ie, sweating) frequently leads to hyperthermia.",
"     </li>",
"     <li>",
"      \"Blind as a bat\" (nonreactive mydriasis) &ndash; Muscarinic input contributes to both pupillary constriction and effective accommodation. Anticholinergic medications generally produce pupillary dilation and ineffective accommodation that frequently manifests as blurry vision.",
"     </li>",
"     <li>",
"      \"Mad as a hatter\" (delirium; hallucinations) &ndash; Blockade of muscarinic receptors in the central nervous system (CNS) accounts for these findings. Manifestations may include: anxiety, agitation, dysarthria, confusion, disorientation, visual hallucinations, bizarre behavior, delirium, psychosis (usually paranoia), coma, and seizures. Hallucinations are often described as \"Alice in Wonderland-like\" or \"Lilliputian type,\" where people appear to become larger and smaller. Patients with altered mental status often present with agitation and may appear to grab invisible objects from the air [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/12\">",
"       12",
"      </a>",
"      ]. Although central and peripheral anticholinergic effects are commonly seen together, in some cases, central effects may persist after resolution of peripheral symptoms.",
"     </li>",
"     <li>",
"      \"Full as a flask\" &ndash; The detrusor muscle of the bladder and the urethral sphincter are both under muscarinic control; anticholinergic substances reduce detrusor contraction (thereby reducing or eliminating the desire to urinate) and prevent normal opening of the urethral sphincter (contributing to urinary retention).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other clinical features not included in the above mnemonic include tachycardia, which is the earliest and most reliable sign of anticholinergic toxicity, and decreased or absent bowel sounds.",
"   </p>",
"   <p>",
"    Clinicians should be aware of the risk for chronic anticholinergic toxicity. Patients treated chronically with multiple psychiatric medications that possess anticholinergic effects, may present with more subtle findings (eg, confusion, alteration in mental status) consistent with anticholinergic toxicity. Such patients may not manifest all aspects of anticholinergic toxicity and their symptoms may be wrongly attributed to other diagnoses. Clinicians should be aware of psychotropic agents and other classes of medications with anticholinergic properties (",
"    <a class=\"graphic graphic_table graphicRef61270 \" href=\"mobipreview.htm?19/40/20107\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any substance or condition that produces an alteration in mental status, tachycardia, urinary retention, or seizure should be included in the differential diagnosis. A wide range of medical conditions and drugs can cause agitated delirium (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"mobipreview.htm?3/43/3773\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"mobipreview.htm?1/11/1214\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organic processes, such as meningitis and sepsis, should also be considered. The timing of onset of delirium may help differentiate toxin-induced causes from organic ones, as delirium from anticholinergic poisoning usually begins more abruptly than that from organic causes, such as sepsis or uremia.",
"   </p>",
"   <p>",
"    Because so many classes of drugs and toxins have anticholinergic effects, clinicians must differentiate pure anticholinergic poisoning from poisonings in which anticholinergic toxicity is but one aspect. Tricyclic antidepressants can produce anticholinergic effects, but these generally occur soon after overdose, and effects from quinidine-like sodium channel blockade (resulting in a prolonged QRS interval) and alpha-blockade (resulting in hypotension) are usually more prominent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .) Phenothiazines have modest anticholinergic effects, but their sedating and alpha-blocking properties tend to predominate.",
"   </p>",
"   <p>",
"    Sympathomimetic overdose and serotonin syndrome may cause agitation, tachycardia, and hyperthermia, but can usually be differentiated from anticholinergic toxicity. Sympathomimetic overdose and serotonin syndrome generally cause diaphoresis, in contradistinction to anticholinergic overdose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In agitated, hyperthermic patients with altered mental status, salicylate overdose should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum drug levels of anticholinergic agents are neither helpful nor readily available in the clinical setting; the diagnosis of anticholinergic toxicity is based on clinical findings and occasionally the results of a",
"    <span class=\"nowrap\">",
"     diagnostic/therapeutic",
"    </span>",
"    trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antidotal therapy with physostigmine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following basic screening tests should be obtained in any patient with suspected overdose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by coingestants that affect the QRS or the QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in all women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is crucial that clinicians obtain an ECG in patients with anticholinergic toxicity. The ECG enables detection of prolonged QRS interval duration and arrhythmias from possible overdose of tricyclic antidepressants, certain phenothiazines (eg, mesoridazine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and other agents. It also allows detection of QTc interval prolongation. Astemizole, an antihistamine with anticholinergic properties, was removed from the market in the United States because of QT prolongation and its association with Torsades de Pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe psychomotor agitation and seizures should have a serum creatine kinase level checked to rule out rhabdomyolysis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/52/17221?source=see_link\">",
"     Doxylamine",
"    </a>",
"    , an antihistamine found in an over-the-counter sleep aid, is unique in that it has been associated with atraumatic rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional tests may be necessary depending on clinical circumstances (eg, cardiac enzymes for patients with chest pain; coagulation studies for suspected disseminated intravascular coagulation; assessment of renal function testing in patients with rhabdomyolysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the poisoned patient must always begin with stabilization of the airway, breathing, and circulation. Patients should have intravenous access, supplemental oxygen, cardiac monitoring, and continuous pulse oximetry. General discussions of the basic facets of the management of poisonings are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .) A summary table to facilitate emergent management of anticholinergic overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef74091 \" href=\"mobipreview.htm?40/43/41660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    should be used in the treatment of prolonged QRS intervals or for arrhythmias related to anticholinergic poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The use of sodium bicarbonate, including dosing, in the treatment of poison-related cardiotoxicity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agitation and seizures should initially be treated with benzodiazepines. Benzodiazepines are effective, have a very high safety threshold, and can be used in high dose to control symptoms. Phenothiazines and butyrophenones should NOT be used to sedate patients with anticholinergic toxicity; they are themselves anticholinergic, and may exacerbate rather than improve symptoms.",
"   </p>",
"   <p>",
"    Hyperthermia should be treated in typical fashion, including evaporative cooling for moderate to severe cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although systemic anticholinergic toxicity has been reported from cutaneous and ocular absorption, most anticholinergic toxicity results from ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the poison and the route and timing of exposure, gastrointestinal (GI) decontamination should be performed; in the vast majority of cases this consists only of administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC). If the patient's mental status is intact and ingestion of an anticholinergic agent is likely, we suggest activated charcoal (AC) (1",
"    <span class=\"nowrap\">",
"     g/kg;",
"    </span>",
"    maximum 50 g) be given. Charcoal should be withheld in patients with a depressed mental status who may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed for the sole purpose of giving AC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric lavage is seldom needed, and induced emesis should be avoided. External decontamination may be necessary for topical agents (eg, removal of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    patch).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antidotal therapy with physostigmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with anticholinergic toxicity do well with supportive care alone, but some may benefit from antidotal therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/24\">",
"     24",
"    </a>",
"    ]. We believe that physostigmine is indicated when patients manifest",
"    <strong>",
"     both",
"    </strong>",
"    peripheral",
"    <strong>",
"     and",
"    </strong>",
"    moderate central anticholinergic toxicity (moderate to severe",
"    <span class=\"nowrap\">",
"     agitation/delirium).",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given if a condition other than a purely anticholinergic poisoning is suspected (eg, tricyclic antidepressant overdose).",
"   </p>",
"   <p>",
"    Clinicians should note that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/25\">",
"     25",
"    </a>",
"    ]. A major study designed to determine the safety and efficacy of the drug has yet to be performed. Caution should be used when giving physostigmine to patients with reactive airway disease, intestinal obstruction, epilepsy, and cardiac conduction abnormalities, as these are relative contraindications.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    is a carbamate acetylcholinesterase inhibitor that binds reversibly to inhibit acetylcholinesterase in both the peripheral and central nervous system (CNS). Once physostigmine blocks acetylcholinesterase, the concentration of acetylcholine at muscarinic receptors increases, and usually overcomes any anticholinergic blockade. Physostigmine is a tertiary amine and crosses the blood brain barrier; other medicinal carbamates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    ) are unable to traverse this barrier. Physostigmine is thus extremely useful in reversing the peripheral and central effects of anticholinergic toxicity.",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is uncommonly used and unfamiliar to many clinicians, we recommend it be given after consultation with a medical toxicologist or regional poison center. In the United States, the nearest available poison control center can be reached by calling 1-800-222-1222. The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ). The results of a small review suggest that EM physicians can administer physostigmine safely to patients with undifferentiated delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/26\">",
"     26",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    Before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is given, the patient should be placed on a cardiac monitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and resuscitative equipment should be available at the bedside.",
"   </p>",
"   <p>",
"    In adults, the recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is 0.5 to 2 mg (0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, up to a maximum of 0.5 mg per dose in pediatric patients). The drug should be given by slow IV push generally over five minutes. Overly rapid infusion may result in cholinergic symptoms or seizures.",
"   </p>",
"   <p>",
"    The half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is approximately 15 minutes, but its effects often last significantly longer. Additional, smaller doses may be repeated after 20 to 30 minutes if agitated delirium recurs. Although patient symptoms and signs should guide the duration of physostigmine therapy, it is worth noting that in one retrospective study none of the 14 patient with anticholinergic toxicity required additional physostigmine more than 6.5 hours after the initial dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/27\">",
"     27",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    There are case reports of TCA-poisoned patients with a wide QRS interval (greater than 0.10 seconds) by ECG who developed asystole following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/28\">",
"     28",
"    </a>",
"    ]. Although it is commonly taught that physostigmine should not be given in the setting of known or suspected tricyclic antidepressant overdose, some have questioned the basis for this proscription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/29\">",
"     29",
"    </a>",
"    ]. On a practical level, it is uncommon for patients with significant TCA poisoning to develop the agitated delirium suggestive of severe central anticholinergic toxicity. While TCAs are weak anticholinergics, they are strong antihistamines, and TCA-poisoned patients are usually sedated, not delirious. Physostigmine would therefore not be considered in these patients based on their mental status. As a general rule, we do",
"    <strong>",
"     NOT",
"    </strong>",
"    use physostigmine when TCA poisoning is known or suspected, or when the duration of the QRS interval is at or above 100 msec.",
"   </p>",
"   <p>",
"    If the patient is not poisoned with an anticholinergic substance, or if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    is given injudiciously, cholinergic toxicity may result. Symptoms of cholinergic excess include: diarrhea, urination, miosis,",
"    <span class=\"nowrap\">",
"     bronchospasm/bronchorrhea,",
"    </span>",
"    emesis, lacrimation, and sweating (the mnemonic often used is DUMBELS). Seizures and bradyarrhythmias may also ensue. In patients who develop cholinergic toxicity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    may be administered. A reasonable starting dose of atropine is half the dose of the physostigmine that was administered, titrated to clinical effect. The clinical findings of cholinergic toxicity are described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H4#H4\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Acute toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    appears to be superior to benzodiazepines in the management of agitation and delirium due to anticholinergic toxicity. In a retrospective study of 52 consecutive patients treated for anticholinergic poisoning, physostigmine was significantly more effective than benzodiazepines in controlling agitation and delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients treated with physostigmine experienced fewer complications and had shorter recovery times. Although patients with very minor anticholinergic toxicity may respond well to small doses of benzodiazepines, those with moderate to severe agitation will likely respond better to physostigmine.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    may clarify the diagnosis of anticholinergic poisoning. In the absence of a clear history of anticholinergic ingestion, patients who present with fever, agitation, and delirium usually require diagnostic testing (eg, computerized tomography of the head and lumbar puncture). In such patients, if physostigmine leads to dramatic clinical improvement, further workup is often unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintentional ingestions are the leading cause of anticholinergic poisoning among children. The clinical presentation and management are similar to that in adults. Management consists of close observation, supportive care,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) administration, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    , if indicated. The pediatric dose of physostigmine is 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 0.5 mg).",
"   </p>",
"   <p>",
"    Adolescents may ingest a variety of substances for their hallucinogenic properties. Plants such as jimson weed are easily found in the environment and a popular item for consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43319/abstract/10\">",
"     10",
"    </a>",
"    ]. Management is the same as that for adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following disposition suggestions are based on our clinical experience. Asymptomatic patients who have ingested an anticholinergic substance should receive gastrointestinal (GI) decontamination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) and be observed in the emergency department for a minimum of six hours. If they remain asymptomatic during this observation period, they may be discharged.",
"   </p>",
"   <p>",
"    Patients with mild anticholinergic toxicity should receive gastrointestinal (GI) decontamination with AC (if possible), and may be treated with benzodiazepines (if necessary) and observed for resolution of symptoms. If symptoms resolve within a reasonable time frame (six hours) they may be discharged; if not, they should be admitted for observation, including pulse oximetry and cardiac monitoring.",
"   </p>",
"   <p>",
"    Patients who have severe anticholinergic toxicity, and patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    , should be admitted to an intensive care unit for observation.",
"   </p>",
"   <p>",
"    Certain anticholinergic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ) can have effects for 24 to 48 hours following exposure. In rare instances effects have lasted up to two weeks. Such patients require a longer period of observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13151981\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pharmacology and presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 600 compounds have anticholinergic properties, including prescription drugs, over-the-counter medications, and plants (",
"      <a class=\"graphic graphic_table graphicRef61270 \" href=\"mobipreview.htm?19/40/20107\">",
"       table 2",
"      </a>",
"      ). Examples of classes of medications with anticholinergic properties include: antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ), tricyclic antidepressants (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ), sleep aids, cold preparations,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      , and tainted illicit street drugs. Anticholinergic overdose is common, and occurs most often through oral ingestion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anticholinergic poisons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic description of anticholinergic intoxication is well known:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"Red as a beet\" (cutaneous vasodilation)",
"     </li>",
"     <li>",
"      \"Dry as a bone\" (anhidrosis)",
"     </li>",
"     <li>",
"      \"Hot as a hare\" (anhydrotic hyperthermia)",
"     </li>",
"     <li>",
"      \"Blind as a bat\" (nonreactive mydriasis)",
"     </li>",
"     <li>",
"      \"Mad as a hatter\" (delirium; hallucinations)",
"     </li>",
"     <li>",
"      \"Full as a flask\" (urinary retention)",
"      <br/>",
"      <br/>",
"      Other clinical features not included in the mnemonic include tachycardia, which is the earliest and most reliable sign of anticholinergic toxicity, and decreased or absent bowel sounds. Although central and peripheral anticholinergic effects are commonly seen together, in some cases, central effects may persist after resolution of peripheral symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any substance or condition that produces an alteration in mental status, tachycardia, urinary retention, or seizure should be included in the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef59893 \" href=\"mobipreview.htm?3/43/3773\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70449 \" href=\"mobipreview.htm?1/11/1214\">",
"       table 4",
"      </a>",
"      ). Organic processes, such as meningitis and sepsis, should also be considered. The timing of onset of delirium may help differentiate toxin-induced causes from organic ones, as delirium from anticholinergic poisoning usually begins more abruptly than that from organic causes, such as sepsis or uremia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate emergent management of anticholinergic overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef74091 \" href=\"mobipreview.htm?40/43/41660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum drug levels of anticholinergic agents are neither helpful nor readily available in the clinical setting; the diagnosis of anticholinergic toxicity is based on clinical findings and occasionally the results of a",
"      <span class=\"nowrap\">",
"       diagnostic/therapeutic",
"      </span>",
"      trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following tests should be obtained:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by anticholinergic drugs or coingestants. It is crucial that an ECG be obtained in patients with anticholinergic toxicity to detect prolonged QRS interval duration and dysrhythmia.",
"     </li>",
"     <li>",
"      Pregnancy test in all women of childbearing age",
"     </li>",
"     <li>",
"      Patients with severe psychomotor agitation and seizures should have a serum creatine kinase level checked to assess for rhabdomyolysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest agitation and seizures should be treated initially with benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Benzodiazepines are effective, have a very high safety threshold, and can be used in high dose to control symptoms. We suggest phenothiazines and butyrophenones",
"      <strong>",
"       NOT",
"      </strong>",
"      be used to sedate patients with anticholinergic toxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); they are themselves anticholinergic, and may exacerbate rather than improve symptoms. Hyperthermia should be treated in standard fashion. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient's mental status is intact and ingestion of an anticholinergic agent is likely, we suggest decontamination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) (1",
"      <span class=\"nowrap\">",
"       g/kg;",
"      </span>",
"      maximum 50 g) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. Tracheal intubation should not be performed solely for the purpose of giving charcoal. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      is controversial, we suggest this antidote be given to patients manifesting",
"      <strong>",
"       both",
"      </strong>",
"      peripheral",
"      <strong>",
"       and",
"      </strong>",
"      moderate central (moderate to severe",
"      <span class=\"nowrap\">",
"       agitation/delirium)",
"      </span>",
"      anticholinergic toxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We believe consultation with a medical toxicologist or regional poison center should be obtained before physostigmine is given. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antidotal therapy with physostigmine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      is administered, the patient should be placed on a cardiac monitor, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      and resuscitative equipment should be available at the bedside. In adults, the recommended dose of physostigmine is 0.5 to 2 mg (0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, up to a maximum of 0.5 mg per dose in pediatric patients). The drug should be given by",
"      <strong>",
"       slow",
"      </strong>",
"      IV push. Caution should be used when giving physostigmine to patients with reactive airway disease, intestinal obstruction, epilepsy, and cardiac conduction abnormalities, as these are relative contraindications. The benefits and risks of physostigmine are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antidotal therapy with physostigmine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients should be observed in the emergency department for a minimum of six hours. If they remain asymptomatic during this observation period, they may be discharged. Patients with mild anticholinergic toxicity should be treated and observed for resolution of symptoms. If symptoms resolve within a reasonable time frame (six hours) they may be discharged; if not, they should be admitted for observation, including pulse oximetry and cardiac monitoring. Patients who have severe anticholinergic toxicity, and patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      , should be admitted to an intensive care unit for observation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/1\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/2\">",
"      Litovitz TL, Klein-Schwartz W, Dyer KS, et al. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1998; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/3\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/4\">",
"      Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/5\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/6\">",
"      Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/7\">",
"      Litovitz TL, Klein-Schwartz W, White S, et al. 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/8\">",
"      Litovitz TL, Klein-Schwartz W, White S, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2000; 18:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/9\">",
"      Litovitz TL, Klein-Schwartz W, Caravati EM, et al. 1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999; 17:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/10\">",
"      Shervette RE 3rd, Schydlower M, Lampe RM, Fearnow RG. Jimson \"loco\" weed abuse in adolescents. Pediatrics 1979; 63:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/11\">",
"      McCarron MM, Challoner KR, Thompson GA. Diphenoxylate-atropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature). Pediatrics 1991; 87:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/12\">",
"      Richmond M, Seger D. Central anticholinergic syndrome in a child: a case report. J Emerg Med 1985; 3:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/13\">",
"      Wiley JF 2nd, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/14\">",
"      Hasan RA, Zureikat GY, Nolan BM. Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate. Pediatr Emerg Care 1993; 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/15\">",
"      Mendoza FS, Atiba JO, Krensky AM, Scannell LM. Rhabdomyolysis complicating doxylamine overdose. Clin Pediatr (Phila) 1987; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/16\">",
"      Soto LF, Miller CH, Ognibere AJ. Severe rhabdomyolysis after doxylamine overdose. Postgrad Med 1993; 93:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/17\">",
"      Frankel D, Dolgin J, Murray BM. Non-traumatic rhabdomyolysis complicating antihistamine overdose. J Toxicol Clin Toxicol 1993; 31:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/18\">",
"      Leybishkis B, Fasseas P, Ryan KF. Doxylamine overdose as a potential cause of rhabdomyolysis. Am J Med Sci 2001; 322:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/19\">",
"      Clark RF, Vance MV. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med 1992; 21:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/20\">",
"      Sharma AN, Hexdall AH, Chang EK, et al. Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. Am J Emerg Med 2003; 21:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/21\">",
"      Reilly JF Jr, Weisse ME. Topically induced diphenhydramine toxicity. J Emerg Med 1990; 8:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/22\">",
"      Bernhardt DT. Topical diphenhydramine toxicity. Wis Med J 1991; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/23\">",
"      Thompson HS. Cornpicker's pupil: Jimson weed mydriasis. J Iowa Med Soc 1971; 61:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/24\">",
"      Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med 1998; 16:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/25\">",
"      Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/26\">",
"      Schneir AB, Offerman SR, Ly BT, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med 2003; 42:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/27\">",
"      Rosenbaum C, Bird SB. Timing and frequency of physostigmine redosing for antimuscarinic toxicity. J Med Toxicol 2010; 6:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/28\">",
"      Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980; 9:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43319/abstract/29\">",
"      Suchard JR. Assessing physostigmine's contraindication in cyclic antidepressant ingestions. J Emerg Med 2003; 25:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 305 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43319=[""].join("\n");
var outline_f42_19_43319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTICHOLINERGIC POISONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antidotal therapy with physostigmine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13151981\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pharmacology and presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/43/41660\" title=\"table 1\">",
"      Anticholinergic poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/40/20107\" title=\"table 2\">",
"      Antichol drugs and plants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/43/3773\" title=\"table 3\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/11/1214\" title=\"table 4\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43320="Second generation (atypical) antipsychotic medication poisoning";
var content_f42_19_43320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second generation (atypical) antipsychotic medication poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Raffi Kapitanyan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Mark Su, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43320/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second generation of antipsychotic medications, commonly referred to as \"atypical antipsychotics,\" was introduced in 1998. The term \"atypical\" refers to an antipsychotic medication that produces minimal extrapyramidal side effects (EPS) at clinically effective antipsychotic doses, has a low propensity to cause tardive dyskinesia (TD) with long-term treatment, and treats both positive and negative signs and symptoms of schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/1\">",
"     1",
"    </a>",
"    ]. Atypical agents currently available include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    (Clozaril&trade;),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (Risperdal&trade;),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (Zyprexa&trade;),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (Seroquel&trade;),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    (Geodon&trade;),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    (Abilify&trade;), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    (Invega&trade;), the active metabolite of risperidone.",
"   </p>",
"   <p>",
"    Atypical antipsychotics have largely replaced traditional agents as first-line therapy in the treatment of schizophrenia. Toxicologic exposures and fatalities associated with atypical agents continue to increase in the United States with 32,422 exposures and 72 deaths in 2003; 38,315 exposures and 94 deaths in 2004; and 43,540 exposures, but only six deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Consequently, it is important for the practicing clinician to be familiar with the pharmacology and toxicology of these medications.",
"   </p>",
"   <p>",
"    This topic review will discuss the basic pharmacology, presentation, and management of acute intoxication with atypical antipsychotics. Discussions of the clinical use of these drugs, details concerning potential side effects, and general management of drug overdose are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacology of atypical antipsychotic agents is complex. As a general rule, all exhibit dopamine (D2) receptor blockade, similar to first-generation antipsychotics, but with a lower binding affinity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to lower D2 receptor potency and occupancy at therapeutic doses, atypical agents selectively antagonize mesolimbic D2 receptors more so than those in the nigrostriatum and prefrontal cortex. As a result, side effects attributable to nigrostriatal D2 blockade (eg, extrapyramidal symptoms, such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia) occur less frequently, as do side effects attributable to mesocortical (ie, prefrontal) D2 blockade (eg, neurocognitive impairment and negative symptoms).",
"   </p>",
"   <p>",
"    Atypical antipsychotics are also serotonin (5-HT) antagonists at the 5-HT2A receptor subtype. This pharmacologic effect mitigates the negative signs and symptoms of schizophrenia by disinhibiting the dopamine system in the nigrostriatum and prefrontal cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serotonin-dopamine antagonism is the reason why atypical antipsychotics may be given at smaller doses, producing fewer extrapyramidal side effects, while maintaining clinical efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the common mechanisms noted above, each atypical agent has a unique pharmacodynamic profile that can be used to predict adverse effects in both therapeutic use and overdose. Although each agent has different affinities for specific receptors, most drugs fall into one of two groups. The first group consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , all of which demonstrate multiple receptor antagonism (alpha-1, histamine-1, and muscarinic-1). The second group consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , which demonstrate alpha-1 adrenergic and histamine-1 receptor antagonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The atypical antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    possesses a unique receptor profile. Postsynaptic partial dopamine agonism blunts positive symptoms, while basal D2 receptor activation produces fewer movement disorders than nonspecific dopamine antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Aripiprazole also binds to presynaptic dopamine autoreceptors, reducing dopamine release and synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These pre- and postsynaptic actions result in a neurotransmitter-level stabilizing effect, blunting excess activity and augmenting deficient activity. Aripiprazole also has a low affinity for serotonin, alpha-1 adrenergic, and histamine-1 receptors. This novel receptor affinity pattern explains the efficacy and favorable side effect profile of this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotics are completely and rapidly absorbed after oral administration, but undergo significant first-pass hepatic metabolism (",
"    <a class=\"graphic graphic_table graphicRef60825 \" href=\"mobipreview.htm?29/44/30412\">",
"     table 1",
"    </a>",
"    ). Time to peak plasma concentration ranges from 1 to 10 hours. Atypical antipsychotics have a large volume of distribution. They are highly lipophilic, highly protein-bound, and accumulate in the brain, lung, and other tissues. Plasma concentrations with therapeutic dosing are quite low (nanograms per milliliter). These agents enter breast milk and fetal circulation.",
"   </p>",
"   <p>",
"    The liver metabolizes atypical antipsychotics predominantly via cytochrome P450 enzymes (isoenzymes 1A2, 2D6, and 3A4). Therefore, serum levels may be affected by other medications that stimulate or inhibit the cytochrome P450 system.",
"   </p>",
"   <p>",
"    Some atypical agents have active metabolites. Long elimination half-lives and active metabolites allow for once or twice-daily therapeutic dosing. The correlation between doses, serum concentration, and clinical effects is quite variable. Fetuses, infants, and the elderly have less ability to metabolize these agents because of decreased cytochrome p450 activity, while children metabolize them more rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is subject to drug interactions affecting the CYP2D6 enzyme, in vivo studies suggest this isozyme plays a limited role in the clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    , the major active metabolite of risperidone. This property of paliperidone makes dose adjustment unnecessary in patients with mild to moderate hepatic impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute overdose, atypical antipsychotics cause only mild to moderate toxicity in the majority of patients, and may produce no symptoms (",
"    <a class=\"graphic graphic_table graphicRef60456 \" href=\"mobipreview.htm?2/34/2604\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the number of reported exposures has increased dramatically, mortality remains low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Toxic effects that do occur following overdose are largely an extension of a drug's physiologic effects (",
"    <a class=\"graphic graphic_table graphicRef62403 \" href=\"mobipreview.htm?9/35/9787\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'History and physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The toxic and lethal doses of atypical antipsychotics are highly variable and depend largely on the specific drug, the presence of cointoxicants, age, and whether the patient is taking the drug for the first time. Children and unhabituated adults are more sensitive to the toxic effects of these agents. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pediatric considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Toxicity from atypical antipsychotics usually begins within one to two hours and peaks by four to six hours following ingestion, and the effects are similar for both adults and children. Resolution of toxicity usually occurs by 12 to 48 hours following ingestion but has reportedly taken up to six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of atypical antipsychotic overdose is primarily based upon a history of ingestion and clinical findings. Central nervous system (CNS) effects occur most frequently (",
"    <a class=\"graphic graphic_table graphicRef62403 \" href=\"mobipreview.htm?9/35/9787\">",
"     table 3",
"    </a>",
"    ). Extrapyramidal side effects (EPS) and neuroleptic malignant syndrome (NMS) are infrequent, but are more common in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common clinical presentation consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lethargy and sedation (from histamine blockade)",
"     </li>",
"     <li>",
"      Miosis, tachycardia, and orthostatic hypotension (from alpha adrenergic blockade)",
"     </li>",
"     <li>",
"      Anticholinergic toxicity, including confusion (from muscarinic blockade) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain effects may be more common with specific agents. A large retrospective case series found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    overdose appears more likely to cause respiratory depression, depressed mental status, and hypotension compared to other antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/12\">",
"     12",
"    </a>",
"    ]. Numerous case reports have described rapid fluctuations between sedation and agitation in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    overdose, deemed \"agitation despite sedation.\" The incidence of seizures is higher for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    (10 percent) than for most atypical agents (less than 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology of atypical antipsychotics is complex, and presentations of patients who have overdosed on these drugs vary, especially if the patient has ingested a multiple receptor antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Possible historical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CNS -",
"      <span class=\"nowrap\">",
"       Fatigue/lethargy/sedation/agitation,",
"      </span>",
"      confusion, dizziness, slurred speech, seizure, delirium, coma",
"     </li>",
"     <li>",
"      Cardiopulmonary - Dyspnea, chest pain, palpitations",
"     </li>",
"     <li>",
"      Anticholinergic manifestations - Blurry vision, dry mouth, constipation, urinary retention",
"     </li>",
"     <li>",
"      Gastrointestinal (rare) - Nausea, vomiting, abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Possible examination findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CNS - Miosis (sometimes mydriasis), ataxia, dysarthria, dystonia, hypotonia, extrapyramidal side effects (eg, acute dystonia, parkinsonism, akathisia, tardive dyskinesia), rapidly fluctuating mental status (depression and agitation), hypersalivation, myoclonus, seizures, coma",
"     </li>",
"     <li>",
"      Cardiopulmonary - Tachycardia, orthostatic",
"      <span class=\"nowrap\">",
"       hypotension/mild",
"      </span>",
"      hypertension, respiratory depression",
"     </li>",
"     <li>",
"      Anticholinergic - Facial flushing, dry mucous membranes, decreased sweating, mild hyperthermia",
"     </li>",
"     <li>",
"      Gastrointestinal - Abdominal tenderness, usually localized to the right upper quadrant, decreased bowel sounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotics interact with multiple receptors. Therefore, signs and symptoms of atypical antipsychotic overdose are similar to those seen with many other agents, which can make differentiation among potential poisons difficult. Below is a list of drugs commonly encountered in the overdose patient and the potential manifestations of acute intoxication they share with atypical antipsychotics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional antipsychotics (",
"      <a class=\"graphic graphic_table graphicRef60456 \" href=\"mobipreview.htm?2/34/2604\">",
"       table 2",
"      </a>",
"      ): extrapyramidal side effects (EPS), tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), anticholinergic, alpha adrenergic-blockade, prolonged QTc,",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      depression (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cyclic antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      ): sedation, prolonged",
"      <span class=\"nowrap\">",
"       QRS/QT",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anticonvulsants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ):",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      depression (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41863?source=see_link\">",
"       \"Phenytoin poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antihistamines (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ): anticholinergic, sedation, prolonged QRS (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Opioids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ): miosis,",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      depression (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link\">",
"       \"Opioid intoxication in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Muscle relaxants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/60/13254?source=see_link\">",
"       cyclobenzaprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/61/41940?source=see_link\">",
"       metaxalone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24677?source=see_link\">",
"       methocarbamol",
"      </a>",
"      ): sedation",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Sedative/hypnotics",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ):",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      depression",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ethanol/toxic",
"      </span>",
"      alcohols (ethylene glycol, methanol):",
"      <span class=\"nowrap\">",
"       CNS/respiratory",
"      </span>",
"      depression (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20694?source=see_link\">",
"       \"Ethanol intoxication in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antidysrhythmics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ): dysrhythmia, prolonged",
"      <span class=\"nowrap\">",
"       QRS/QT",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No specific clinically useful test for atypical antipsychotic intoxication exists. Of note, atypical antipsychotics, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , may produce a false positive test for tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinus tachycardia is the most common abnormal ECG finding, but other aberrations can occur. These include dose-related repolarization abnormalities (QTc prolongation, ST depression, T wave flattening) and",
"    <span class=\"nowrap\">",
"     supraventricular/ventricular",
"    </span>",
"    dysrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ]. Such ECG findings are usually clinically insignificant, and despite cases of QTc prolongation, Torsades de Pointes has not been reported following overdose of atypical antipsychotics.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     Ziprasidone",
"    </a>",
"    has the greatest effect on the QTc interval compared with other atypical antipsychotics.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    did not cause QTc prolongation or cardiotoxicity in preclinical trials or in the few published case reports of drug toxicity (",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"mobipreview.htm?22/2/22571\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/13,15-29\">",
"     13,15-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although unrelated to overdose, certain atypical agents have been shown to increase serum prolactin levels (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ), cause hyperglycemia (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ), increase liver transaminases (clozapine, olanzapine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , risperidone, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ), and induce agranulocytosis or",
"    <span class=\"nowrap\">",
"     leukopenia/neutropenia",
"    </span>",
"    (clozapine and olanzapine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Most of these effects are idiosyncratic.",
"   </p>",
"   <p>",
"    Additional testing may be needed depending upon the clinical situation, such as creatinine phosphokinase and urine myoglobin in a patient found down and at risk for rhabdomyolysis, cerebrospinal fluid analysis in a patient with altered mental status of unclear etiology, or liver transaminases in a patient with significant abdominal pain.",
"   </p>",
"   <p>",
"    Qualitative screening by gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry may be used to confirm the presence of atypical agents, but this is almost never clinically indicated. Quantitative drug concentrations are not generally used, since they are not readily available and do not predict toxicity or guide treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for atypical antipsychotic overdose is primarily supportive. The general approach to any poisoned patient must always begin with stabilization of the airway, breathing, and circulation. General discussions of the management of poisoning are found elsewhere. Detailed management of intoxication with atypical antipsychotics is discussed immediately below. A summary table of signs and symptoms is provided (",
"    <a class=\"graphic graphic_table graphicRef62403 \" href=\"mobipreview.htm?9/35/9787\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Every patient requires continuous cardiac monitoring, intravenous access, an electrocardiogram (ECG), and continual reevaluation for mental status changes. Altered mental status can range from profound depression to signs of extrapyramidal side effects (EPS), tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or seizures (",
"    <a class=\"graphic graphic_table graphicRef80747 \" href=\"mobipreview.htm?22/2/22571\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever feasible, we suggest a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) with or without a cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ) be given as soon as the patient has been stabilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/35\">",
"     35",
"    </a>",
"    ]. Gastric lavage is not recommended because these agents are associated with low mortality in overdose. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. However, tracheal intubation should not be performed solely for the purpose of giving AC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypotension secondary to alpha adrenergic (alpha) blockade is treated initially with intravenous crystalloid. Refractory hypotension, due to peripheral alpha blockade by atypical antipsychotics, can usually be treated with vasoconstrictive alpha agonists such as norepinephrine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    . Drugs with beta 2 agonist effects (eg, epinephrine) should be avoided as they can exacerbate the vasodilatory effects of alpha blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac dysrhythmias (supraventricular and ventricular) are treated according to standard advanced",
"    <span class=\"nowrap\">",
"     cardiac/pediatric",
"    </span>",
"    life support guidelines, with a few exceptions. Antidysrhythmics that prolong the QTc interval, such as type IA (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ), IC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ), and III (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ) medications, however, should be avoided, as they may exacerbate conduction abnormalities. A type IB antidysrhythmic agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) may be used. QRS prolongation may be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , as with cyclic antidepressants and other Na+ channel blocking agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seizures secondary to atypical antipsychotic toxicity are usually isolated and self-limited, and treatment with anticonvulsant agents is rarely needed. If treatment is necessary, benzodiazepines (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) are first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute EPS (eg, dystonia) may be treated with anticholinergic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    . Patients with NMS require supportive treatment, which may include active cooling, benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , or neuromuscular blockade, depending on the degree of symptoms. Treatment for TD includes benzodiazepines and supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticholinergic effects of atypical antipsychotics may contribute to the severe agitation and altered level of consciousness seen in acute overdose. Benzodiazepines are usually adequate to control these symptoms.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    , a short-acting acetylcholinesterase inhibitor, has been successfully used to reverse the anticholinergic syndrome seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    has potential adverse effects (bradycardia, bronchospasm, bradypnea), and its use as an antidote for atypical antipsychotic overdose is not clearly defined. We recommend that physostigmine only be used in the treatment of atypical antipsychotic poisoning in consultation with a medical toxicologist or poison control center. Patients with cyclic antidepressant toxicity should not receive physostigmine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Anticholinergic toxicity and physostigmine therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high-protein binding, large volume of distribution, and low plasma levels of atypical antipsychotics make extracorporeal removal, by either hemodialysis or hemoperfusion, unlikely to be of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/33\">",
"     33",
"    </a>",
"    ]. We do not recommend its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotic agents are associated with a rapid onset of symptoms following overdose, so disposition is generally determined within four hours of ingestion. Patients who remain asymptomatic after a four-hour observation period require no further medical evaluation, assuming no other clinical issues exist. Psychiatry consultation is needed for suicidal patients. Patients with moderate to severe toxicity",
"    <span class=\"nowrap\">",
"     (CNS/respiratory",
"    </span>",
"    depression, hypotension,",
"    <span class=\"nowrap\">",
"     agitation/delirium,",
"    </span>",
"    dysrhythmias) should be admitted to a monitored bed or intensive care unit, depending on symptom severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health clinicians are treating children and adolescents with atypical antipsychotics at increasing rates for a range of psychiatric illnesses, despite limited data on their efficacy in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/42\">",
"     42",
"    </a>",
"    ]. This diversity of indications has contributed to the increased use of these agents, and increased episodes of overdose. There were 9437 and 11,263 exposures to atypical agents in youths 19 years of age or younger in 2003 and 2004, respectively. Significant adverse effects, including mortality, were uncommon (0.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most published reports of overdose do not contain data on long-term consequences and are unable to provide conclusions about the significance of blood levels, the differences in duration of symptoms by age or size, or the relationship between the severity of symptoms and the dose ingested. Assessment and management in children is similar to that of adults; history and clinical presentation remain paramount. The most frequent clinical presentation of overdose in children includes nausea and vomiting, lethargy, drowsiness, somnolence, tachycardia, and central nervous system (CNS) depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/8,34,43\">",
"     8,34,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children may be at increased risk of toxicity with atypical antipsychotics. Children metabolize these drugs more rapidly, and, because children generally have less adipose tissue and lower levels of protein-binding, there may be increased drug bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/33\">",
"     33",
"    </a>",
"    ]. Therefore, we suggest that children who have ingested atypical antipsychotic medications and are asymptomatic be observed for six hours. Clinicians should maintain a low threshold for admitting mildly symptomatic children.",
"   </p>",
"   <p>",
"    Supportive treatment and close observation are the mainstays of management.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     Sorbitol",
"    </a>",
"    should not be given to young children because of the risk of excessive fluid loss. As with adults, the majority of toxicity in children due to atypical antipsychotics results in good outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/43\">",
"     43",
"    </a>",
"    ]. Nevertheless, a small number of case reports describe instances when endotracheal intubation and admission to an intensive care unit were necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43320/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15126944\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical (second generation) antipsychotic medications have largely replaced conventional first-generation drugs for the treatment of schizophrenia because of their effectiveness and safer therapeutic and overdose profile (",
"    <a class=\"graphic graphic_table graphicRef60456 \" href=\"mobipreview.htm?2/34/2604\">",
"     table 2",
"    </a>",
"    ). As use of these drugs has increased, so has the incidence of overdose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pharmacology of atypical antipsychotic agents is complex, involving several types of receptors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute overdose, atypical antipsychotics cause only mild to moderate toxicity in the majority of patients, and may produce no symptoms. The toxic and lethal doses of atypical antipsychotics are highly variable and depend largely on the specific drug, the presence of cointoxicants, patient age, and whether the patient is taking the drug for the first time (",
"      <a class=\"graphic graphic_table graphicRef62403 \" href=\"mobipreview.htm?9/35/9787\">",
"       table 3",
"      </a>",
"      ). Children and unhabituated adults are more sensitive to the toxic effects of these agents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because they work at multiple receptors, atypical antipsychotics can cause a range of signs and symptoms, most often involving the central nervous system. The most common clinical presentation consists of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lethargy and sedation (from histamine blockade)",
"     </li>",
"     <li>",
"      Miosis, tachycardia, and orthostatic hypotension (from alpha adrenergic blockade)",
"     </li>",
"     <li>",
"      Anticholinergic toxicity, including confusion (from muscarinic blockade) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid fluctuations between sedation and agitation can occur in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      overdose.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      overdose is more often associated with seizures, although they are still uncommon.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      has the greatest effect on the QTc interval. A description of possible signs and symptoms is found in the text. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of atypical antipsychotic overdose are shared by many agents, which can make differentiation among potential poisons difficult. Drugs commonly encountered in the overdose patient that may share manifestations of acute intoxication with atypical antipsychotics include: traditional antipsychotics, cyclic antidepressants, anticonvulsants, antihistamines, opioids, muscle relaxants,",
"      <span class=\"nowrap\">",
"       sedative/hypnotics,",
"      </span>",
"      <span class=\"nowrap\">",
"       ethanol/toxic",
"      </span>",
"      alcohols, and antidysrhythmics. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific, clinically useful test to identify atypical antipsychotic intoxication exists. Obtain an electrocardiogram, salicylate and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      levels, a fingerstick glucose, and a qualitative pregnancy test in women of childbearing age. We suggest obtaining liver transaminases and a complete blood count in patients with altered mental status, abdominal pain, or other concerning findings (eg, possible acetaminophen coingestion). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for atypical antipsychotic overdose is primarily supportive. Care includes continuous cardiac monitoring, intravenous access, and continual reevaluation for mental status. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest giving a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) with or without a cathartic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      ) to the patient with an acute overdose of an atypical antipsychotic medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). AC should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. Tracheal intubation should not be performed solely for the purpose of giving AC. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe effects from atypical antipsychotic poisoning are uncommon. Hypotension is treated initially with intravenous crystalloid. Refractory hypotension, due to peripheral alpha adrenergic blockade, can usually be treated with vasoconstrictive alpha agonists such as norepinephrine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      . Seizures are generally brief and self-limited, but may be treated with benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ), if necessary. Acute extrapyramidal side effects (eg, dystonia) may be treated with anticholinergic agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical antipsychotic agents are associated with a rapid onset of symptoms following overdose, so disposition is generally determined within four hours of ingestion. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/1\">",
"      Freedman R. Schizophrenia. N Engl J Med 2003; 349:1738.",
"     </a>",
"    </li>",
"    <li>",
"     Watson, WA, Litovitz, TL, Klein-Schwartz, W, et al. 2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. file://www.aapcc.org (Accessed on July 06, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/3\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/4\">",
"      Gill JS, Pillai SK, Koh OH, Jambunathan S. [Non-fatal paliperidone overdose: a case report]. Turk Psikiyatri Derg 2010; 21:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/5\">",
"      Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 2001; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/6\">",
"      Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl 10:5.",
"     </a>",
"    </li>",
"    <li>",
"     B, Thakurta S. Drug Class Review: Atypical Antipsychotic Drugs: Final Report Update 2. Portland, (OR): Oregon Health &amp; Science University; 2008 Jun. www.ohsu.edu/drugeffectiveness/reports/final.cfm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/8\">",
"      Lofton AL, Klein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 2005; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/9\">",
"      Seifert SA, Schwartz MD, Thomas JD. Aripiprazole (abilify) overdose in a child. Clin Toxicol (Phila) 2005; 43:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/10\">",
"      Tamminga CA. Similarities and differences among antipsychotics. J Clin Psychiatry 2003; 64 Suppl 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/11\">",
"      Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999; 19:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/12\">",
"      Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008; 52:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/13\">",
"      Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/14\">",
"      Caravati EM, Juenke JM, Crouch BI, Anderson KT. Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays. Ann Pharmacother 2005; 39:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/15\">",
"      Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; :CD001359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/16\">",
"      Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; :CD000967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/17\">",
"      Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000; :CD002306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/18\">",
"      Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; :CD005237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/19\">",
"      Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; :CD001945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/20\">",
"      El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004; :CD004578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/21\">",
"      Pollak PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther 2000; 68:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/22\">",
"      Palenzona S, Meier PJ, Kupferschmidt H, Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/23\">",
"      Balicka-Slusarczyk B, Szczeklik J, Szpak D, Groszek B. [Clinical course of acute poisoning with olanzapine]. Przegl Lek 2005; 62:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/24\">",
"      Hodge CH, Jewell M, Gummin DD, Leikin JB. Atypical presentation of risperidone toxicity. Vet Hum Toxicol 2001; 43:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/25\">",
"      Magdalan J, Wasyko-Smolarek M, Antoczyk A, et al. [Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocaw]. Przegl Lek 2004; 61:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/26\">",
"      Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/27\">",
"      Burton S, Heslop K, Harrison K, Barnes M. Ziprasidone overdose. Am J Psychiatry 2000; 157:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/28\">",
"      House M. Overdose of ziprasidone. Am J Psychiatry 2002; 159:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/29\">",
"      Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 2003; 41:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/30\">",
"      Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association. Isr Med Assoc J 2004; 6:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/31\">",
"      Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/32\">",
"      Stergiou V, Bozikas VP, Garyfallos G, et al. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/33\">",
"      Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 2005; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/34\">",
"      Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005; 15:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/35\">",
"      Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/36\">",
"      Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/37\">",
"      Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/38\">",
"      Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004; 14:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/39\">",
"      LeBlaye, I, Donatini, B, Hall, M, Krupp, P. Acute overdosage with clozapine: A review of the available clinical experience. Pharmaceutical Med 1992; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/40\">",
"      Ferraro, KK, Burkhart, KK, Donovan, JW, O'Donnell, SJ. A retrospective review of physostigmine in olanzapine overdose. J Toxicol Clin Toxicol 2001; 39:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/41\">",
"      Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/42\">",
"      Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/43\">",
"      Catalano G, Catalano MC, Nunez CY, Walker SC. Atypical antipsychotic overdose in the pediatric population. J Child Adolesc Psychopharmacol 2001; 11:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/44\">",
"      Catalano G, Cooper DS, Catalano MC, Butera AS. Olanzapine overdose in an 18-month-old child. J Child Adolesc Psychopharmacol 1999; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43320/abstract/45\">",
"      Theisen FM, Grabarkiewicz J, Fegbeutel C, et al. Olanzapine overdose in children and adolescents: two case reports and a review of the literature. J Child Adolesc Psychopharmacol 2005; 15:986.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 304 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43320=[""].join("\n");
var outline_f42_19_43320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Possible historical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Possible examination findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15126944\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/44/30412\" title=\"table 1\">",
"      Pharmokinetics of second generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/34/2604\" title=\"table 2\">",
"      Common antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/35/9787\" title=\"table 3\">",
"      Signs of antipsychotic medication overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/2/22571\" title=\"table 4\">",
"      Adverse effects of atypical antipsychotic medications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41863?source=related_link\">",
"      Phenytoin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43321="The roles of diet, physical activity, and body weight in cancer survivorship";
var content_f42_19_43321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The roles of diet, physical activity, and body weight in cancer survivorship",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Jennifer Ligibel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Jeffrey A Meyerhardt, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Patricia A Ganz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/19/43321/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/19/43321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H86925732\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 13 million people worldwide are diagnosed with cancer each year, and almost 8 million people will die from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/1\">",
"     1",
"    </a>",
"    ]. With advances in detection and treatment, it is estimated that over 25 million people are alive with a past cancer diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most efforts in cancer prevention and treatment strategies have largely focused on pharmacologic therapies, these are costly and can result in long-term morbidity and even mortality. Therefore, novel methods to improve outcomes, especially those that can improve quality of life and offer other health benefits, are an area of continued investigation.",
"   </p>",
"   <p>",
"    In this topic, we will review the evidence that links diet, physical activity, and body weight to cancer-related outcomes and will provide an overview of the many studies that have looked at the feasibility and potential benefits of energy balance interventions in cancer survivors. In addition, we provide consensus-based recommendations for cancer survivors.",
"   </p>",
"   <p>",
"    Topics addressing diet, physical activity, and weight in patients without a history of cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"       \"Healthy diet in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"       \"Dietary therapy for obesity\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9161?source=see_link\">",
"       \"Physical activity and exercise in older adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"       \"Overview of the benefits and risks of exercise\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=see_link\">",
"       \"Role of physical activity and exercise in obese adults\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link\">",
"       \"Pathogenesis of obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"       \"Screening for and clinical evaluation of obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link\">",
"       \"Cancer prevention\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link&amp;anchor=H2446695404#H2446695404\">",
"       \"Factors that modify breast cancer risk in women\", section on 'Lifestyle factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an overview of cancer survivorship is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=see_link\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271204397\">",
"    <span class=\"h1\">",
"     ENERGY BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet, physical activity, and weight are collectively considered energy balance factors because they describe the relationship between energy consumed (diet), energy expended (physical activity), and energy stored (adiposity). They have each been linked to cancer outcomes, particularly in survivors of breast, colon, rectum, endometrial, and prostate cancer. A positive energy balance results from excess of energy intake relative to the energy expended, which results in increases in the storage of energy and weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271204412\">",
"    <span class=\"h2\">",
"     Role in cancer survivorship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, inactivity and poor dietary quality are increasingly being linked to decreased overall and cancer-specific survival in individuals with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have demonstrated that interventions targeting weight, diet, and physical activity are feasible, can improve quality of life, and may minimize disease and treatment-related side effects for cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Some preliminary evidence suggests that lifestyle change may also improve prognosis in individuals with early-stage cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/10\">",
"     10",
"    </a>",
"    ], but much work still needs to be done to validate this and to determine which types of lifestyle change are most important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435221609\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies of diet and chronic diseases have facilitated major advances in our understanding of the contribution of diet to the pathogenesis of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/11\">",
"     11",
"    </a>",
"    ]. They suggest that changes in dietary patterns might help reduce the risk of many common diseases in the United States, including some cancers. The potential impact of dietary patterns upon prognosis in patients with cancer has also been widely studied, especially in survivors of breast and prostate cancers, with some data also available in survivors of colorectal and gynecologic survivors. The data are summarized below.",
"   </p>",
"   <p>",
"    The role of specific dietary regimens as a complementary or alternative treatment for cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H3#H3\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Dietary treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457684783\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have examined the relationship between dietary factors and the risk of cancer recurrence and death in individuals diagnosed with early-stage breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Some evidence suggests that reducing dietary fat intake after cancer diagnosis could improve outcomes, but data have not been consistent, and dietary modification is not a standard part of adjuvant therapy for women with breast cancer at this time.",
"   </p>",
"   <p>",
"    Studies have focused both upon intake of specific dietary nutrients and upon broader dietary patterns (for example, ingestion of a fruit and vegetable based diet versus a diet high in processed foods, red meat, and fat) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there have been no consistent relationships between any dietary pattern or intake of a particular nutrient and the risk of breast cancer recurrence, especially after adjustment for body weight and other related factors. A number of reviews and meta-analyses on the impact of dietary factors on breast cancer outcomes have been conducted. The results are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2002 systematic review of 13 studies evaluating the relationship between fat consumption and breast cancer outcomes found an inverse relationship between dietary fat intake and breast cancer prognosis in 6 of the 13 studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/12\">",
"       12",
"      </a>",
"      ]. However, the results became non-significant in four of the six studies when results were adjusted for total caloric intake and body weight.",
"     </li>",
"     <li>",
"      The relationship between dietary fat intake and breast cancer outcomes was also addressed in another recent review that looked at the relationship between nutrient intakes and risk of breast cancer mortality in eight large (each including at least 500 participants) observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/15\">",
"       15",
"      </a>",
"      ]. This report demonstrated a trend toward increased mortality with increasing intake of dietary fat, but results were significant in only one report. The study went on to look at the relationship between cancer prognosis intakes of other nutrients, such as protein and fiber. The report failed to show consistent relationships between any of the dietary factors tested and risk of breast cancer recurrence or mortality. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274551217\">",
"    <span class=\"h3\">",
"     Interventional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large-scale randomized trials have examined the impact of dietary modification on disease outcomes in early stage breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women&rsquo;s Interventional Nutrition Study (WINS) randomized 2437 women with stage I-IIIa breast cancer to a low-fat dietary intervention or usual care control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/10\">",
"       10",
"      </a>",
"      ]. Participants randomized to the dietary intervention decreased dietary fat intake and body weight (approximately six pounds) compared to controls. After a median follow up of 5.6 years and 227 relapse events, disease free survival was significantly better in patients randomized to the dietary intervention as compared to controls (HR 0.76, 95% CI 0.60-0.98), although with longer follow-up, the difference was no longer significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/16\">",
"       16",
"      </a>",
"      ]. An exploratory subgroup analysis suggested that improvements in outcome were particularly pronounced in patients with estrogen receptor negative tumors (HR 0.41, p=0.003) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Women&rsquo;s Healthy Eating and Living (WHEL) study looked at the impact of a low fat, high fruit and vegetable diet on disease free survival in 3088 women with stage I-IIIa breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/17\">",
"       17",
"      </a>",
"      ]. Participants randomized to the dietary intervention significantly increased intake of fruits and vegetables and decreased percentage of dietary calories from fat, but did not lose weight compared to controls. After a median follow up of seven years and 518 relapse events, there was no difference in the rate of recurrence in the diet and control groups (16.7 versus 16.9 percent, p=0.63).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason for the differences in outcomes of these studies is not clear. Many experts have attributed the improvements in disease free survival seen in the WINS trial to the weight loss experienced by participants, but this hypothesis has not been tested in the setting of a randomized trial. Given these discrepancies, dietary change has not been widely adopted as a part of the adjuvant treatment of breast cancer patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551142\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an association between dietary fat intake and outcomes for men with prostate cancer. However, the impact of dietary interventions aimed at reducing fat intake on cancer outcomes has not been tested in the setting of large-scale clinical trials. Therefore, as in breast cancer, dietary change has not been uniformly recommended as part of the treatment strategy for men with prostate cancer.",
"   </p>",
"   <p>",
"    A number of reports have evaluated the relationship between dietary factors and prognosis in men with prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A 2008 review of the literature suggested that soy intake or consuming a low-fat, vegan diet may have a favorable impact on prostate specific antigen [PSA] or PSA doubling time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/22\">",
"     22",
"    </a>",
"    ]. Other reviews suggest that high intake of saturated fat may be associated with an increased risk of prostate cancer progression, while a plant-based diet could be linked to a lower risk of progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two prospective observational studies found that prostate cancer patients with higher intake of saturated fat had worse disease-specific survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/24\">",
"     24",
"    </a>",
"    ] or PSA failure after prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/25\">",
"     25",
"    </a>",
"    ]. In one of these studies, higher BMI and higher intake of saturated fat were both independent predictors of biochemical failure, whereas total caloric intake was not associated with prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/25\">",
"     25",
"    </a>",
"    ]. Other notable findings were that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Men who were both obese and consumed a diet high in saturated fat had the shortest biochemical-failure-free-survival (19 months).",
"      <br/>",
"     </li>",
"     <li>",
"      Men who were not obese and who consumed a diet low in saturated fat had the longest biochemical failure-free survival (46 months, p&lt;0.001).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379192846\">",
"    <span class=\"h3\">",
"     Interventional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nine studies have looked at dietary interventions in prostate cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/22\">",
"     22",
"    </a>",
"    ]. These studies have all been too small to draw definitive conclusions, and have focused on decreasing dietary fat, increasing",
"    <span class=\"nowrap\">",
"     tomatoes/lycopene,",
"    </span>",
"    and increasing ingestion of soy products. Examples of these studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Prostate Cancer Lifestyle Trial (PCLT) enrolled 93 patients with early-stage low grade cancer undergoing watchful waiting and then randomly assigned them to treatment with usual care (controls) or to a multifactorial intervention arm that included counseling and group-based support sessions designed to lower fat to ten percent of total calories, consume a plant-based diet, increase exercise, and practice stress management [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/26\">",
"       26",
"      </a>",
"      ]. The main results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At one year, the multifactorial intervention resulted in a decrease in the PSA by four percent while the PSA rose in six percent in those in the control arm (p=0.016).",
"     </li>",
"     <li>",
"      By two years of follow-up, 13 of 49 (27 percent) and 2 of 43 (5 percent) patients in the control and experimental arm experienced disease progression requiring additional treatment (p&lt;0.05) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Men&rsquo;s Eating and Living (MEAL) Study was a feasibility study that tested a telephone-based intervention aimed at increasing the intake of vegetables among 74 men with early-stage prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/28\">",
"       28",
"      </a>",
"      ]. Men in the intervention arm increased daily intakes of total vegetables, cruciferous vegetable, tomato products, and",
"      <span class=\"nowrap\">",
"       beans/legumes",
"      </span>",
"      by 76, 143, 292, and 95 percent, respectively, whereas fat intake decreased by 12 percent (p=0.02).",
"      <br/>",
"      <br/>",
"      A",
"      <a class=\"external\" href=\"file://cancer.gov/clinicaltrials/search/view?cdrid=687958&amp;version=healthprofessional\">",
"       large-scale trial",
"      </a>",
"      testing the impact of this intervention on PSA progression is underway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551150\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that dietary factors may influence outcomes in some patients with colorectal cancer. However, whether changes in diet after a diagnosis of colorectal cancer would be beneficial to colorectal cancer survivors is not known. In addition, many colorectal cancer survivors do not adhere to dietary recommendations. As an example, 84 percent of survivors were not following the American Cancer Society recommendations regarding fruit and vegetable intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data on the role of diet and outcomes for patients with colorectal cancer come from two prospective observational studies specifically evaluating patients with stage III colon cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the dietary status of 1009 patients enrolled in a cooperative group trial was assessed at enrollment, midway through eight months of adjuvant chemotherapy, and 14 months after surgery (six months after completing adjuvant chemotherapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/30\">",
"       30",
"      </a>",
"      ]. Outcomes were analyzed according to the extent to which patients reported following a \"prudent\" diet (high in fruits, vegetables, fish, poultry, whole grains) or a \"Western-style\" diet (increased amounts of red and processed meats, sweets, desserts, refined grains). In multivariate analysis, patients following a Western-style diet had a significantly increased risk of recurrence (HR 2.85, 95% CI 1.75-4.63) and death (HR 2.32, 95% CI 1.36-3.96). The intake of a prudent diet had no on cancer recurrences",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mortality.",
"     </li>",
"     <li>",
"      In a separate follow-up study, the investigators focused on glycemic load and total carbohydrates in these patients&rsquo; diets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients with the highest quintile of dietary glycemic load had a higher risk of recurrence compared to those in the lowest quintile (HR for disease-free survival 1.79, 95% CI 1.29-2.48). A higher glycemic load was also associated with worse disease-free survival among overweight or obese participants (BMI",
"      <span class=\"nowrap\">",
"       &ge;25kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ;",
"      </span>",
"      HR 2.26, 95% CI 1.53-3.32) but not in those patients with a lower BMI. In addition, higher total carbohydrate intakes were associated with lower disease-free and overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although analyses for both studies were controlled for known factors that influence prognosis in stage III colon cancer, these data should be interpreted cautiously because dietary differences may have antedated the diagnosis of cancer, influencing the subsequent natural history of disease.",
"    <br/>",
"   </p>",
"   <p>",
"    Despite this data, a 2006 systematic review on the impact of nutritional interventions and outcomes reported there was no evidence that dietary modification by colorectal cancer patients improved disease outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, there have been no randomized trials have tested the impact of dietary interventions in individuals with early-stage colorectal cancer.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435220049\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported a link better survival and exercise, with most of the data coming from survivors with breast, colorectal, or prostate cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/4,7,33,34\">",
"     4,7,33,34",
"    </a>",
"    ]. In addition, interventional studies have shown a direct effect of exercise on other outcomes, including fatigue and quality of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H7#H7\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2010, the American College of Sports Medicine published a comprehensive review of this topic that included data from 85 randomized trials and concluded that exercise could safely be performed in both the adjuvant and posttreatment settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/33\">",
"     33",
"    </a>",
"    ]. Aside from cancer-specific outcomes, the benefits of exercise included increased flexibility and physical functioning and improvements in patient reported outcomes (eg, quality of life and fatigue) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435224330\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies show that women who participate in a moderate amount of physical activity after diagnosis have significantly better outcomes as compared to less active women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/4,7,36-38\">",
"     4,7,36-38",
"    </a>",
"    ]. For example, the Nurses&rsquo; Health Study that included a cohort of 2987 women diagnosed with stage I-IIIa breast cancer found that after 96 months median follow-up, patients who were active (defined as participating in at least nine",
"    <span class=\"nowrap\">",
"     MET-hours/week",
"    </span>",
"    of physical activity, the equivalent of walking at an average pace for three",
"    <span class=\"nowrap\">",
"     hours/week)",
"    </span>",
"    had a 50 percent lower risk of breast cancer recurrence, death, and all-cause mortality than women who were inactive (engaging in less than a hour of moderate-intensity recreational activity per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dozens of studies have tested the feasibility and potential benefits of increasing exercise after diagnosis in breast cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, none have been large enough to examine the impact of physical activity upon breast cancer outcomes. Still, exercise improves aerobic fitness, strength, quality of life, anxiety, depression, fatigue, body image, body size, and body composition in breast cancer survivors. Although there is no clear consensus on the &ldquo;best&rdquo; type of physical activity, benefits have been seen with a number of types of exercise, and the safety of moderate-intensity exercise for breast cancer survivors has been shown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of upper body strength training on symptoms such as lymphedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention and treatment of lymphedema\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435224718\">",
"    <span class=\"h2\">",
"     Endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether physical activity improves cancer-specific outcomes in women with endometrial cancer is unknown. However, a randomized trial has demonstrated that an exercise intervention is feasible in this population.",
"   </p>",
"   <p>",
"    In the Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED) study, women with a BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    were randomly assigned to a lifestyle intervention (consisting of a six-month education and counselling session) or to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/42\">",
"     42",
"    </a>",
"    ]. Adherence to the intervention arm was 84 percent. In addition, women in the intervention arm reported greater endurance measured by physical activity minutes compared to women in the usual care group (mean difference of 89 minutes at 12 months, p&lt;0.001). Whether this had an impact on survival outcomes requires further follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435224726\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher levels of physical activity may reduce the risk of colorectal cancer-specific and overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/43\">",
"     43",
"    </a>",
"    ], in addition to having a beneficial impact on fatigue, quality of life, and functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2012 systematic review included six studies conducted in colorectal cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/43\">",
"     43",
"    </a>",
"    ]. All examined leisure-time activity, and all but one adjusted for stage, colorectal cancer risk factors, and BMI. Three studies found that higher levels of physical activity after diagnosis were associated with a significantly reduced risk of CRC-specific mortality, ranging from 43 to 61 percent. In addition, all five studies that examined physical activity after a diagnosis of CRC found that postdiagnosis activity was associated with reduced risks of death from any cause; four were statistically significant.",
"   </p>",
"   <p>",
"    Despite these findings, some data suggest that colorectal cancer survivors do not adhere to physical activity guidelines. As an example, 65 percent of colorectal cancer survivors were not following recommendations for physical activity proposed by the American Cancer Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/29\">",
"     29",
"    </a>",
"    ]. The ongoing Colon Health and Lifelong Exercise Change (CHALLENGE) study will evaluate the impact of exercise on disease outcomes for colorectal cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874029399\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the relationship between physical activity patterns and prostate cancer prognosis, although it remains an area of active interest. Two studies illustrate the potential benefits of exercise in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 1455 men with localized prostate cancer, men who walked for at least three",
"      <span class=\"nowrap\">",
"       hours/week",
"      </span>",
"      at a brisk pace had a 57 percent lower rate of disease progression compared to men who walked at an easy pace for less than three",
"      <span class=\"nowrap\">",
"       hours/week",
"      </span>",
"      (HR 0.43; 95% CI: 0.21&ndash;0.91; p=0.03) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report looking at physical activity patterns and outcomes in 2705 men taking part in the Health Professionals Follow-Up Study, men who walked for at least 90 minutes per week at a moderate-to-brisk pace had a 46 percent lower risk of all-cause mortality as compared to men who performed less or slower-paced walking (HR 0.51, 95% CI 0.36-0.72) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435222400\">",
"    <span class=\"h1\">",
"     WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a well-established risk factor for many common cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/51-55\">",
"     51-55",
"    </a>",
"    ], and a number of studies have also linked obesity to an increased risk of cancer recurrence and mortality, especially in patients with breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/56\">",
"     56",
"    </a>",
"    ] and prostate cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The morbidity and mortality associated with being overweight or obese have been known to the medical profession for more than 2000 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/58\">",
"     58",
"    </a>",
"    ]. Overweight refers to a weight above the \"normal\" range, which is determined by calculating the body mass index (BMI, defined as the weight in kilograms divided by height in meters squared). Overweight is defined as a BMI of 25 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    obesity as a BMI of &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435223121\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity at diagnosis appears to be a risk factor for worse outcomes after a diagnosis of breast cancer. However, the impact of weight gain following diagnosis and the influence of interventions aimed at weight loss on outcomes require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379192897\">",
"    <span class=\"h3\">",
"     Weight at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher weight at diagnosis appears to predict worse survival outcomes for patients diagnosed with breast cancer, although the reasons for this are not clear. This was shown in a 2010 meta-analysis of 43 studies, which found that women who were obese at diagnosis had a 30 percent higher risk of breast cancer-related and overall mortality as compared to leaner women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/56\">",
"     56",
"    </a>",
"    ]. Other important findings of this meta-analysis were that the association between obesity and poorer outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was seen in both premenopausal and postmenopausal women (HR for risk of death in obese versus non-obese individuals 1.47 in premenopausal and 1.22 in postmenopausal women, p=0.25 for comparison).",
"     </li>",
"     <li>",
"      Was independent of the type of study performed (observational versus treatment trial), year of study report (prior to or after 1995), and type of weight measurement (BMI versus weight).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear if the association reflects a causal relationship because these studies often did not take treatment factors into consideration, which may have impacted cancer specific survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/56\">",
"     56",
"    </a>",
"    ]. For example, obese patients may have received relatively lower doses of chemotherapy (eg, chemotherapy dosed using ideal rather than actual body weight) due to concerns of excessive toxicity with high drug doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. This is important because treating obese patients with lower doses of chemotherapy is associated with an increased risk of cancer recurrence in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], leading the American Society of Clinical Oncology to develop guidelines recommending the use of full, weight-based doses of chemotherapy for obese individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these concerns, it is notable that a number of more contemporary studies (in which dosing was taken into account) reporting the relationship between weight at diagnosis and breast cancer prognosis for women treated on adjuvant clinical trials continue to show an adverse impact on survival associated with obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who had a BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      had a 60 percent higher risk of recurrence as compared to women with a BMI &lt;25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       Anastrozole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      , Alone or in Combination (ATAC) trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/62\">",
"       62",
"      </a>",
"      ]. A similar result was noted among obese premenopausal women treated with ovarian suppression and anastrozole in the Austrian Breast Cancer Study Group 12 study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H72864709#H72864709\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Obese women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obese women with hormone receptor-positive tumors treated with chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and a taxane) in the Eastern Cooperative Oncology Group 1199 trial had a 20 percent higher risk of recurrence as compared to leaner women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H2719278#H2719278\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Obese women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379192905\">",
"    <span class=\"h3\">",
"     Weight after diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain after a breast cancer diagnosis may be associated with an increased risk of recurrence, although the available data do not consistently report this association. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nurses&rsquo; Health Study (NHS), non-smoking women previously treated for breast cancer who gained 0.5 to 2",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and women who gained more than 2",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      had a significantly increased risk of breast cancer death compared to women who maintained a stable weight (RR 1.35, 95% CI 0.93-1.95; RR 1.64, 95% CI 1.07-2.51, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a combined analysis of 3215 women from the Life After Cancer Epidemiology (LACE) cohort and the Women&rsquo;s Healthy Eating and Living (WHEL) Study control group, weight gain after diagnosis was not associated with an increased risk of recurrence, even in individuals who gained &gt;10 percent of body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23452002\">",
"    <span class=\"h3\">",
"     Interventional studies evaluating weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the abundant data linking obesity and poor prognosis in early breast cancer, there have been relatively few studies evaluating the efficacy and potential benefits of weight loss interventions in breast cancer survivors. A few small trials have demonstrated that weight loss programs can successfully be implemented in breast cancer survivors and that weight loss can be achieved through a number of different approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. However, more research is needed to determine whether purposeful weight loss after breast cancer diagnosis leads to improvements in the risks of breast cancer recurrence and related mortality.",
"   </p>",
"   <p>",
"    The largest weight loss study to date in breast cancer survivors has been the Lifestyle Intervention Study for Adjuvant Treatment of Early Breast Cancer (LISA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/73\">",
"     73",
"    </a>",
"    ]. In the LISA study, 338 postmenopausal women with hormone receptor-positive breast cancer were randomly assigned to a telephone-based weight loss intervention or to usual care. LISA demonstrated that women randomized to the intervention lost approximately 4.5 kg more than the control group at 6, 12, and 18 months and also reported significant improvements in physical functioning scores as compared to control participants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435223568\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with worse outcomes among men with prostate cancer. &nbsp;However, whether changes in weight following a diagnosis of prostate cancer can modify prognosis is unknown and is an area of active investigation.",
"   </p>",
"   <p>",
"    As illustrated by the following studies, compared to leaner men, obese men are at a greater risk for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More aggressive disease &mdash; A study of 1866 men undergoing prostate biopsy showed that the risk of a high grade prostate cancer (ie, Gleason score &ge;7) increased with an increasing BMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/74\">",
"       74",
"      </a>",
"      ]. However, there was no relationship between BMI and incidence of lower grade prostate cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More advanced disease &mdash; A 2012 meta-analysis demonstrated a linear relationship between BMI and incidence of advanced prostate cancer (RR 1.09, 95% CI 1.02-1.16 for each 5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      increase) and an inverse relationship between BMI and the development of localized prostate cancer (RR 0.94, 95% CI 0.91-0.94 for each 5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      increase in BMI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less responsive disease &mdash; A report of 287 men treated with radical prostatectomy followed by androgen deprivation therapy demonstrated an increased risk for distant metastasis (p=0.027) and a trend toward an increased risk of prostate-specific mortality (p=0.119) in men with a higher BMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/75\">",
"       75",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Higher mortality &mdash; A 2011 meta-analysis of 22 reports demonstrated a 20 percent increase in the risk of prostate-specific mortality (relative risk [RR] 1.20, 95% CI 0.99-1.46) and a 21 percent increase in the risk of biochemical progression (RR 1.21; 95% CI 1.11-1.31) for each 5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      increase in BMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/57\">",
"       57",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435223722\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with colorectal cancer, obesity may be associated with an increased cancer specific mortality risk. However, whether purposeful weight loss provides a benefit in survival outcomes is unknown.",
"   </p>",
"   <p>",
"    In the Cancer Prevention Study-II Nutrition study, patients diagnosed with non-metastatic colorectal cancer who had a high pre-diagnosis body mass index (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    had significantly poorer overall, cancer-specific, and cardiovascular-specific survival relative to those with a normal BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/76\">",
"     76",
"    </a>",
"    ]. However, there was no association between postdiagnosis BMI and outcomes, which is consistent with the findings of at least one other study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/77\">",
"     77",
"    </a>",
"    ]. In contrast, another study demonstrated that stage II and III colon cancer patients with BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    after surgery had a statistically significant 38 percent worse disease-free survival compared to normal weight patients (BMI 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435223974\">",
"    <span class=\"h2\">",
"     Endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although obesity is associated with less aggressive histologic types of endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/79\">",
"     79",
"    </a>",
"    ], it is associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/51,79\">",
"     51,79",
"    </a>",
"    ]. As in other cancer types, whether purposeful weight loss after endometrial cancer can improve outcomes is unknown and is a topic of continued investigation.",
"   </p>",
"   <p>",
"    In one study, obese women (&ge;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    who developed endometrial cancer were more likely to have a less aggressive histologic subtype than women with a BMI &lt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/79\">",
"     79",
"    </a>",
"    ]. This is likely due to the greater likelihood of developing an estrogen-responsive tumor in women with a higher level of circulating estrogen. Accordingly, severely obese women were also more likely to present with stage I disease (77 versus 61 percent) or low grade tumors (44 versus 24 percent).",
"   </p>",
"   <p>",
"    Despite this, among women with endometrial carcinoma, obesity is associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/80\">",
"     80",
"    </a>",
"    ]. The magnitude of this risk was illustrated in a prospective cohort study of 495,477 women followed for 16 years in the Cancer Prevention Study II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/51\">",
"     51",
"    </a>",
"    ]. The risk of dying from endometrial carcinoma among those with the highest BMI (&ge;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was 6.25-fold higher than that of normal weight women (BMI 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102010331\">",
"    <span class=\"h1\">",
"     CLINICAL LIFESTYLE RECOMMENDATIONS FOR CANCER SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Cancer Society and the American College of Sports Medicine have developed nutrition and physical activity guidelines for cancer survivors based on the available evidence linking diet, weight, and physical activity to cancer outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/19/43321/abstract/33,75\">",
"     33,75",
"    </a>",
"    ]. Key points of these recommendations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain a healthy weight and attempt weight loss if overweight or obese",
"     </li>",
"     <li>",
"      Adopt a physically active lifestyle engaging in at least 30 minutes of moderate to vigorous physical activity on five or more days of the week",
"     </li>",
"     <li>",
"      Consume a healthy diet, with at least five servings of fruits and vegetables per day and limited ingestion of processed foods and red meats",
"     </li>",
"     <li>",
"      Limit alcohol to no more than one",
"      <span class=\"nowrap\">",
"       drink/day",
"      </span>",
"      for women and two",
"      <span class=\"nowrap\">",
"       drinks/day",
"      </span>",
"      for men (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link\">",
"       \"Overview of the risks and benefits of alcohol consumption\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102010488\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With advances in early detection and treatments for cancer, there are over 25 million people alive with a history of cancer. Novel methods to improve outcomes, especially those that are also associated with improvements in quality of life and other health benefits, may offer attractive additions to the currently available treatment options. (See",
"      <a class=\"local\" href=\"#H86925732\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diet, physical activity, and weight are collectively considered energy balance factors because they describe the relationship between energy consumed (diet), energy expended (physical activity), and energy stored (adiposity). They have each been linked to cancer outcomes, particularly in survivors with breast, colon, endometrial, and prostate cancer. (See",
"      <a class=\"local\" href=\"#H86925732\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary intakes have been linked to outcomes in some cancers. However, there are few randomized trials testing the impact of dietary change on cancer outcomes. The WINS trial demonstrated a 24 percent reduction in breast cancer recurrence in women randomized to a low-fat dietary intervention, but the WHEL trial showed no impact of a low",
"      <span class=\"nowrap\">",
"       fat/high",
"      </span>",
"      fruit and vegetable diet upon prognosis in a similar group of breast cancer survivors. Further prospective evaluation is needed. (See",
"      <a class=\"local\" href=\"#H435221609\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Observational studies have shown an association between physical activity patterns after cancer diagnosis and prognosis in individuals diagnosed with early stage cancers of the breast, colon, and prostate. However, there are no data from randomized trials to date testing the impact of increased physical activity on rates of cancer recurrence or mortality. (See",
"      <a class=\"local\" href=\"#H435220049\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple interventional studies have evaluated the safety, feasibility, and benefits of exercise in cancer survivors. The benefits include a reduction in fatigue, improvement in quality of life, and improvements in fitness and physical functioning. (See",
"      <a class=\"local\" href=\"#H435220049\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity (defined as a body mass index [BMI] &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      is associated with an increased risk of developing most common cancers. Obesity at diagnosis is also associated with an increased mortality risk in women with early-stage breast cancer as well as potentially men with prostate cancer and individuals with colorectal cancer. (See",
"      <a class=\"local\" href=\"#H435222400\">",
"       'Weight'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The American Cancer Society and the American College of Sports Medicine have developed energy balance guidelines for cancer survivors that recommend maintaining a healthy weight; adopting a physically active lifestyle (ie, engaging in at least 30 minutes of moderate to vigorous physical activity on five or more days of the week), and eating a healthy diet rich in plant sources. (See",
"      <a class=\"local\" href=\"#H102010331\">",
"       'Clinical lifestyle recommendations for cancer survivors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/1\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/2\">",
"      Parkin DM, Fern&aacute;ndez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006; 12 Suppl 1:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/3\">",
"      Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol 2009; 472:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/4\">",
"      Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/5\">",
"      Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128.",
"     </a>",
"    </li>",
"    <li>",
"     Goodwin P. Energy balance and cancer prognosis. In: Cancer Prevention and Management Through Exercise and Weight Control, McTiernan A.  (Ed), Taylor and Francis, Boca Raton, FL 2006. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/7\">",
"      Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/8\">",
"      Galv&atilde;o DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005; 23:899.",
"     </a>",
"    </li>",
"    <li>",
"     Segal R, Pond GR, Vallis M, et al. Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. J Clin Oncol 29: 2011 (suppl; abstr 512).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/10\">",
"      Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006; 98:1767.",
"     </a>",
"    </li>",
"    <li>",
"     Willett WC. Nutritional Epidemiology, 2nd ed, Oxford University Press, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/12\">",
"      Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002; 20:3302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/13\">",
"      Goodwin PJ, Ennis M, Pritchard KI, et al. Diet and breast cancer: evidence that extremes in diet are associated with poor survival. J Clin Oncol 2003; 21:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/14\">",
"      Berrino F, Krogh V, Riboli E. Epidemiology studies on diet and cancer. Tumori 2003; 89:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/15\">",
"      Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas 2010; 66:5.",
"     </a>",
"    </li>",
"    <li>",
"     Chlebowski R, Blackburn G, Elashoff R, et al. Mature analysis from the women&rsquo;s intervention nutrition study (WINS) evaluating dietary fat reduction and breast cancer outcome, San Antonio Breast Cancer Symposium. San Antonio, TX, 2006",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/17\">",
"      Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007; 298:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/18\">",
"      Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/19\">",
"      Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 2011; 105 Suppl 1:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/20\">",
"      Berkow SE, Barnard ND, Saxe GA, Ankerberg-Nobis T. Diet and survival after prostate cancer diagnosis. Nutr Rev 2007; 65:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/21\">",
"      Hori S, Butler E, McLoughlin J. Prostate cancer and diet: food for thought? BJU Int 2011; 107:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/22\">",
"      Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J Urol 2008; 180:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/23\">",
"      Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008; 17:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/24\">",
"      Meyer F, Bairati I, Shadmani R, et al. Dietary fat and prostate cancer survival. Cancer Causes Control 1999; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/25\">",
"      Strom SS, Yamamura Y, Flores-Sandoval FN, et al. Prostate cancer in Mexican-Americans: identification of risk factors. Prostate 2008; 68:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/26\">",
"      Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/27\">",
"      Frattaroli J, Weidner G, Dnistrian AM, et al. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology 2008; 72:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/28\">",
"      Parsons JK, Newman V, Mohler JL, et al. The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology 2008; 72:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/29\">",
"      Blanchard CM, Courneya KS, Stein K, American Cancer Society's SCS-II. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol 2008; 26:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/30\">",
"      Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007; 298:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/31\">",
"      Meyerhardt JA, Sato K, Niedzwiecki D, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst 2012; 104:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/32\">",
"      Davies AA, Davey Smith G, Harbord R, et al. Nutritional interventions and outcome in patients with cancer or preinvasive lesions: systematic review. J Natl Cancer Inst 2006; 98:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/33\">",
"      Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/34\">",
"      Mishra SI, Scherer RW, Snyder C, et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012; 8:CD008465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/35\">",
"      Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2006; :CD005001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/36\">",
"      Irwin ML, Smith AW, McTiernan A, et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 2008; 26:3958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/37\">",
"      Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007; 25:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/38\">",
"      Chen X, Lu W, Zheng W, et al. Exercise after diagnosis of breast cancer in association with survival. Cancer Prev Res (Phila) 2011; 4:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/39\">",
"      McNeely ML, Campbell KL, Rowe BH, et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 2006; 175:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/40\">",
"      Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Recent Results Cancer Res 2011; 186:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/41\">",
"      Maruti SS, Willett WC, Feskanich D, et al. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst 2008; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/42\">",
"      von Gruenigen V, Frasure H, Kavanagh MB, et al. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol 2012; 125:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/43\">",
"      Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/44\">",
"      Lynch BM, Cerin E, Owen N, et al. Prospective relationships of physical activity with quality of life among colorectal cancer survivors. J Clin Oncol 2008; 26:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/45\">",
"      Peddle CJ, Au HJ, Courneya KS. Associations between exercise, quality of life, and fatigue in colorectal cancer survivors. Dis Colon Rectum 2008; 51:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/46\">",
"      Morey MC, Snyder DC, Sloane R, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA 2009; 301:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/47\">",
"      Buffart LM, Thong MS, Schep G, et al. Self-reported physical activity: its correlates and relationship with health-related quality of life in a large cohort of colorectal cancer survivors. PLoS One 2012; 7:e36164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/48\">",
"      Courneya KS, Booth CM, Gill S, et al. The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol 2008; 15:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/49\">",
"      Richman EL, Kenfield SA, Stampfer MJ, et al. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 2011; 71:3889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/50\">",
"      Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011; 29:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/51\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/52\">",
"      Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011; 47:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/53\">",
"      Kant P, Hull MA. Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol 2011; 8:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/54\">",
"      Anderson GL, Neuhouser ML. Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res (Phila) 2012; 5:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/55\">",
"      Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/56\">",
"      Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/57\">",
"      Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011; 4:486.",
"     </a>",
"    </li>",
"    <li>",
"     Bray GA. The Battle of the Bulge: A History of Obesity Research, Dorrance, Pittsburgh 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/59\">",
"      Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/60\">",
"      Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/61\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/62\">",
"      Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/63\">",
"      Pfeiler G, K&ouml;nigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29:2653.",
"     </a>",
"    </li>",
"    <li>",
"     Hepp P, Rack B, Annecke K, et al. Multivariate Analysis of Obesity and Disease Free Survival in Patients with Nodal Positive Primary Breast Cancer &ndash; The ADEBAR Trial, San Antonio Breast Cancer Symposium. San Antonio, TX, 2010",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/65\">",
"      Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012; 118:5937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/66\">",
"      Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005; 23:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/67\">",
"      Caan BJ, Emond JA, Natarajan L, et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 2006; 99:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/68\">",
"      Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer 2007; 109:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/69\">",
"      Djuric Z, DiLaura NM, Jenkins I, et al. Combining weight-loss counseling with the weight watchers plan for obese breast cancer survivors. Obes Res 2002; 10:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/70\">",
"      Goodwin P, Esplen MJ, Butler K, et al. Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Res Treat 1998; 48:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/71\">",
"      Mefferd K, Nichols JF, Pakiz B, Rock CL. A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors. Breast Cancer Res Treat 2007; 104:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/72\">",
"      Pakiz B, Flatt SW, Bardwell WA, et al. Effects of a weight loss intervention on body mass, fitness, and inflammatory biomarkers in overweight or obese breast cancer survivors. Int J Behav Med 2011; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     Segal R, Pond G, Vallis M, et al. Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results (abstract #512). J Clin Oncol 2011; 29:512.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/74\">",
"      Fowke JH, Motley SS, Concepcion RS, et al. Obesity, body composition, and prostate cancer. BMC Cancer 2012; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/75\">",
"      Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/76\">",
"      Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/77\">",
"      Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008; 26:4109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/78\">",
"      Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006; 98:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/79\">",
"      Everett E, Tamimi H, Greer B, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003; 90:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/19/43321/abstract/80\">",
"      Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009; 114:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14222 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43321=[""].join("\n");
var outline_f42_19_43321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H102010488\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86925732\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271204397\">",
"      ENERGY BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271204412\">",
"      Role in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435221609\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457684783\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274551217\">",
"      - Interventional studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551142\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H379192846\">",
"      - Interventional studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551150\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435220049\">",
"      PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435224330\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435224718\">",
"      Endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435224726\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H874029399\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435222400\">",
"      WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435223121\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H379192897\">",
"      - Weight at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H379192905\">",
"      - Weight after diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23452002\">",
"      - Interventional studies evaluating weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435223568\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435223722\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435223974\">",
"      Endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102010331\">",
"      CLINICAL LIFESTYLE RECOMMENDATIONS FOR CANCER SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102010488\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9161?source=related_link\">",
"      Physical activity and exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_19_43322="Intermediate case 1";
var content_f42_19_43322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1212px;\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Intermediate case 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFRAlIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2S80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TVLl1PqZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP8A892xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/AMSzT/8AWJ/zDCf+WzD8PTHcfL1FVba7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/wASzT/9Yn/MMJ/5bMPw9Mdx8vUVVtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/AKPJ/rE/5g85/wCWzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/nu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/wBHk/1if8wec/8ALZh6cccY7j5eoqpY3dsljcA2753Xxyukz/8APdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNC5dSZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/APWJ/wAwwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUULlKqutd2cunR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/AOe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmqltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/wAWMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8SzT/APWJ/wAwwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/892xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1cZ8Wb5FvvBaWgeFpPFtjE2LOS1LIyEMvzAZUgkFffnhhXZ3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0ofKctGtVlOULy92L/ABXoSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ03y3N063vay2XR9/QtJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NW0vbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/+e7Y5xwR6/wdDzR7twTrWest10fZ+Qa3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulC5bgnW5VrLeXR+XkR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TXndxrNwf2jbbTjJIdIXS/tAtP7Ok2iTDru8jG/OCf59BXolte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUyVSrOneLlorbdm/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6iqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq5b3NtLO8awMGaaNRv0mZQMzsOSRhR9e3y9jQuU0qusm3eXTo+y8jxnxIiReItUjjRUjW6lVVRNgUBzgBf4R7dqKPEhVvEWqFBtU3UpA8sx4G8/wnlfoeRRXG9z9Bofwo37L8j2u+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOa4fxLqN7b/Fz4Z2cE95HaXMF6Z7eO4nVJ9luShYAZOCSRgEDJweTXW3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12J7n5vVoSlTS8l1Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf8APZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mmmaVaTu9O3Vdl5hp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/wB3t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6aKk/bJ2+0+q7vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/j/ADx51xn/AI9ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DGnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9S1SfvadF1Xf1NdGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIqnp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGhLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqJUnZ6dV1XZ+Za15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4z7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05qS2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaE9yZUnyLT7Pdd35has39pS/upj/olj/wAtZv8AnrL/ALPftjgfw5NY/j/xE3hnwzfaiiyxyiaGON3WaWNGa4YAvlo1VeSNzyIAec7jtp9hrBk8QXmn+TCt/DZafIQ2ousRjMkvIbbncCDlduFxkHPFaqXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mhMU4+0vyeS3XRLzPAr/AMZeJpPC2heJ7WK7lXxTYXuhpZW+oS28Vrfy3TlLlNxIYnkY7bBufJrL8Saj4k03xF4p0W51vWJYLCKwtG1mXUblILFjGhkeS3BIcTsjIfM+UO43MM5r6Hsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mp+yQsFN1Fd3fN3Xn56XNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/AI/zx51xn/j1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNU3oaU6Ttt9l9V29TQtmbzrP91Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyaLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzQ3qWqT97Touq7+prox3S/upv9Yn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0JcXm6X91p/+sT/AJi0o/5bMf8AnnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUSpOz06rquz8y1rzN/YWp/upv+PS86yzev8Au9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUFSfKtOsuq8vMnvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTQmVVpO707dV2XmGns32C4/dTD57/wD5azf8929V7d88H+LBo15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7poqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUF9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Vl+LdefQrU6veQW0lvZXElyyW+qyu7qtpITj5B2z83r8vTmnJqxjCm0rv8Alf2l29TR1W1udR0iWysp7mxuriy8mG7jectC7RShZFAAOQTuAU9uDgkjyn4Rajr3irVdRlvZtT0z+xdLtvDtxGt89yZrxJSWus7WQOuCAGVhl+C2CD6lo+pT3tvpd3BHYeTNbwyqX1WVCAY3Iz+7yp5HHbOP4jUdtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNDauiHh+eXP2S6rXX1OZ+A+o3up/CrRbzUp72+u5SxkuJrid3ci8lAJODnpgc8Y4yciux09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDQlxebpf3Wn/AOsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1RdOhKMOXzXVdn5lrXmb+wtT/dTf8AHpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5rI1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elCepSpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaEyqtJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX900VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qC+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9OabehjTpO232X1Xb1NC2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJotri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzQ3qWqT97Touq7+prox3S/upv8AWJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDQlxebpf3Wn/AOsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1EqTs9Oq6rs/Mta8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVy+Ylbj91MMyN1lmOP3Puv48844+7zWRrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KE9QVJ8q06y6ry8ye+dv7V079xP8A8f54864z/wAesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuTKk+RafZ7ru/Moapa3Oo2urWNlPc2F1c6XbQw3cck5aB2aYLIAAOQSCACMEfKc15P4D1rx1qNrrWp21hfXGpaBYw6B/ZlxqLyJeailxukuHIIAZQeQTltx2vmvT/wC2/s3iS106VbMXt7ZW7xINRm27YpG3ksI8KR5i8HG3OVzzjYS4vN0v7rT/APWJ/wAxaUf8tmP/ADz545z2HzdTQmRWoupK8Xtbquy8+h5v8B9S1u70jxZbeIW1S6u7PVL2Jrm6lIG4iMvGERmCFWyzKPkzIMMa9I15m/sLU/3U3/HpedZZvX/d7d88H+LBqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NK/umtHDypzjF62l3Xn5nn/AMebp4/Evw/jVZo2PiKGYbnduVEX98Dnn64PpjPqV87f2rp37if/AI/zx51xn/j1k4+7nPfPXHGMc1498bLuc/Er4XxTLaqra8rhob17jo9qOrKOOTz36fw16teXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNDZy4eDdWcbbLuv5fU0LZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmi2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc029TrVJ+9p0XVd/U10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaEuLzdL+60/wD1if8AMWlH/LZj/wA8+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKL6iVJ2enVdV2fmWteZv7C1P91N/x6XnWWb1/wB3t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msjW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6gqT5Vp1l1Xl5nm9y0Z/artWRJDINEw6ebMWBy/GdgccbT0P1xwPVLZm86z/AHUx/dx9JZhn5JOmF4/DI4OOCceG6Xczt+1vrLHySUskAD3rrGP9GiOBLgtjk4OOfQZr2a2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaUXuc1GDlSuuz6rvLzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTTTOmrSd3p26rsvM8c8T8+JdWJBH+lzcEkkfOe55/Pmik8SEt4i1Qtt3G6lJ2SGRfvnoxALD3I5orje5+h4f+FH0X5Htd9cy/wBq6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFdae+h+cSjDkWsfh8+78iC1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v8ApkIzIh/16c/vmOfuevP0OeQcDPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMU0/IqrGF3rHp37LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KjsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u0r+7saKMPbLWPxPv3fkaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzRqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrQ3psYwjC28fhfft6Fi2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKntLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYpt67FKMPe1jsu/wDN6Ggk8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pSXnn6fZ6he3mq6rFa2oE88hW1wiJNIzMfk7YJ47g54xUGkLcXmifa7bUtTa1uI72aJ1FsVkjeUsHB2cqwIYkdc/LxRfXYEqdmrx3Xfs/Isa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681Q160vU0bU86hqkiLaX2QVttrDdznCA49cYP92rWo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3oT12BRhyx1jvLv5eQX1zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99CZRhyLWPw+fd+Rxmju5+LmsSC4jXZo2nISZQB/rpCBnaRxjnjjB64Oe4SeTdL/pkIzIh/wBenP75jn7nrz9DnkHA4Lw7Hcy/FPxFGt3e+bDpulJ5iLD5mC7sAcrtxyMcZ+7nvXcR2l9vn/4mOrf62POFtev2h+vydc59s5zximn5GFGMLSu18Xn39CDT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSo7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tK/u7Haow9stY/E+/d+RoX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv8Aaunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzRqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tDemxjCMLbx+F9+3oWLaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0qe0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxim3rsUow97WOy7/wA3oaCTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6VPHaX2+f8A4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4ovrsCjCz1juu/Z+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzWfrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvQnrsCjDlWsd5d/LyC+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCK95a341awBv8AVyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziknvoTKMORax+Hz7vyILWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8/8AxMdW/wBbHnC2vX7Q/X5Ouc+2c54xTT8iqsYXesenfsvIg0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Sv7uxoow9stY/E+/d+RoX08jLcZvIXzIx4nQ5/c4zwgzxx254681xfxsmeTwHrKvcRT7luPlWZWyfsUgDcKOnr04xjvXX6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeuH+Oy3lr8P8AWZJbvUJRvkXFwsG0E2rjPyKDux+GPeiT02OblhyOzj8Mu/b0Ou8MNNb6RoUT3sQkisrZCTOnykROMElOMcjnPUdcgh9rPINSlAvIRi0sRjz04xLLgfc7dT6d93SprOxvo5rBFv8AVVKxRKqottwAkuAu5OnXG7nGc84qra2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKG9tCqMYcj1jtHv3XkaCTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6VPHaX2+f/AImOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4p312LUYWesd137PyJNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaz9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3aV/d2NFGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/5vQ0Enk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8UX12BRhZ6x3Xfs/Ik16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rP1y1vV0TUma/wBVZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935HC61Ix+Mfg5jPGSmkTAMJFITEkXBO3jHuDj3rv0nk3S/wCmQjMiH/Xpz++Y5+568/Q55BwPP9Wtblvi94QQ3V60i6NK6yMId6jzYQNuF24z03DPPNd3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5GFKMPfu18Xn5eRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92lf3djtUYe2Wsfiffu/I8r+PUpf4m/ClpJVl/4nhJdHDA/PZ9CAB29BXr99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM815j8XLSCX4heC11K7ma8t79J7Y3LRrIZGu9NTaAgCn5DIcDJwCe1el3lrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD60mzzsKo+1qXa+H9OmmxBquvW+gaX/AGtqeoRwWVlbxvLIJA2wbXUDAjJzlguME5YDnIIo+Fdfg11P7Q0+8xbSW1rGomPlMDHcTIQVaMEbWVs+nXLdK5/xLa3Gr/EPwL4fmu7y5t44TrM8LCEOpgUrbum0AbRJITh8g7OQelU/hBa3dvdeLdKS6u4hp+pxqn2fyTujllaeMt5inBxLxjjOc5FNvXY1jUi6ko+7bRX87p9vXp0PSUnk3S/6ZCMyIf8AXpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767HQows9Y7rv2fkSa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681n65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x70J67Aow5VrHeXfy8jwLwXftd/tb+ILlbqPcqzxecZQFyiIn3ipH8OPu/TFfQdnJM1xZLHdR7/LjC4mX5cJJx9w4xkjHOMjrkEfPfwoXUbn9onxc8kl88o1G5jN2I4mmXa06qu9lKDKoRtHBC8D5Rj3+zsb1pLMjU9UBSGEqAlrlvlkAC5T3JGewbPOKUXvoclJR9hq1t19ZeWxRXUY7XWIILjUraGW8t7SK2je4RTKySOWVQU5KBlJAyVDAnOQK0knk3S/6ZCMyIf8AXpz++Y5+568/Q55BwPA/E2jJ8QPCvi7xbcajdynRrTydDkwoWOKByzTgoQCZJI5Y1IUEKoLdQa9j8J3F/rfhrTdVN/qim/t7W7IRbXA8yQuOqerce+c8YpplRqKpOXNZbW312V9vR9N0eU+JyW8S6sxYOTdzEsCCD855yAM/kKKPE4ZfEurLI0jOLuUM0m3cTvPJ28Z+nHpRXE9z9Ow/8KPovyPar6xX+1dPX7LP/wAf5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKz7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JrtTep+dSceRav4f5fN+YWtoDqUp+zzHNpYnISHndLKO/r27n+LiuD+NN4dKt/DIjeS2M3iKzRidinYJZSeV7fIAe34AV2NtpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwK8Y/aVmi0m98JQ2ltb29ub57yYx2/kr+6lCqWGO3mkdQB06ild2Zlj2vZys+3TyXme5afaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKx9Q/4R3QdEub3xBHpOn2yteDzrrTynWVjGFzySVHygAkDgA1wOqLL8Q7C/l8O20WgeHNOWW6i1aLT2SfUzsDhI0IHlxLu5ds9UA/iou+WxrKvCNZKLbfM9Leb8/xPYr6zCLcf6PMu2RhykIx+53dvz44x/tVFfWK/2rp6/ZZ/+P8AK48u3z/x6yHHpnv6Y9685+GWoQ6tY6joPiSx03/hL9JuJYruIacqPKgQhJlVQMIcp/CPmIbviu9u9G08ajZlNLsfL+2EyY0ltuz7O45H93fjj+9g023YmlVptXUvsv7Pl6l62tFaazH2eY7o4zgJDzlJDxn6d+eDnnFU7W0B1KU/Z5jm0sTkJDzullHf17dz/FxVYW2g291ax3NtpETrGm9ZLAZBCuDkd+SuT3JU9q5DWvGPgDw/cXLanfaBmKG0iNvFZiaUSB5C4KKScgAbiQARtHHFDbuU6lOKk3Lounn6mv8AFi5g0f4ZeMbqeGVU+wS2wJSL5WmeSFc7RkcsBx6H+HFXPh9bB/hn4WkMEhJ0GJtwSLHEMfPPOB+fpXEfFZ/DOvfDLWotCudDmkuZ7SCOWzt1JUveDoyn5flz9QMdjWf4V8feGYvBmgWa6Jc63e22kw291LYaMbkRSeVGAHkyMsowMjO3OMHsXdzhdWnHE8zlpbt/wfxPXtY09pdH1COG0uHka1uwqrHCSSDgYAGeOnHP93imQ3Om6paXVxpM8V5Ak7xmW3e3kVWEOSpKZwR1wO3+1XlN1o2ueN7TUr+6tD4T8Lpazy2trbWKR3t6oGT5rrkxIclSobplTwQSa94WsPhh4lfXNM0hJvB89uLTU4Tas5s5FQCO4VXO4/e+YAsRhnweABSdzf270f2LvW2vTpfbbr8j2G604PqdkPs8iql6chltwT/oz/KB3OSDgcY56gkOtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xXm9/8Q/hml1ZyQ6locoa480RQaRJI0qGErt2qpx8xB2tjkE9sUweN/DzbP7M8Ianqc8USfuYPDbku3K4O7Az8wOTgHb6gBkm9RvE0eVL2nTt6+Zc8KRiX4teL0MMh2WWkjG2Mn5tx78YO768jPeu+W0XdNm3mwJEH3IOP3zD+mOOMjn5cV84R6d4k1PxR4y1eGKHQNW0mytLqPRY4kvIJwEfbHKANpdgCQwGMyds12XizULHxPoHhTS/D1lYwTeMnUGa3tU8y1tlLSXOxuR5iKQpA5/hHK01JnPTrwjGbu977b6+p1kPjLwdaRz28/iHSEn8y64+2WhwWlZkyQeODz3HQYo1Pxp4NutKvoYPEejGWS3uFQG9s1yzfc53e/PcdsDNXvD3hbQ9P8NjT7fSdPNtAt3CofTCWYJKVUsx6tgD5jyO+Sak8R+GdBl0nUJ5dD0h5o7O6CSNpA3KF4XDEcYAAB/gAxRrynTGWI9qr2vzdnvqU5fHngmczLB4i0rdvO0Nc2q5HlkDof73p2560/wAXeKvDWgaroq6pdSIbm8ZoUgto7h3T7ORkLErE/M69Bjn1BrY1nw/o13a3MF1o+lzQ+Yf3b6T8vEJI4PA55x2PzdKwtG+Hnhbwxr0M2iaTDA13dG3mD21xKrR+Q8mzY7kBd4Vtvqqt0AobdjOnKt5bPo9rEVt8RPBhs7W+k1KVLM3K6eXexKk3IVsptaPI6rywA65OQK6i3ssapMGtpw32SxzmOHqZZQevPPbPP97ivnvw74bHi74hjR9Zthc6WNe1m4vECu5dAkRjZthDffuODkdfrXeXHwl0W0S5PhH7Vo+pRWUcsBiEssUss29MSpN5iMo2ggqASfunIFDbFTrVXzWV1on96/rc9TS0BaX/AEeY4kQfch4zMw/pjjjI5+XFcvP4i8NaK1zY6vq9hYXyyXe63ubi1jkXdKzISpIIBXnPoRt4Nctpni3TE8DeJL7X9D0zT/Efh+PbqGnSWiL+/DEpsflQkhKqpOc/dG7ALafwx8GafpngtJNTs7e81q+huZdSubvTy8ss/mAsCxJyFYYB4AxkgFjRdtlPEOelHW7vqn29X5/cXtT8YeDrrSLqODxJohkntbgRhr+yXlvuA/Nx156EdsDNXdQ8XeEYmdDr+ko7sWjDXloMr5WBjB/vHtx6fNUeueD/AAymi6k6eHNDVxaXh3Loqg5B4OccEY4P8PQ1Yu/BPhWKG6SPwxoKKzMhC6KqZHk5wTj15wehAboKavcalX5Vt16PyLniC503TIrbVdQfyNLt7vzJblxb+WiNbsFJPTlmUDsdwx8xFc9p3xF8GXXh+51+LUmbSdNMMV5L9lUMjuGC4jZNzAllwcHOGz93iO3+Fvg7SvEun3dposBb7a6LFPbTzQoDA8h2xOxUfMAQAMjAI4rhfGkdi/jXWdKvYYDHrN34eiKCLy/NJmcvkBTvYgPksRnrk8KVdoxr16tOnFtLZd/P0PYNJFtfXH2q0Vp7eaysXSWMQMrhpZRkHuD27/3uK0ktAWl/0eY4kQfch4zMw/pjjjI5+XFeXw/CPRrW4uYvDeo6voO61t5DHaiSWGWSR3AMscu9ZApUEAYz0BBq98MbxdVj1bR/E+l6LH4k0a6itrpYbDcJ1L7lnCgDaGDfdwM4wAvAAm9jodV83LV0emyutl5o6zzLHTdJuJ9QdbSESX/7yc28a5Wdu5x0745H8PFYus+MPB0miaiIvEmiM5trpVUX9kSWOduAGyfw5/u8VzngXwxpfjLSJfFXiTTjd/bpb250yzvLWTybK03qsSLCCIlJCbi4BzuBJJOa63W/CHhmPRNRaPw5oaMlreMpXRVUqQeCDjgjsf4eho15RU61WrUjOKWstLp+Zcj17w7qN1PaaZq2n3V2CziGC5tHfZ5Oc7UOcZI5HH/Aq5z4+qlj8OtYlKXUA3vDuWOLPzWzgKdmDgluccbSTgnir/ij4a+E9T0u6tF0PT7FhKxiuLDTTaywsItwZXH3eQDg5Hc5HFeR+P8AUzbfCbXNB1S1sYfFmizxW94RYBWuLdh5aXKluSrgoSSAVkYH5SVok3YzjVai1U0vF2030/A+j3t0m1GJhbzEShHxsgOcrIeOx6d/Q5521nWtoDqUp+zzHNpYnISHndLKO/r27n+LiuDt/A+veIYrGHxRe6focJQebb+H9KKzMCrFd08oY7l287FGdx5O0YmT4eodQjNv4o8SiSOK3kYXYF/GwlkYPtWdHCudmd44boF45G2XGq0vcTasunn66/erbnoSWgLS/wCjzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFefyfDfXIy8emeNPKgVkGLvwzbXL7jKVJ3bVIHy/dPqVqBvh1rDia703xrfCWSKeKf+09HjvVVopSoMCsqrAh5+RRhAcZ4FF3fYtVXa3K7X7Ls/7x02ueJdE/tnVPCoaUaymlXd2UKQbQASAueu/aC2ByFGRgYz1t9ZhFuP9HmXbIw5SEY/c7u358cY/wBqvHPFfgez0PV/DGs31/Je3013dwX9/cWEcQINi0YKqoUKqC3DIgB2Etls4q74Z8Jf8JjoI8ReJ7m7it9UY3MGh2DS29lbwmPfFkR7d0mACWJ6EdgcibuYQxMmuS3vXelumnU9BvbzSD4psNKN3bLqQuzJ9jaa0ExTyHXhCcn5j0Ax17g41ba0VprMfZ5jujjOAkPOUkPGfp354OecVwWtfDHw9HpEGj6DY2mlzvfq8N8ulmedJEiaZCWlDMy71GUJyVLchTVeHwd4puriESaz4ds1G1Y/s/hjzfMTa2HcO33zgkgZGTkE7eC71L9pNRXtF00sr997tHc2toDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/wCjzHEiD7kPGZmH9MccZHPy4rzux8P+JraeOAS+E78hLZpZbnw/KhEbuwBAR9rMMH03jA3HtZ0vQvFUk0g1KDwPBGcZaDQriYq/mkBQDIny/eOcg9FwegE32NKlZN7S6fZXZf3jr9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4rnfF3inw9pt+fDl5cTRazfxSwW8P2ZGDSSyGOFWdVKrlgRkkYxwQKwBovjJYXu7WDwVcsxmha0m0eeKKPEjLJKJAWf5WC4HQKSPkIAPM+MPC2qaQY9c1yfT5rm71nTRHbWVrLDBa+TMVIj3H+JpXOO2TwCQFSbtYzr4mUXzwTTTb1Vl182e531mEW4/0eZdsjDlIRj9zu7fnxxj/AGqwfFOteH9C1rToNav7WwlN5u8u5ktY22GBlBwe25hz938a4LQNE/4TnU/EerarJcWOjW2pTada6Xpgltba4WBTmWQx7Wcsw4GRt+ftXWH4deFLKU2cOjWzJqN7Kl1LNazzTSq9s7MDI7GTG4Btu7hgHptuwoVaktae1nun210V/lqdhBZf6RaI9tPkpHlfLhySVk9fp354OecVStbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFef6b8ONbsnt7ex8XQvaHDRC/8Nx3cyqwdgHkJBlIxjdjnOeijFez+H/iQzSRyeNYWlEFpIrDwrbbMM7jBXbzjb94Eb845xQ3K+xtGq7Sunsui7/4j1NLRS8w+zzHbIg+5BxmZhj9MccZ6/Liqmn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8V5/NqWreFriRfGXhzTdT8PwhEXWdN0tibcK7sxmtySVViHyU+UcLwW+WpZXfiLxFazXPhjwlo1jpipNNHPr2mSRyXivKzDyghbaixlSHbpkAcAmld3JWJp2abd7rTl12fmd/41uLDRvCerX2p77a1jtboGV0hwG3hFHAznLAcc5IC1NpeoaZ4h0NdX0My3GnXDuYZjBHGGAiPYgMOQT0HHP3q4+w8Ga34gvtM/4S608MWmn214b02ek6fPvnK7sRSyNtG1XKHGCp284wAfOfhjbya7oPg7Qob6PTgul3uqXU0NrBNPOqXIhjjy6MUA2v82COuQcHDu7mKxTU+R3trbTVtv1/U+gr+zRdT08NbTBRflTmO36fZZDj09/THvS6clvdvaNbq06FUBMQgYE7ZMj07d+eDnnFcLN8LdEa6htNYvdZ1q1uL85gvnnWFCIpJQVhhMaD5iRtC8AkgAE1n3vg688L63HqHgTw/peo2t/bKLjSruNo4Ibgg7bhFKnjarBlUqG+UgfLlRN6lyq1EldaW6J3662/NXNi9tgfjB4dURyDdoMjldseWzcQDIxwc5/i/Gu3S0BaX/R5jiRB9yHjMzD+mOOMjn5cV4nb3zeH/itpkfj6Tw3Y2tzoX7p4LZoLUsZ43ZXEjfOQIj83G7gdcV3SeJ/h3mU/214P270IO2IjHmsT/FwNuOO4wvahNk0JwtK7a97t6eZ02n2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HisjSR4dvILuKBdGnniku42RLIMyFpm8tTzwSoO30AxVLXNU8HRPfaQt34dj1o29wsdoLZVnMjt+6VVznecjaOoBHBzmld8p2+0pqsm5fa7eb8zzb45u8fxr8E2irsWK4t5FSRUGC1xDnO35cfKP617lqVpHHqNiZLeZUW+YMWS3GALWRue3v6Y96+ffizZ2tz8bbFLOyVI7G80mzaOG3MURaaR5DmPsSFX67TXbW6p8SLtY7Gwh0jwVcXU1uL+xth9o1QKhBjUKN0EJ8qTdht7qwGAGYgbZ51Csoubjq9enlvvojV+F9q3iHXdS8W3VrdFL147PTN8Ma5sY0cq6BwCBJJvfkdAD1xUfhO3SD4v+MoZYZjNe2ek3UYKxksiqYiRkYxkgDn655x2ljoekxmwjj0rTUjWKIBF0r5QNknGB16DpwcAj7teeeL5LLwx480rW7/S1k8Of2PFaXsyacZIrRvOaSKRkGSQ2JVLKMHdz1pttGk4KCUr7NN6d73692eopaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXC23xA+G9w0n2SbT7rLBsW+gzy7VErHnanGR27jA4xmmWnjfwCv+jXsmn2kk32kxyXujS26Es5dF8yRQoIXgZOF6DPFF3c3WJoWa5+q6eT8zvdetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VclqV/wCEZvDuqXVnc+HXjitbhjNDbphCx/dncDhSeNp7dOasWuo+DNamubfRbrw1f3ALS+XZ26OwTysbsAkhc/kfmoTdzRThypc3WXT08zzj4axx3fxgvJEDFZpbpkhjSNsr9r1DruOARtHBHIOeMDPYfFzV5tF8ETJpMVx/bOoLb6bZKsS5ea4V1GwoM7tu5lPXKjPO2vKPA/iKy0rX7vVdWSKezdZHFoqi5W5ma6vxHGiA4kYs2FI4Gd2cAmvS/CvhTU9Z8Xafr/izTLLSbezjEdlokFuLmMlonVppnUASsfm244AOQeGzKvrY86E+agoRettdL6Xfn+htweFrDSPC95oun206WUOjWsKtIIstuaYM7Ec5YknjnJOcDAp/wmhkn+GfhiS4tZlf+zrNRiOLld21T83PzKBj17/LitS00vTxqDgWFiAtrZMMaaeCZJMkEdzgZI+9gAdK828L6/4Q8F2Vz4f8UwQ6ZJZahcW9nJqOlSv9pt0uWZXWQg5AR1XBOcLj0JaujprOFKqruyslt5R8zP8AE67PEurIFK7buYYIAI+c+nH5cUVzGt+OPC0us38lnqlv9me4kaLy4XRdhY4wuPlGMcdqK5XF3Pv6GZ4NU4p1o7L7S/zPWvEem6/ea/v07xP9htZLwrDD/wAIk8jW/wDo7HI3ffPUbSD13Y4zUVhoeutqlub3xvq76eyLiKDwvGkwBEhGZDCwcjABYIA3XAxx3l87f2rp37if/j/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE46knqfBypw5E7S2/m83/XY81i8G20+rfa7rxN4ykuY2gu4JlhlUwmRmVkEQi8nZtVQcx4k+YewzvHvg7UfEfgi8s59TuNQ16OD7HBJ/Y0trBIr3kTs7KqMVkxbr0OP4QoIr0+1Zv7Sl/dTH/RLH/lrN/wA9Zf8AZ79scD+HJq4jHdL+6m/1if8ALWb/AJ7N/s/hzznkfNkUKLYq2Go3a5ZdOq7LyPLvDPw08E6TEl0dIuby+t1nVZ7qzu5uYnKh8H5AxwCTtAU8YHSu61u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0a8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg0WfKdFKnTp1UoRa97uvPyOa8c+FPCniq4F1rmkTT3NszRxSx6deW7Knl79uUxxkHg5xuZhgE1g3Hwp+H63ttH/Yd4yvcmJi8OpZx5LPkDzMk7gOOTjJ6V6ffMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaGnY540aMtXB7P+Xt6Hn1p8Mvh6HtlHhklXVHO6wvZDllcnknJ6DkHnt0OdjQdF8N6RcXCadoVrbxS2tnvCaHKS2ZJA275ckEHGejDgdK662ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmm07ouNKkua0Hsv5e68jj77wL4NurpLu20JNPv7SZXtbix0e4gMUnmkB8IACRtUgNnkYHOSb/AIF03TfC/gy00e0hldbSG6jaY6VcFpXWTBkJwdpJycZ+TO09K61GO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBos7hGlSi3OMWne267PyKmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83SjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7miceVaPeXVeXkUb29t31GwXyHKLqDttOj3GPmt3JwuOcsclRznLdKdbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTgV9SXyqmkk/h7ru/I8w8F3EI+LXjqVonMbQaQAv2GVzny+coBuHfno2ePvCr+geBfDujeKZdatDrB8qZmtbB7CdrO0MsgWQxxlMqW8vn5sEMVxwMReBTn4s/EJvLcssejKMPIDjys9QM8/kOMZwM+iox3S/upv9Yn/AC1m/wCezf7P4c855HzZFFmctOEJXck9JO2q7+hkWN3bJY3ANu+d18crpM//AD3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg0teU9BNe2Wj+J9V3fkF9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulaF8xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOabvYxptW2fwvqu3oeP8AgVYk/aD8UTGN/skVpDthWxeZQ88EDs5RPm3Hye47knBHPp9td232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrh/hZp96fid451m6jkaJ7u2soipZd2y3JI+QFhhWj7c5PXnHoVqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0tTLC2UJ6P71/N5o4zxF4Q03WfG+k+IoZ7ywnsJk+0x2+j3H+mqt0HiVz0UI8YPA3MDsyNox1Fjd2yWNwDbvndfHK6TP/AM92xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGnZ8xrCEIqTUXq11XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVy+Ylbj91MMyN1lmOP3Puv48844+7zQr3KTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpXjXiH7NefHvw9YTq6rcfYNRQC1fOLeG6JBjI3NlsdPvZyOte4Xzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNeV3mmm7/AGnPDVw0EjC08OfaQEMmT80sYJIBYDL9hjoBxS1OLG2dOmkn07d5f12PQ7a7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ1y3jLwrHr2sJq+i61qvh7WIYzZtc2mjTSCSBpn+UoQNrBsFWBBHI5IGOztWb+0pf3Ux/wBEsf8AlrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RTSdjrxEYT0kn06rsvI53w1HZaP4ZttMhW7mhsYLm2ikm0yd5DHHJsTc+3G4KAM4GzoQOlW9bu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg0teU1jyqqkk/i7ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpXkP7UWm6Te+B7jVRY7NTtLuKKK4/s+a2IjYLlCzAAjPO05OcsMZNe1XzErcfuphmRussxx+591/HnnHH3ea85/aTw/wg8Rl4nUi4tipdpXwd8Q/jUYOM8/exx0ptOxx1pQVL3ovZ9Vv06HdW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0O90dKcfe0ey6rv6Al7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/8Az3bHOOCPX+Doea10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaNbgnHlej3XVdn5HlX7S166fD20udMaW0urTUzcCVbKa2Yf6yP5WK9R5gI5G0A98V6Fo8Nronhmx0sRzv9hgS1DnSZwx2WwXOSvHTP1+bpUfxE0C18TeGZbLUfPhtYZHu5GCyTMVimV2UBgACQpXOR97Lc8Ho75iVuP3UwzI3WWY4/c+6/jzzjj7vNCTuc1OCjVc+V2fmu/p6GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8AF0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8Jqe+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6m8muRaP4e67vyMm2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RRas39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea4346X0MPw4vbuGKRJLS4juAwsZLcjbeRdC4AY88Dt0Nd7p7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGuN+PkQufhH4ijceUBE0geVpnGVuo2wPkOCdu3PAyfmIoV+UxxlnGej3l1Xn5EPwgunT4VaS+pxySXsxnuZJBp8shfzfMlB8xRt/jBx24Pau0vLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpVTwtp02i+CtK0u5ikE9naxW8h3Sgb1tQrcbcdQT9OPu81rXzt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzQ07Dw6jGCVn8L6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdGqcfe0ey6rv6Al7a7pf8AR5P9Yn/MHnP/AC2YenHHGO4+XqKqWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea10Y7pf3U3+sT/AJazf89m/wBn8Oec8j5siqens32C4/dTD57/AP5azf8APdvVe3fPB/iwaNbgnHlej3XVdn5FfVr+FNKvngiljmW2uyjjSp0KsDwQ2PlI7N/B0NeKfA2aK58Q+ILp2lkXTIH09EWywAJLi8m/1cYIXseDhc+gFe568zf2Fqf7qb/j0vOss3r/ALvbvng/xYNeafA2xW3sfG12LeRXn8RXke8GRQURDjGBtOC7d/UHjJo15jnqJOdJ2e8u3kej3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qW0v7QTWe60kcGOLIOk3H9189F+Y8deh6/wANTXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOBX1Np8vItH8Pdd35HAXX9mXXxV0pmheWRfDrGeF9OkwFN3bhGKFcyZJcEjOcdu/UQRaPFcTSx6XEknEW9dCmzsadty8Lwp2rle4AXqK5RXP/AAvq1GybI8KQ/L5kuP8Aj9XkcZ5xjA4HGCTxXoSMd0v7qb/WJ/y1m/57N/s/hzznkfNkUWZzU4QfM5Rb97y8vI4F/Bfgq902eO58L2HD3jBoNCliYbZztG5FBGBx1wo+VhV7UdA8Lw+CbzRItBg/spYrmb7KdIuI0aRSArs4wQ2FA8wtlRwTXSaezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBpWfKdXsaLq2cH8T/l7vyPHfiXo3h7wRo2k3mkWt5GyeJNPkuZ7iC5EkiRIxUeZMSBgEgKMcYPSur+EsFppnw/8E26wSMMrcNu06WfJltXkOGUYYbnJ2jkdexqv+0zZpd/CfWbmRbiKSwvbe5i/eyEbyUjwwdeeJGPZunbr2mkW4sLDwzZxWnlJbyRxLHBJOEULZMuF4J7dclseo5pNM4sOoxrysnblfbt6WLdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVO90dycfe0ey6rv6Al7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKp2d1ajT7lHt3IY3+QNInIIMzcZxgcHH+z0PNbCMd0v7qb/AFif8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/8Ay1m/57t6r2754P8AFg0a3D3XF6PddV2fkcjrnhDwY9hdXCeF9PjuIoLt43TQJYgGGQCSFA43HBPC4GeQCNHxXoHh3WY2a502WC6gmzBd2el3NrPDiHokiAFRgYKnj+LGBW7rzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNFncz9lRcVeD3l/L5eR85a9pml6H8cfCfh3R7FxYQvY3EcTWsmQIjcMxaN/nJJfdjvyR1FfQNte2plswbeQ5jjznR52z8knUY+b6jrwf4TXluu2hm/ay8PzGOTMWjtMEYy5PE6cNt3nrnOOMegzXr9qXMtoVgnYLFGTiSfptkGeF4HPbj0yCcCucWEslU0f3r/L/gGRbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoauQ6hAjT7Iply6KcaRcdPPbjpwOBx3GF6im2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKEnY9GtyttNPp1XZeR5D4g8QasuvaksGqahHELmUIiyyRBRvOAEJyv+6enSis7xPz4l1YkEf6XNwSSR857nn8+aK423c+9oYai6UfcWy6Lsev3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1PfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BHYk9dT4CT9xe6vh7y7syLae6F/J+7sN/wBlsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/pkIzIh/16c/vmOfuevP0OeQcASZVV6v3V06vsjJsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KNenkOhamPtkJzaXgx56c5PI+536j17belKz5TRP98vdXxPq+7C+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2ILa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/pkIzIh/16c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSizuCfuv3Vuur7Mqa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmhJ3BP3V7q3l1fkZ95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7PN/AstwvxJ+IbMlqtwTooKNeNEuBATkMEyeCCeOM5zwM94lxebpf3Wn/6xP8AmLSj/lsx/wCefPHOew+bqah05IrbVb17d7KGW4gsZZnRo1eRgzqN7eXklVVRgk7QO+cVpJPJul/0yEZkQ/69Of3zHP3PXn6HPIOA0jONN0k4uK3vu+tmZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qbPlOpP98vdXxPq+7C+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2MLw9YXumaxf3QlsXi1KaC6MJ1Jo1hcW3lN8wizkiNc5J28AfeObdtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDi7ocUoqSUV06v+YEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO40/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmqdvp0X/CS2OuGx00aqtill9pOsTAiH53KH5ML8wB4GRkDJB41765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnqTOzgrxXw95eZkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/0yEZkQ/69Of3zHP3PXn6HPIOAJMqq9X7q6dX2Rk2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVvT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSlZ8pon++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elee/tGTTyfCPxGJltAvn25Bh1B7gn95F/CyDI/2uueK9Ovp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qDUpWk1LTxJeWzj+0C3zTxkZFq/wA3+rx7Zx14xnmm07HJOn7WHIklo+r6akVtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOa2bS4ZZLbN1DnyogrG4UeXhX6/J2GRg5xuHXIIo2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnc3Tvze6tl1fdeYJcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZlTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP8Ar05/fMc/c9efoc8g4Akyqr1furp1fZGTY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUazc3Y0e/JSxUC2uzuTVZGYc5BA2DJ7gZ+bqcVa0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKXvWScV8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuZU3p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1r208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pQ077lJ/F7q2XV9wS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/6ZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NQ2OmpollfW2lWenQxTXk906pq8r7nkjLMQDH0ycf+O+prR16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15os7ismotwW8ur8jPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqKT9xe6vh7y7s82WW8/4XpbM0dmGXwrAoX+0JAuPtuSd+zIOQflxhQMg8YrvUuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NZ9rp1r/AMJhJrJni/tFdLsrNZDdAbYvPkcrt2YzuVSc5IwOSCQdxJ5N0v8ApkIzIh/16c/vmOfuevP0OeQcBpMzjB0+ZOK3vu+tmZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qbPlOpP98vdXxPq+7OL+OcVxqXww8QWb/Y4/tF1Zxq8WoSXBBaeBc7SoyOfvZz2rsLye4Gp2H7rTUUXxKBNWkC/8ezjqIxgdfmHcbcYo8U2K61Zm2u79WgS+hu2jSaJhM0IWRVbMXKlkUHG3ONvck2765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ocWcdCDVSUnFax7vsQW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKbTvudCfxe6tl1fcEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+R5fNO0n7TkD3X2NZo/DhFsPt8hjY+c2f32zcDgv27Y716La3V6stp+7sADFGG/wCJvKo+7JwT5fy8447cD+I1gX3hwf8AC3NP8Yf2vB9o8g6X5PmJjb5cknmb9uMfw/d6/r1drcypLabb2JP3Ua589AAAsnB+TjHoc4yOuQQJPU5401Tg2o7q+78/67mPbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP8Ar05/fMc/c9efoc8g4AkzoqvV+6unV9keH+JCW8RaoW27jdSk7JDIv3z0YgFh7kc0UviclvEurMWDk3cxLAgg/OecgDP5CiuN7n6Hh/4UfRfkez3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84ovrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84rrUVqfnEprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf9HmOJEH3IeMzMP6Y44yOflxTSRVWau/h+z0XZGfZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKNctb1dE1Jmv8AVWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss/wDx/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/xcU2lcpTXvfDsui/mJ47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/wCjzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/AFVlFpekqy22CM8g4TOPXHP92reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrgqi5V8O8ui8iveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/8AH+Vx5dvn/j1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/o8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKVlymimvbL4fifRd2T6jaX2y53ajq3+tbO9bXr9nPXCdcenGPemXlrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrVi+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv9q6ev2Wf/j/ACuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/0eY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4osrgqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x71Br1oo0LUz9nmGLS8OdkPG047enfuP4eKuX1mEW4/0eZdsjDlIRj9zu7fnxxj/AGqElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/AI/yuPLt8/8AHrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP8AaqK+sV/tXT1+yz/8f5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFNpXKU173w7Lov5ieO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/AHat6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/wDEx1b/AFsecLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/yuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZHrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvUGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/R5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFakymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf8AR5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss//AB/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFNpXKU173w7Lov5ieO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xWgloC0v+jzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitSZTXIvh+Hsu7M+1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVbjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v8Ao8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7I8Q8Thl8S6ssjSM4u5QzSbdxO88nbxn6celFHiddniXVkCldt3MMEAEfOfTj8uKK4nufouH/AIUfRfkev3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK5rVvFjWHxA8EaLBZwvZ6rBO1y8ulTmQGKFmXYvBfJb5iARwDxiuxcup+eVJ1Y0025bLo+ra7G9baTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eorjPhR4qfxR4Ys9a1Szgju7i3gR1tdLmkT5LqdMgjd1CjJz8xyo5Bx2aXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKFylSnVmuaLlZ8vR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKap1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8AFjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDQ+W5Sdb3tZbLo+/oWk0fTN0v/Es0/wD1if8AMMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/R5P9Yn/ADB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNC5dSZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1W8Q+JdO0DRtQ1O7tZGgtnjLD+zWi4Nwy/elKIvUcMwyPlHIoXKOq6yb1l06PsvIsWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NeV3vxdtrCwGoLBZ22h6lo+oXWlz3Wmy75tQFy2Lc7WIwqlPmHyqSRuNbPhjxpqeuz+MNI8QaTZ2NzpmmRMUt9PlLLNNBvlVzkhQr5CscADuetL3eUmniZTrqMZN+9+d2vwPRr/R9MVbgDTNPB3sRjTCnHknpnoMg8eo3dKrPZaNcarYpZ2mlShrtnZYtMLAxiB1JKj+EPgY/vc1Zvr21C3GLeQYkbpo86Y/c57rx647H5ulR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKb5bBB17by2fR9vQkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhofLctOt72stl0ff0LSaPpm6X/iWaf/AKxP+YYT/wAtmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NW0vbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/wDnu2OccEev8HQ80e7cE61nrLddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/CaFy6kydbkWsvh7Pu/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/wCJZp/+sT/mGE/8tmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/AFif8wec/wDLZh6cccY7j5eooXKVVda7s5dOj7LyKllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5S063tlrL4n0fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bGUHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBUeq6lLBpEs2j6ebvU0st9rbyaTPtmmEUpRW4GQWCgnIB65G01514U+IWoeKrt28L2ekXzR6BYm6lfT7kR2+pGY/uWKhmKbTISQp37AoYZzQ+W5E69SEuSTld2tp2foeqJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4Nc74A8V3Guy6293bWt1pcN1Cmn6rZaPcLDfIZD5hVCXKhXDJncQ4G0cqa6Kxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNHu3Lpzqzg5Jy3XTyfkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpVTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpQuW5SdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JoXLqTJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6ihcpVV1ruzl06PsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0WN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5S063tlrL4n0fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bGUHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVu2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/AAjg1bS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8ACaFy6kydbkWsvh7Pu/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKtpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eorG1XUJrex1W50fT/tepppls1pBJpUwEswaUqrHjhjgFsgN0BGDXnOl/FHXvEtjcS+DNG0vVriDSbS4uI10+bEWovdfNb5Lj5PL8wg9DtC7ieCLlJxFapCXLeV3a33K56pZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1ynw98V/2odfsNTRI9S055/Os10KSOWDzGMilik0y85IHIKbGBzkE9Xrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKa051Z1FJOVuZ9PN+QarBoNvqKafJZ6Yl5defLDENNKMyRwpvI9ADInB7nd0Bqe80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXJ+JbuI/FLQisEqwpYakcfYZUGSlt0iI3Dtz2znoK6y8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulD5bHPQqV5c13LRNbPsvLckttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/wCQTOTnzJM547569H6Doab5bm6db3tZbLo+/oWk0fTN0v8AxLNP/wBYn/MMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/R5P8AWJ/zB5z/AMtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/AM92xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIoJFoF/qkKafb6TMINUe1uEj0wnY62zkoy9Rg4O09xuq/baPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmuJ8D6nZX3iDxDcRQuY18VzwlW06RyPLsVjI8teVG5ThTzgZ/hNdtbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0ly63MKdSvUpKV5bdn3l5FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1bF9as8ubd+JIxxo0/TzmHTbxx27/d6g01ym9V1r6OXTo+y8jxrxIiReItUjjRUjW6lVVRNgUBzgBf4R7dqKPEhVvEWqFBtU3UpA8sx4G8/wAJ5X6HkUVxvc/QKH8KN+y/I9rvnb+1dO/cT/8AH+ePOuM/8esnH3c575644xjmqcmj2F7r2g6rdWMsmoabERaS+fcKUEkbq+Ao6EAcYIGOO5C3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12prU/OZ0W4K6+z3Xd+ZneFNHsPDsS6Xo1jLbWEFraGOJZ7hgC08zsckE8sxPUgE/Lk8Vuox3S/upv9Yn/AC1m/wCezf7P4c855HzZFZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNYdr4tvJPiZe+GPs1oUj01NQ8wX0uA4vNm0vjldrg525B575oTVhV4qm0mt3FLVdl5nT6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBo15m/sLU/3U3/AB6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7puqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzUF9cXhW4xFp5zI2MatK+f3OO8fPpnufl6VHeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNNvQxp0nbb7L6rt6mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0W1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmhvUtUn72nRdV39TXRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIqnp7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwa5H4ha7qWmf8I/HC8Nut/4hsbSVrbUJJHaM3Duyj5BwQgBOeh/2yK6SxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ov7xnFNuULbNdV1T8y1rzN/YWp/upv+PS86yzev+72754P8WDVy+Ylbj91MMyN1lmOP3Puv48844+7zWRrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KE9S1SfKtOsuq8vMnvnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcZ95cXP8AalgWTTx/pxK41iUg/wCjOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyai1rR7DXbf7PqljLOkV1FcRMJ7hHhlWdyro6gMrckbgQeT3LCuQ+F2tX2qaZdzXFzDeXiT+TM9xevb7dl7cBVUBSCoTb0wFHTmu0S4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U0J6EuPtY81tHy9V2Xmc9p3g/QR4a07TP7Ib7Do95d3dhEbi5IglS4cowyOdu48E4OfmwadrnhTSEl13XIbO+g1O7tp3uZodQvIxOYxtTzEUhHCgYwwwcndgk51bG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppXXKaxw6VVJR05u67vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzTb0Ip0nbb7L6rt6mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP8Aolj/AMtZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/wBjr1yP4eozmhvUtUn72nRdV39TXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57/8A5azf8929V7d88H+LBoS4vN0v7rT/APWJ/wAxaUf8tmP/ADz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqJUnZ6dV1XZ+Za15m/sLU/3U3/HpedZZvX/AHe3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaEyqtJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX900VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qC+uLwrcYi085kbGNWlfP7nHePn0z3Py9KwvFeqahb+IvC8UMtrCtxrJVxFqDSrIos5ThnZAVHGNwyeo7DLb0OWV6UOZrpbddbLv5nU2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjk7Twjoapr2mppcyWWsJbXV/HHdXSfaJJJZN7EryA+ANoO3GQM5IroLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzQ2rm3sW+a66Lqu/qO8OaFY+H7eS20qC/jtlMMaRSaheTJEiTOFVA+4KMcYGOnduBZ09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNCXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUXVwjRai0l1XVdn5lrXmb+wtT/dTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93muU1rxGWv9T8PvbwLdDSLq+Mg1GUoYmlZBtJQBmyp+X+Ick1v31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQmrijC8VbvLqvLzJ752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcZ95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe4pUnyLT7Pdd35has39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIrItp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5q2lxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upoTKq0nd6duq7LzDT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0a8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKoeJtdS1ibTbprFLq/tNQMCJqUzlgmCx/1e3oRgMRv+tK65S+S1ZN/wA38y7vzOlvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DKnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9S1SfvadF1Xf1NdGO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBoS4vN0v7rT/9Yn/MWlH/AC2Y/wDPPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+olSdnp1XVdn5lrXmb+wtT/dTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msbxBeSQ6Bqkt42nwWqWd40sv9pzSeWmcltojJbAycD72M9atXN5dTQSyRR6eyO5ZSNVlbIMHBwY+fqe/wAvShPUSjtHrr9pd15lq+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnGfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuKVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8ALWb/AJ6y/wCz37Y4H8OTWYPCWhNpuvaa+j+ZY6xdm6voXmuGE0rzHcxyCQflXGMYK5X5sgYHhHXtau/HvjPTLx7N7fTl0oW0Ul6YvKV4y7AOse5xkk/N9zJ212SXF5ul/daf/rE/5i0o/wCWzH/nnzxznsPm6mhNEOPtryt1tuull38jK8K6DpujQarcafYTJdXst4bq5kuLmWWbZKVXe7gswVRjBOOSTgk51deZv7C1P91N/wAel51lm9f93t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6dEaNqysvtPqu78zkdclZfj7Zjym+fQblSGZyy8oc5Zd3b244J25r0C+dv7V079xP8A8f54864z/wAesnH3c575644xjmvNdWuLg/tCqqGylb/hF5H2fbHZEYzFTiXbuYkKvBGOce9d/eXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNDehx4WHNz2/vLdfyrz/H8TQtmbzrP91Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyaLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzTb1OpUn72nRdV39TXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57//AJazf8929V7d88H+LBoS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKL6iVJ2enVdV2fmWteZv7C1P91N/wAel51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msjW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6gqT5Vp1l1Xl5nnfwjc/wBseKQI5CR421A7VeUEfuH4yF3Z+vPB45OPULZm86z/AHUx/dx9JZhn5JOmF4/DI4OOCceT/CWVhrfip4PIYHxnfkGa8eHP7mTGWAJ7n5vXA/iJHpltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0ovc5qEHKhFrs+q/ml5has39pS/upj/AKJY/wDLWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/PZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upppnTVpO707dV2XmeOeJ+fEurEgj/S5uCSSPnPc8/nzRSeJCW8RaoW27jdSk7JDIv3z0YgFh7kc0Vxvc/Q8P8Awo+i/I9rvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgiveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziutPfQ/OJRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0rzDQriWT9pzxCZLtZPK0ZAjeerCMfaYG64woyS33R97djnn0u1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMV5Z4Ps7l/2g/Fd60lwskqy2gnVYxIWiksD3GwthxnjHPQChMxxnIqkEmt4/kt9D1fT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSo7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xXEfF/wAcjwZZ29nLc6re3N8LhJ4v9HC21s0oRppNsZOC7BQPl3HOGXAyX93Y6ZypUqnPJxspPv3fkej308jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNJqFretHck6jqpBkY5ZbXB/0c9cJ6enGPem3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrQ3psRCMLbx+F9+3oWLaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0qe0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxim3rsUow97WOy7/zeh5x8dLxxqHgaAyLIX8SW0u5WDY2ySdwB1356d88dB6Xp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvIvjvb36eL/h9ve+ubcaqZ5WlSM+UEuo03HywABumUZP8TYHavWbK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xSv7xhSUHUqareP5S8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmuQ+J+tXXhjwnNP9tvJ7y9eWws7W6+zrHcTSyhdjMqggY3Mx3L907WHWmeA9W17xL4XvbrXL25TUbfUbqyuFtYoEi3xIyfdZSwOByM4xnHOKaeuxSnT5lT0+1rrbppt5HW31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99C5RhyLWPw+fd+R5l+z6Db+HdQMNyiQy3e9N8ioSou5wDgqemMnHA9+lepJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBwvws0ltP07ULDTrm/ihtb2SENF5JLhdTu1UtvU84UY2gDPXiu1jtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xRF6bGcIwdNXa+zv6LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KjsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u0X93Y6lGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv8AWtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1ob02MYRhbePwvv29CxbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulT2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMU29dilGHvax2Xf8Am9DQSeTdL/pkIzIh/wBenP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0qeO0vt8/wDxMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRfXYFGFnrHdd+z8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXms/XLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPehPXYFGHKtY7y7+XkF9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99CZRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Gfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8Ypp+RVWMLvWPTv2XkQafPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6VHZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92lf3djRRh7Zax+J9+78jQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rlfG8rv4w8FFriKTGtO3mCVSFP2KXnIQADjrgj5enBz0uo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3rzT44a43g/WPB+tXt9dStba6GaO7jjP7owBZWBiA5CsODnqvHDAtvTY8/EqCo3TW3T1XkeoW08gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pU9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecVUtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFDeux2KMPe1jsu/8AN6Ggk8m6X/TIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belTx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKL67Aows9Y7rv2fkeey35ufi542Tzo1a38NmAsZF/eBpHc4O3nO/oMZ7Yr1K+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvEfDsr3Xxn+LRhuLjcmmlZGj8os/loqOHyMdQd2zBz0xXp3xF1ebwp4V1nWb3UdSK2zNsSZLcrLM0G2ONtiZ+ZiqkjgKc5BGaSer0OajKHsnNtbyf5eRga38Rp4vGyWtjZyXunWOrWtldX63CoI7mdGiyv7kh0RSoY8cyKAP4j39tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR4r4/0LVfh/wDBXy/tVxPqUOqwXt60Yi8qe53LM8hO3exyoILZG1RkZGB7JZ2t6ZrApqOrHMUW0qtr02S4xlOmM4zzjOecUJ76Cpx921SUdY3Xprpt0IbWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMU0/I6qsYXesenfsvIg0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pXmnj+4ll+LmjwtcwlYdC1OdT5y87/MU4+UZzt4AGTyeB09HsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFeI+Jr03X7RtxaCe8eex0W7gldlj3ljHNKQcDbjbIASAO+OcGpb90isoqrGzXx/q/I9+vp5GW4zeQvmRjxOhz+5xnhBnjjtzx15ryH4u+ONa07xa7eH7m5mXw2I9RvRbvG0c0kqqBE5MYx/o6ztuAP3hxkZr1XWIri3tr2a71bUoII3d5ZZ/sqogFuSWYhOMLkk9NvvXmfhbQbvxZ4Hur+9kv1ufF+oXd00RjhHlpJbTLCuSNxxEEI5wA5xhuacnoc9SMZWhFr4W9PJenc9VtrhvOs2jv7cqI49ridQANkmOSnHXvn7w65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pXPfCW5uNZ8DeE7y21PU3U2MEX7tbfho0ljZRvTPBVhz6NyflJ3bW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xQ3todNPklBtuOqj37ryNBJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFO+uxSjCz1juu/Z+Rynx01mXTPhV4gkW5jkaaCW1CrIr8SzIjdEGMhievOMjHQ9dZmaHQ4IJZ0R0jVWjMq7gRbbSMbM/wCz168dfmry79qBb63+GccZubydbrUHgK3Cw4ABeUkeWoOf3POTjnjivVbm0u/ssu2+1NE3nC+Xbqo/0fpgpuHH/jv+1QnrsclNQddq60X6+hyPxQnvtX1XQfDWm6zc2dzf6ibm4vLKfDQW0UOJH8xUHl7i6RhjxliNp72/hXrF5eaQ9rfanLPeaNqNxpMtxdTIHYwtKEJYx/N+7eMFyMknnk8Y+g282ufGDWNejluZVsbmLQrW/iMBmLJbzS3CsMeXkO6LkLjCf3uTN8OLa8svG3i3SIp7+FFvLXUo5Ilh3y/aLQgk78rwYmxgDjOf4QEmZ8qvGd1Zpr0Wv4XX47Iq/Dy4Y/FX4lFJo4OdGGGdUzthIzgqc4xnP4nPSvSEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwPO/h3BdP46+ICw3N1Eq3Wl5NvHb7nPkJgszrk+oA4BJ45Nd/HaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKafkbUIw5Hdrfz7+hBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8AdpX93Y7VGHtlrH4n37vyPMbe5ku/2ofERMyObbQPL80SAg5ER+8FAP38dB6dea9ZvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmvKdPd3/aC8U22+4N2tnNvvMRCZlNtZYVsLswu1h06Mcc8n1O8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9aV9Njz8EoNTu19r8vTb+rGfr3izTPC1vYXmuazb2UBEUaM0gY52uAMLGTxnng4B5PcXLWeQalKBeQjFpYjHnpxiWXA+526n077ulebf8I/8A8LC+IWr2WrXN7c6Xo+mx6TCWhiV45rmIvI8bhdpKogU5BID+uM7PwevrrXfBWjXcV9qgK6bYW7lfs7HdFNLFj5kz95CRnnJO4kYNNvXY1pzUpzi+W2nfpJeR3iTybpf9MhGZEP8Ar05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belTx2l9vn/4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4p312N1GFnrHdd+z8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXms/XLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3oT12BRhyrWO8u/l5Hk3wLuVF/r4S6SP/irLqRiZFXrBKM/MpB4H6+4I9et5nWe0xewjbHGA3nqAuEk9U4xnvnGR1yCPCf2XYLuXw+bhbi5SS41pnJthEWybWQ5JkB5+917Fu+017hbWt6stif7R1UYiiIIW16bJemU6YzjPbOecUovc5aEYuhFtrZ7+svIz01i2t/EcGny6vZJfXdlatBbG6j8xlieRmO3ZkBQSefRuW2kDWSeTdL/pkIzIh/16c/vmOfuevP0OeQcD5ySCS4063+JE0LWt/wD29Y36Xc8iqw07e1tHG+cAcR7iVwrBueFXH0RHaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKafkOFRVHLnsvh+7p0fRI8V8Tkt4l1Ziwcm7mJYEEH5zzkAZ/IUUeJwy+JdWWRpGcXcoZpNu4neeTt4z9OPSiuJ7n6dh/wCFH0X5HtV9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFeaS+PvBE1zbzW2nl4FufNOzw5NiWMwsowMcjcVbB+vXikufGGkTYs/DHhGfVdeEapDZyaE0KFwj/NK0m0BOmT1JA44rsUnqfmksTQ5Eufp2835noFraA6lKfs8xzaWJyEh53Syjv69u5/i4rxv4dwtF8XdT2pcyfadV1mORCyYQLc2wHy42n7qrjoOO1bGmeLbDRLxbP4l6DYaDeP5UUN4mmGTT7lVkYiWOTJZSynBDDooJIzheQv5mtPFHgu58N6TbeITd6z4gngsYJEjhuovPwCrEFdm2PcOvCj2pXZzYqvTqTjKLejV9NVZLzPebK2SLTbqR4ZUVGv2LMkAChZ25J9B37j+HivJ7vw8PFngvx14zvIZBHq2l3P9lK+AYbO3O9CQQuPMkXzMBeAUwcFhVhNC8SeNdOFnq/h7T/CukeZdNevauZL2dQ75hR0TakYbajZP3eMgEg+k6npmnWejXT2+naerW1nciLOl52CPAQc5GFAAGeFAwaetjoqweJquOqV3unu79L7L+kLotzHrPhew1aOKRlvYI7nd5USAb7USYxkkYJzjJ+pbmr99Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3rybRLa58AaRdaJqfgTUNU0y2v54tO1CwsY7yeeN97IJUZ1dCqsO2MgenOuLzxJcX9u5+GOj2ifazshuLhVeX92wCsscThRsy+3JwVzk8AjbsKjXgopXd+V3XL5ep6PbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ri7K18W2traSXfhDwXqFyiITFamaLzh8+MB4CAdpyTk5MeR6Vzsei+PtP1RtS/s/wzrI8qFpNChtPJjCMdsRinePJclXL7iFI4BbOFbbuae3S5tJdPs+fqRfGu8EXimyti1xCmmWQv3Eapu2vq1pHkqpAcfuuFPG5R0ABHren2iiwuD9nmGHvzkpDxtnYdvTvjkfw8V8+/FnTb26g8V+Jv+EduNCtLLSLWzRZ7WONjO+opLuTy3YDC/LuzxgoeRXc6b4J17xDpFvea3rcGkxXNnJNLYaRoqRSQSEhmQzuHdWUkqcY2EY+XpSTfMc1GrFTmo3d2nt/i89Nya9hHi7xp4guTAx0jwna3cFtJE0ZE166ZkLFflIiRlQryQzkg9hf8Fwiw8Z/EXRWBeSHVBqPSMuBc2vmHP0K/w8dcc7a3P+EW0TQvCVzZ6bplnHHb2V2EdtPYyEg8MXPJb/aP3e9Y3jTwhdweJU1/wnZaU8rI9leWF3bSQW0qmPMU20K2GiZnY9GK5wRxRre5py8kYVHdu8r2XotNfQ7i+sV/tXT1+yz/APH+Vx5dvn/j1kOPTPf0x70qxQwi3luI3jhWFJJHZYAoXZIS2Txj5c5bsDnnFecN4V8YG7tTdah4Whnkm8sQweHHeMSeUzHOSCVCg4GOTglf4qUfD3VtYe2s/EOt2KaTIUM66Vo5tJ54tkn7syhshW5D4zuUdcZwJvXQqdf93on8Pb1/vFXwL458JhtQe71eK3W6vrmS3luYhDFKn9oXEhKyzKEPyTRnAbPJ3DAOOs8S+M/Cfha4lh17VILScMjeRiF5QvmMclFBYZXGOMH/AHcVx3wI0vT9T+GFlDe2NrPDcWiJIJLJnLK17cqQWHqAo9wAo5Fd94S8I6D4T88eH9LtbNzIgMq2cjykecwwXYlscD5Sf9nqDTjexmvaxilFpq0ej7I5S1+J/gSDTpmOtRu5knCpFAkjsZZHaLCIpboOSB8pIHy5Ap+p/EvwHc6HP5WvQE3NvIkarCsjhpQTHmNELjAB3cZU4HGRnudPA/sy+TZHtme/81fsTgP++K/Nz6cZP3Rwai1u3gj0DV1SC3VZba7kkC2DLvYNkMfcHoT93vS15TdOu6yu0nzdn33OKufi98PZNyWesTTSSSERxppzb2yhUDaIwfvc8DGOfvVDqXxQ8Ni/smi0vxLLtuPOVF0UBpFaJ40VQUAJdyu0fdO4dGzj0rVUSaG+jmjhkjllJkVrFwHIgGM5/wB1eD0wG6Cs+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdTlexFNTa1nbR/Zv09Tzrwr8VbO9h0Yap4f1n7VPZtcXI06xW7SAJLPD82F3fM0XGQcZ5Jxkaf8AwsPwta3sj3Y1mF2gtozG+iyhgyM7P1i6EMMdz34rk/gB4df/AISvxpPfwJPp1vqsmnW6zwfaFDRtM7DYPTzFPQfeJHQ16vbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMClduxnhnUqU3Jza2+zfr6nNx/FHwCbeSc64qjz0iMJtcTq3mMSvk+X5h+XAyqlc8E4wKq2fxO8BxW88f9r3JYG5dmGkzYj3yF4937nI+U8+mOOK7e00XSre9urq30vTormULBJKmlkO8ZnbKEjnacD5T1wF6iq1lpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODTd7msY1GnedldfZ8n5nIah8TPBd7ptza2l5fyXd1DcR20I0iXdOzfcK/ueRg8nqO2BTrv4t+BcsBe3yAhpWZ9LdRCuzaN/7vjMhC5Hy++ea7DWtOsYtA1NYrGyQfZruTC6cV+ZSdrexGTg/wZI71durCyhV/JsrOPyZ2kj2ac0exvJByv8AdPyqfXIDdBQua41GfKvf6v7Pp5nDN8RvDN5LHeW9n4heytrnz/OGhsVlgMTJ5qkR427mz82OATjdXLeHPizeRazPpnifwvqU2qh0aHT9E09ZpooPJV8Sq5yZB5q7jgDIbIGBj1m80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXk/g7RY7j9pXxPcTWUMlhDplrFslgMqhmt4dv7sdeI3x27+hpamFdVIqFpt3X8ttNfPXqdHbePtMW+M1z4c8XwQNFbRPLJoR2xlXcuzYUnGGHqTg5zU//AAtTwHEJjc6tNbOpVzFcae0cgXzT0VowWOCOEz3yMAV09tpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKsnRNKkkDSaVpzmCUGItpefLLSsrbf7uQACO4AXqKaub1YzT0nfb7Nui8zj4fiJ4LtIJIZr++SVjcSKDo044lfzIj/qM42sDntn5eKj1H4keC7nTLu3+238M8sE8arLo0w2s33M4hPGOuOR2xXV2Wlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0teU0UJ+1S9o7838vm/M527+IOizbDpejeKdQt5pW/0i30J/LiTy8B2yikjOThAThWOAcZ87+J3iLQfHmuaPoeiQTz3pXU1kt7uyaGS2lFkyqjLhRvEmTgZwUB4z83uN9o+mBbjGmaeMSN00wpj9znv055x2PzdK4fxpaWyfGr4bQx21usJbVIzGlgyqV+yIdpTuuWY7f9pj/FTd7HFiIv2S99v/t23VeZ0/w9vh4j8K+HNUdTcS3lnA8zQxQhTLskEgAIxw6sOf7p9FrRtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFcCPhWV1UDSPEdxpujX0gup7GPRopWjZw5ZYJGBMaHBwApUHkDqAmlfDNLK6kW08VeIHmFtbsHvrWG9A8zcgGJYW4Xy1IwfmGVGKTbN6dSUYtNPZX0815q9/kelpaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXBSfDbU5jNZv4rlOlyOiyldCgS7Cl5FYRzKg2ZJB+7kbQoPBqr4f8ADvivQLLylg8M+KLCBLiHdf2UtpdsUkKlt4R1PIxljkccjmnd32LVayaaluvs+T/vHIfDGFZvFfi/USA6ahol/fqYwhRR9uuFyN38PydRzXeNCPiD4li1OzjZvBOjTs9tL5cam/v0R/3iMvWGLHBGAzZxuxx5FrXhq60S0g8LXLquqT6FaWW9QcrLNqshcAnkcO6k8ZGR0OK+lrvRtLjhkRNM09UiPloq6YUCqtvhVGfugADA7Y3dKSvc4cI+f91N2Su3pfXTTfyKXjrQ5dU0m60y1gmSe8NzaRkrCuGexlAyV56nPHGPeqXwr1FPEvgrw1qPlySyS2kUcxWKEbpUWRJDgju0ZPPof9mte80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXJH4Z2i6lNcaLrF/pQ1CRbqa3TT47mBZWRyzJHLG2CSBnaQp44wgwK+rOyrpyzjd+7Z6eb6X/U7G1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFXEtAWl/0eY4kQfch4zMw/pjjjI5+XFeXyfCTTbrVmkHiXxXGwS3uCFMYT947DaFEIXA2nHGGyABxVt/C3i2zO2wu/CepBSkbG/8PPCfvld37tjySCSOAfugcbQ032LqVddU+nTyX947nT7RRYXB+zzDD35yUh42zsO3p3xyP4eK8J8U6XbxfHVr2HLyS3GqW7gKmR5WkQMAcccGRgQOmDjmuxOl+LtJtPtkGmeHPEsRFwk9mNMNjMjCTazRSMWUgNk/NjCjACkgDjtdOo6P4z8O+I/EGkW+m380mu6gLKKDd5EcGnxJEm4EgkCAMMHCMSeOlTq42MMTX9+M7PSV7NW6+rO68aXcnjS9uPDHheCSbSFuDHreqLtjSFUUM1rG8eA0jKrBwpKqr8gsTj0C402KG/0uCK0nWNL7ylXZBkAWjkD0z39Me9cX8LtB023+FugbrC1eSS0SdnlsvMctJb+YTv8AqxOO33u1dZeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Rupu9jXDpW529XF9PL1OT+DUUCQazotvbKltpOtXFtbwRLGWWB988e4P7SYBPB2HrgV2FraA6lKfs8xzaWJyEh53Syjv69u5/i4rjte+HsuoeIYdV8PazHolzd21vHdq2hpepN5cbrGwWQHBCjadvDAA4BUms8eA9flv5dvjG1TckEhjTwlBtRHkYKELM3IweTktwCW7DbRNKbpxcGn06dL6dUempaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXDXXhTxVY3M/wDYt54c1S3aYbV1nQ9kkamQgfNAqhjkHjavB284wKlv8O9S1OzvbjVPF+rWk7/aAtto1u9naxGOQqwMfIcMc5LdFwvAAAd3fYp1nZqMXut1bo/NlX9oRoUs9H06WKdRPDrNyFZIwhMNlMASUIOQZBwQR1xgcHo/GPiKWCOPQfDkMl14svoPOh/cwtFZxmJA1zPgEoi79wypDEAYJJxxfiPwl4gttC1q/wDEJ0Z49K0TVYYLuytGgku/MUKGkj8sKjAK2cMQNyqAOSd/wBZQatrvjvV7m3tplbUY9OG6HzgGtrPacEcDlvw6/wAJpK9zgi28Q46pS8tbel/1Or8M+ELXwrp2haNbQ3cwgvWEksiws8sjW0juxJzyWJOCSAMdxWY8cWl/F3QIvKuVHiHSnDITERLLbgMhVTxwkshO4Z6Y5znpLzSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1ZPiPwLoniaws7K4hfT3AhkjvNNtWhuIjtk3bWAO7cuVOQQwOcfLkCud1aC9lDkeyX2fN+ZmfDu0SXxX48l+zTM51CxQyKYmUj7PF8uGGQeTznByMgYOe5S0BaX/AEeY4kQfch4zMw/pjjjI5+XFeP8Aw+8K3Op3Hi43niC+82DWFiSSPTbWRCTFEASrQsFwCg2rtDBQABmtyPwN4ihecReJtMnTzgV+1eFYiwHmOApKFR15PyjoFHQimm+xjRqWg7p79r9f8R3Gn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HivP28HeJLqzlMHiDRbcD7SCy+FlLZVyrcs5A+bp/dGB8vSqupfCt9MhvNV0vxVqzXywzyTJqFik9tIqcMqxBUEZY4IZSCnI6nNK75TrVb96pWl8T+yu+3xEHhiCNvjL4juQp+eXUrcARoxBiisOD/CuMn7vPBArovFfjXRknitvC8kOu68Loi20+zNvMWYwmMbygKoodwWLEKAD/FXnfi/whdadrXhfw9PckyeINQ1O41UWaG3ieMi2maKNCAyR7YkGCSflPOCBXtEfh3RdMurK007R9LtbaTUP3kUWkFVfbayY3KOuOuDzn5qNbHBhPaLmitFr0u9u3oVfh74TPhzRrO0ufOvNRu3+3X9yPLf7TcyiRpJBvHQ4AGQDhBkZxXKfBZoo217w9NAY73R7pYfKVYxuikuppUkVX52ssy4wMdM8V6BbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmuN8T/DnSPFGt2VxJcX2lS2VlbIr6Tb+Q0iySvuVyVYMMqCOME5x3pu+h1ezUP4b2S6dL+u97fid8loC0v8Ao8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXntv8GNKWV2n8ReKLgKBEqvKyAZdk3fIqncMbuc5PHOCKh0b4S29pbXM9t4q8SGYfaVX7TDHOgMUjIpIkiI56t0x0OOMF3c1U/de+66eT8z0jXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VPrJh0qzvr6a1fyrQvK4kECrtSAuQSBx0zxxjn71eZ6p8O9VksZptW8VytFZQzXEX9laMunSSSRtkF5EywGeMKQFwOhputfDXWLNdZtdE1q3udLvleNk1qwluJ4GaEhjHMTvHB4DE4IDeppXdzKdSTp2Sdve6a9Ol9vn8jK/Z4sYo7BIIEaaL7baSYjVCA0ml72HzjruJz24P+zW3471GDxZqmn/Dvw1Nv1DUYw2r3ESqxsrVVy4BXgNJnZ85PUBsZU1xPg3wTPd+O9T8KalNO/hrTpYbWeSGOWKS8m+xKArbfm8vbCSYwwOXUncBx7P4b8H+HdDjgttL0XT4IZhFJIDpzyb22S4LZJL4ycducjABoV7Oxy0/aToxjskvO+7/4Y574k+GYtS+HniTS7KyukVNEs2toLaOLrG8jRooALEExqoA+Y9D2rpPBVy2u+EtI1aeAGa+tLW5kFukWxWkYllGeRzlceoweMU+z0vTxqLYsLEbbWydf+JaThjLJk59TgZP8WAB0rhbf4fa1obXNj4VvdF/sYShoI9U0hp5oMy42BwBld28gNk4wmWwcCujrrWp1LxvayWi7JW6+pgeJ12eJdWQKV23cwwQAR859OPy4orB1Xw3qcGqXkNx44uhNHM6P5Xh+BE3BiDtXzRgZ6DA+gorla13Pt6OZSVOK9hUei6L/AOSPfby6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjrV9T42TXItH8Pdd35GKstjcXUy3Fn5sUlpZBkfR5nz+9kzkY5zxz0foOlZ97oWi33iPQ9XeO/hm0EvHZwQaXKsBWVzGQ6bCcBVAVQV/u84retWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyauIx3S/upv9Yn/AC1m/wCezf7P4c855HzZFCTHWUHK7T+z1XZeRkWN3bJY3ANu+d18crpM/wDz3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf8A/LWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNLXlNU17ZaP4n1Xd+QX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VoXzErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5pu9jGm1bZ/C+q7ehBbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTQ73RScfe0ey6rv6Fe8/svUba5tdQ05bq1eSPdDPok0iNidiMqVx2HB64C9RTLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNa6Md0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RVPT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg0a3Bctm7PddV2fkVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulGvM39han+6m/49LzrLN6/7vbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VNY3ds91YKIJQWSIZOmTLyVk5LEY9Pm6cA9FNS3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc0kkrRwxOI5MrboQTJLjiOTnpwPpxwcHBYgV9SKjXslo/h7rz8jy/9n24gj+HGk+ZCWP2eMfLp0s3/AC+3P8SjB4IH+193qDXpSXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqK8//AGeyy/DnSAYpT/okJ4eUf8vlyeirjnt+YycivTEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIojexMWuSN09o9V2XkZFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1c0zc9nMnlyLukvhlppsDNw3JyuMDvng/xYNN112Ohal+5mH+iXnWWbjn/AHccd+x/iwaWvKdCcfbpWfxPqu78hb69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNN3sZU2rbP4X1Xb0Od8HaPpHhuW6FiNTnGqXh1OcXemzShZZUfcqAIPk+UY6k9cnbWjbXdt9vkcwPg2tkP+QTOTnzJM547569H6Doa1rZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyaGndDgoRUlFPp1X83oCXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/wDz3bHOOCPX+Doea10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNbjTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/3U3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7gnHlWj3l1Xl5GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSqmk2ukWWszajb2Uy3epJbNdO2l3LiTy4pFT5cY4GeVAyTnsa1r52/tXTv3E/8Ax/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcCT1ImouEbp/D3Xn5GTbXdt9vkcwPg2tkP8AkEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKLVm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJq4jHdL+6m/1if8tZv+ezf7P4c855HzZFCuXVau9H06rsvIyLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGjXmb+wtT/dTf8el51lm9f8Ad7d88H+LBpa8pomvbLR/E+q7vyC+vbULcYt5BiRumjzpj9znuvHrjsfm6VwfjK5tj8bPhwwt2MayamCp0uZM5tI8YjK7mwecDp1OAa9IvmJW4/dTDMjdZZjj9z7r+PPOOPu81wni8NJ8bfh6whmzEdTcjzZs820S9du7v2GeeeMGm72OGu17NaPp1XdeR19te2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdHUnH3tHsuq7+gJe2u6X/R5P8AWJ/zB5z/AMtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/AM92xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+R4d8U7mNfjF4dlWRYY2u9MQpJE0J2C9unLbWHyqNgzkg8jGRnHuN9e2oW4xbyDEjdNHnTH7nPdePXHY/N0rxH4pzRj47aJFJCsjmwa4VJAXAMZvSM7h83JHBHbmver5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvdnFhYpVJyaerfVdPl5mfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6nXJrkWj+Huu78jJtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf8APZv9n8Oec8j5sihXKqtXej6dV2XkZFjd2yWNwDbvndfHK6TP/wA92xzjgj1/g6HmvIP2i9Qt4dR8MyrEFBs9eiPmWMkH37fYMb8biM8Afd4Br2rT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNeGftV2p1DUPAtoRPEs11exM4LyEBpYVOA+0ZGfXk9cGlrynNmDXJKye76rv6Hs9slrpGjRactmYfsaC3CRabcOqbLfGFcg5AxwT/v8ASrF5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc03exvSsklZ/C+q7ehBbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0O90UnH3tHsuq7+gJe2u6X/R5P9Yn/MHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/APPdsc44I9f4Oh5rXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57/8A5azf8929V7d88H+LBo1uCceV6PddV2fkc98Sbm3k+HvidY4XVjpeoYJ02aIcA/xMMDjj2+71NZHwzij0/RfEk9yk7zX/AIi1O5b/AIlkjbCC8eA65BGY84wCCemFyeg+JzE/DjxRmOVf+JXqHLSSkdD/AHlA/wDr8nBwKxfgmw/4U5oR2ytJIbmZ2BkVQXaZ8AAYyA3P5dMkGtzh0+tR0ez7d35HXXl1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8Jqe+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6nZJrkWj+Huu78jz34S3MP2PxfLIjSB/E0oXFjJORhLfIO0fL1wQeT0rtkvbXdL/AKPJ/rE/5g85/wCWzD0444x3Hy9RXJ/CT5IfHISNyP8AhMLsfI0igYaEAYQEdsDPI7ZNdwjHdL+6m/1if8tZv+ezf7P4c855HzZFCvY5sNKMqV7Pfuu/oZFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNLXlO9Ne2Wj+J9V3fkZWuafpV54gstZuIbs3GmLdxW0a6XcRxq00MeXxjqFjZcHP393YVo3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rQvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/4/wA8edcZ/wCPWTj7uc989ccYxzTadjCkoR2T1T6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTQ73Racfe0ey6rv6Al7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP8A892xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vI5qx0+y0zxBcXKG6na/1g3LrLo8+2MfYyoRV25I4+716HoK2ba9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAk9SLRjTSSfw913fkZNtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq0l7a7pf8AR5P9Yn/MHnP/AC2YenHHGO4+XqKLVm/tKX91Mf8ARLH/AJazf89Zf9nv2xwP4cmriMd0v7qb/WJ/y1m/57N/s/hzznkfNkUK5dVq70fTquy8jw/xIVbxFqhQbVN1KQPLMeBvP8J5X6HkUUvifnxLqxII/wBLm4JJI+c9zz+fNFcb3P0PD/wo+i/I9fvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCOxJ66n51J+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf8ATIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmkZryeOGEx6coeBEJOqSYXKSDn93x16dBwP4jVy+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66ky+Be6vh7y7s5DwNpMnhjSrXR7ZrOZbWys13PqboT++lYnCx4ByxyMfLwckk10aXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mi1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwCKdhzSjoor7PWXZeZk2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVvT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSlZ8pqn++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbcxpvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5rXtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCKdrPINSlAvIRi0sRjz04xLLgfc7dT6d93Shp33KT+L3Vsur7glxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/wBMhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZlTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqTJ+4vdXw95d2ZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNW0uLzdL+60/8A1if8xaUf8tmP/PPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpWbewXh8baVqvn6dGsQubLyF1B287zY4pMmYoGVV+z9QDknbwMmt6+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptOxzciqRScVs3u+mpBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/wBjr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnfc1T+L3Vsur7glxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/wBMhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZnjXjW2N38erSeWFDJb+G7uX5LsmNcvcpu3FMuMPwONzEZOM59lvri8K3GItPOZGxjVpXz+5x3j59M9z8vSvNtbMj/G3WH8xcL4NuSX3jDZunHXGDnOOgz2x29Vvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15pJO7OfDvR+79qXV/3TPvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCGk9dTaT9xe6vh7y7syLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7IybG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTivIvj2s9743+F1u62ytJq0yr5N48/W4g5IKjb9Rnd1Nez6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0ryT4+wtqHi/4fRNPHLsm1ObAkDY2hHzwoxnbkdc+g6UrNRuY4yHtLwta8rXu+563fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbc0pvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf9MhGZEP8Ar05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2Zz3xImuX+HnidZUswn9l6hkx6jJK3Q4wpQA/nyPm6iq3w5E9r8MvD8dtb2axtZRShXvnjb57UMTsCEdW6556d60vidM7fDjxQDdROP7L1D5VlVjyCegQdevXkDPA4Ojou228L2FvbSwQ28UEaRwJMCEUWoUAAqTgD5eSTnjr81OzucsP94vyrbu+4+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIST11OiT9xe6vh7y7s4/wVpt9oE/iGFptMuBqWpjW8C+eEwm4k5jOFO4r5YycDHXvx0iXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/pkIzIh/16c/vmOfuevP0OeQcASdglCNP3YwVtOr7LzMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNk/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oa0L6eRluM3kL5kY8Toc/ucZ4QZ447c8deaivrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmm07bmNN6fCvhfWXYgtri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60/wD1if8AMWlH/LZj/wA8+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/6ZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15oSdwT91e6t5dX5GfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df8AZbIEHVZABiST/Y69cj+HqM5q2lxebpf3Wn/6xP8AmLSj/lsx/wCefPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7I8P8AEhLeItULbdxupSdkhkX756MQCw9yOaKXxOS3iXVmLBybuYlgQQfnPOQBn8hRXG9z9Dw/8KPovyPZ7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/j/ACuPLt8/8eshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecV1qK1PziU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/AKPMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/wCP8rjy7fP/AB6yHHpnv6Y96JJWMYTVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/0eY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4osrgqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP8AR5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/ABcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P8AXncT8mevLY7/AHeKNctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dqTT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxSsuU0U17ZfD8T6LuyfUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP8AR5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x70SSsYwmrfZ+F9F2C0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxitC2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFU7W0B1KU/Z5jm0sTkJDzullHf17dz/FxTaVylNe98Oy6L+YnjtL7fP/AMTHVv8AWx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96g160UaFqZ+zzDFpeHOyHjacdvTv3H8PFXL6zCLcf6PMu2RhykIx+53dvz44x/tUJK4KouVfDvLovIr3lrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/x/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1JlNci+H4ey7sz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/o8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKVlymimvbL4fifRd2T6jaX2y53ajq3+tbO9bXr9nPXCdcenGPemXlrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/wDiY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93itBLQFpf8AR5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZxOq6RqS/EbX9QaLUjbDwvNEb0wx4dvtMxaNm27OmCQmGwARXe6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCirkU7QjutXJ7LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitRymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxiobSzVtRmJglz9jsW+5DzulkHHHftn0+araWgLS/6PMcSIPuQ8ZmYf0xxxkc/LimkiqtRXfw/Z6LsjPsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFedfFe1l/wCE98CLdzX1yvk68yibyRtZbcnI2Be4yc56cV6Tp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFc9468Hrqd/pmuiSeE6Lbao3keRCRMJIzH94EbdvHY/wCzjFTZcoqj5qiirfH2X8x1Go2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Ud/YqNU01RbzHN+V2iODI/wBFkOOmM9/TH+1TaVhQqK32fhfRdhLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxTaVylNe98Oy6L+YnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8VoJaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxRZXBVFZ/Duui7MwfihBdQ/DjxO817qMiDTNQBWUW4U5OOdqg9cZweuMcZFdNqlreH7WRe6pGhmc7CtsQv7g8fdJ6e54/wBqsP4iaTNe+AvEVtaWshnk0+9CBlhUHBx1H5fXpxmugvrMItx/o8y7ZGHKQjH7nd2/PjjH+1QkrnPCX71y027Lu/6ZXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xRfWK/2rp6/ZZ/8Aj/K48u3z/wAeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFam0prkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/AEeY4kQfch4zMw/pjjjI5+XFNJFVZq7+H7PRdkZ9la3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/wAf5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxTaVylNe98Oy6L+YnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8VoJaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxRZXBVFZ/Duui7Mj1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrgqi5V8O8ui8iveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/APH+Vx5dvn/j1kOPTPf0x71Nb2SlrI+TId6R/KEhyfkc554wccZ54OeQtJJakyqJQXw/D2XmZ1ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKgtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxVxLQFpf9HmOJEH3IeMzMP6Y44yOflxTSRVWau/h+z0XZHiHicMviXVlkaRnF3KGaTbuJ3nk7eM/Tj0oo8Trs8S6sgUrtu5hggAj5z6cflxRXE9z9Fw/wDCj6L8j1+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUK22gQanpNlcW+jx3d3ErQQSWA3z7UcuVTrJjIJI9j2qa8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulcdr9lPffFL4d6pbafPJp2nwXf2uX+zJdqGWAqmUxukJKn5l9M9BXWuXU/PKkq6pq3Nsuj7vyNbTbzwpd6jaRW8/h+f7dbW32NEtlf7QySyiXy8H5yu3Dlc5xjjFb6aPpm6X/iWaf/AKxP+YYT/wAtmH4emO4+XqK8G+H/AIV1vTNZ+GEl9o91HHo8F3/aH+is/k+dLP5RYDmQMGGCufTsa95S9td0v+jyf6xP+YPOf+WzD0444x3Hy9RTjy2G5YiWr5l8PfsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0WN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5TZOt7Zay+J9H3fkW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS+vbULcYt5BiRumjzpj9znuvHrjsfm6VHeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSm+WxlB1rby+F9H29CS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/AJBM5OfMkznjvnr0foOhofLcpOt72stl0ff0LSaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1bS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/+e7Y5xwR6/wAHQ80e7cE61nrLddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpVTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpQuW4J1uVay3l0fl5Ed5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1HeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmhcupMnW5FrL4ez7vyKltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKtpo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaxfHtzeTeHLuHQtMmu7iS4hWREsbqCRYvtDbjGVaMlsADYZY8j5d2VwwuWw60qyu05dOj7LyLkJ8Owpe290NFjuoIb+6kjkswrxwLcMokIJyqDaQHPCYwaztZ13wMLG6t4dT8LC+ltZ/IjSOMSO0mGh2DdnLAgoR0BHXNeVXfhPxVd+CvDE8K3kPiSa3u9E16R9OM7ixe4Ys7O2VZk7lMSfPgtkV0+geGJ9F8YeO7qGHUbDQHsIoNPjNi0kVykNsYsMXVpI/LOMMWXn7xYUtOUmnUxMqydpJc3+f9f5nq99o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYcHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVu2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/wCsT/mGE/8ALZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODVtL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf8A57tjnHBHr/B0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulC5bgnW5VrLeXR+XkR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/wAXSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmhcupMnW5FrL4ez7vyKltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKtpo+mbpf8AiWaf/rE/5hhP/LZh+HpjuPl6iqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq0l7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKFylVXWu7OXTo+y8ipZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DRY3dsljcA2753Xxyukz/892xzjgj1/g6HmjW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NL3eUtOt7Zay+J9H3fkW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS+vbULcYt5BiRumjzpj9znuvHrjsfm6VHeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSm+WxlB1rby+F9H29BrWGi2cUNzeWelQW0MCSzSzadhEURyFmYnggAZLdDjP8JrGN94RtLh3vp/D8MB0yxvEaW3RV8ppmUzZJwVO5FLjhsqAelat0NN1SyGn31pNLaXdqsE6f2VcjejxyhhlQCSR/EpGeCPu15B4C0TxJotl4kvdRs7i+12wsINJ0H/AEDyWkslkYoylUdAzkAgzIxJXaTgtQ+W5E5YlSaXNbS++mvoeraFP4U103Z0R/D+pLDJF5htLVZhHumfGdpO3IHQ9QNo5FWLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGuL+EFle6FBr1pqGn6hFppvopbJtS0wzX8pZv3zzvCCpy+QMkuQCpOAuO0sbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80e7cunKu4NvmvddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VwfgO78z4e6sbtri4neTVcPLbTXG0CZlUB+QgAHsF5J+9XeX17ahbjFvIMSN00edMfuc9149cdj83ShctxUqlapSjNOWt/08iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1HJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eoqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoatJe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6ihcpVV1ruzl06PsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NUdQPh64h1+wsotKfUtOtLhriKLTyJLcvloy390kAkH+EdavWN3bJY3ANu+d18crpM/8Az3bHOOCPX+Doea848PSxN8SPjFJ5TGM21sqg2Uh2n7O+PlxmPofmbgUvd5RTqVoVo6ys52/F+R6lfaPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2FB1rby+F9H29CS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhofLcpOt72stl0ff0LSaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1bS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNHu3BOtZ6y3XR9n5FXxVFoel6NI1zbaZbS3fn2dpnTirSXDk+Wif7Z2nb/AHeh5IrVvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpXCfF64glh8DCKMxn/hL7Mc2Ulvn55O7j5seg+70Nd3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3OelXrzqSpXl7vr176fcR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/CaFy6m0nW5FrL4ez7vyM9rLR7SW6nvbXTILSCxs5pJJtPwka75d7sx4AwOW6MBjtS2X/CM3l0sFouhTzzxR3kMcdmrtJAZ2AlUA58s5Az0OQuciorpNO1NL6yvrSSS0vNPtbeZBpdwGZWeVXGVAIyDjcMbuinIrxeDwF4iPgzxlBcvd3Otw20WhaJIdOkgaXT4p93Bj4Uy4K4ky3G0tgmknEnETxEZe7zPbv2XkeyeHP8AhHda0m5udLXRdQhSS9Qy21mJVUiXKjcCQDsZSP7qkeoq7reladHouovHp1grra3jKy6YVIIPBB7Edj/D0Ncf8MJdYtLPWrbWrGaHSYnmXSln0kC5VBjeHFuvlKFbIXHKHeDgba7DW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NHu8prCVd1E3zfF2fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bEQda28vhfR9vQkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/wCQTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/6xP8AmGE/8tmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NW0vbXdL/o8n+sT/AJg85/5bMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JoXLqTJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6ihcpVV1ruzl06PsvI8b8SIkXiLVI40VI1upVVUTYFAc4AX+Ee3aijxIVbxFqhQbVN1KQPLMeBvP8J5X6HkUVxvc/QKH8KN+y/I9rvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12p7n5zKk+RafZ7ru/MLVm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJq4jHdL+6m/1if8tZv+ezf7P4c855HzZFZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNYvh7xPqeoeNvF+jy2+mrDpMtl5Z/tCZC3mlpD820hx0O4KuAc8k5oTQVo2kk+tuq7LzOl09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX902VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOagvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05pt6GNOk7bfZfVdvU0LZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmi2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc0N6lqk/e06Lqu/qa6Md0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RVPT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg1zfiXxddaDrugWUlnayJq9+LUumpSEJ88jAltowM7ecHjLDk1tWNxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF1ciMb80Vumuq7PzLWvM39han+6m/wCPS86yzev+72754P8AFg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUpUnyrTrLqvLzJ752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qG9vm06w+2rZ3Vyba0Ewhilm3y7Y5TtX5eCe2OPTgtiK8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaw/HV3cxeBdakmtdPljTR5S8Z1OUhgLebKkBAfbaCMZABG4mhPcipTapr/D3Xn5mr4e1KLVY7fUbWC6Fvd6bp1xGJJJlbazyMMgAgHB6AkA/dJNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVxXw3nuB4T8P7EsT/xI9JHzapIvADdthweuV6J1BOa6lLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTRF6DcJSSb/u9V2XmGns32C4/dTD57//AJazf8929V7d88H+LBo15m/sLU/3U3/HpedZZvX/AHe3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7psqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNVdXuo7W8s7i6DwQRXrSSSS3E6qii0kJLMV4AHJJ5x/s802+uLwrcYi085kbGNWlfP7nHePn0z3Py9K5X4t3Ui+CtdN0lsEMF2AbfUZJ2JNhKo4KrkZPLZ/2cYpt6GCg4xu/5X1Xb1Ow0q8ivYdNurPfPbzQRSRyRzTYdSkhBBC9DntkdccE4htWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmuI+Bl5dyfDXws6xWvliDYrTajJCSFadegQ7Rxjg+n9411ltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNDewUYucHK26XVd15mujHdL+6m/wBYn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89//AMtZv+e7eq9u+eD/ABYNCXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUtUnZ6dV1XZ+Za15m/sLU/3U3/HpedZZvX/AHe3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oa4D4G+I9X13T9XnvZo7nyNangja61GSLy49rMEXCthF34HpwMYNCe5lNNKMLbx7ro35+Z6Has39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaEzWrSd3p26rsvMNPZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg0a8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+LqaV/dNFSftk7fafVd35mvfMStx+6mGZG6yzHH7n3X8eeccfd5rC1HxJaL8R9M8M/Zr7+0WT+1N3my+X5flyxbc/f3ZAOdvQ4zgVo31xeFbjEWnnMjYxq0r5/c47x8+me5+XpXE3yzN8frS88qxLpo8Me86k4Vdz3fAlxuIIXk7DggLkZ5JPQ5HGUeXzTW6/lfn+P4noVszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOabep0Kk/e06Lqu/qa6Md0v7qb/AFif8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/8Ay1m/57t6r2754P8AFg0JcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF9RKk7PTquq7PzOQ+HJI+GWr4SRv3mr8q8gH+vbsoI/Pg98cZ9FvmJW4/dTDMjdZZjj9z7r+PPOOPu815p8PZJV+HGqKi2xjMmrbi948TDM79ECkN7AkbuQcYFd/fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elKL1McLTboQfr1Xl5k987f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOOFsPiDb618SpPDVrZMlzp88k73UuoyLbSOkRjeNJNu4kCRDu25OSvQAnrra4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RpprUcbVYe50Vt1vd+f4has39pS/upj/AKJY/wDLWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/PZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upoTNatJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNeX6C7D4p/GNfLkIaytycPJlf9HPUgZPX+IAeuK9Gsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK830Mzx/E34webHbLI9pak/6a23abdiNr7cyEjB2kDPc1LfukVoNVof4+67vzPXr5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elcPr3xGex+Jdnob6M08EWoWttLdwaq5SO6uoXWFMlcsu0ElgARnHIADU2rGcpRoRTn1TW/dev4nolszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9ToVJ+9p0XVd/U10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaEuLzdL+60/8A1if8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+olSdnp1XVdn5nA/HC6Ya98NLYxuqyeJUkyzyNysyjHzAf3+3J74NeqXzErcfuphmRussxx+591/HnnHH3ea8S+OEs0nxD+E/nLbLjWpMeTevcdbm36hlG32P8XU17DfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elCepxUKbeIqL9V/mT3zt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE48/8f+OtQ0TxHY6dpOgDXNVHm6kbey1WVtkKQ7NxJTncWZVxyWG30DdZourPqdrpV/YpZmzubaGaJptTliYo0blSw2HYcEZAJAyACQ1Ca1NuaM/3a3Ue/r1v5mV8P/E0Hi3S4dasrS7hguLW1VUkml3Dy7mdD90EclDgA8duciupRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIryz4BefbfDvSEjW0ObWFv3moPEcG7uG+6EPqc+gwwyScejpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaIvQtQlOKk+qj1XZeYaezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBqrp9xcrZzbYtPcb77htVl5JnPGNnPfH98cnBo1y4u30bUvMSwAa1vNxTVJCeT2XywD7DgN1OKV/dN1Tft1p9p9V3fmVtM8Ryazq/iaxOmzW8el3f2cTm8kkEzG3LH5doK4BH3uucdAcbV87f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc15r8NbuabUfiC8EECt/wkV0jpLftwyw7TtYJ84JBxkA8gc7ia7+8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05ob0OXCxlOnzPXSXVf5mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk0W1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df8AZbIEHVZABiST/Y69cj+HqM5pt6nQqT97Touq7+prox3S/upv9Yn/AC1m/wCezf7P4c855HzZFU9PZvsFx+6mHz3/APy1m/57t6r2754P8WDQlxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1EqTs9Oq6rs/Mta8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvWyJ90cqKZGyzyzkL+575X8eeccfd5rI1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upqzqWq3GnQ3V9NDYNFbO87BNWkclVgJOMx89MZPU/L0ovqTOEo07pbc3VeXmZfhXxRbeMdL0HXtOtL2G1u7+QpHNNKXG2CVCCUDDOVJyCTjjAFdFbM3nWf7qY/u4+kswz8knTC8fhkcHHBOPJ/gDPMPhd4P2LabRe3O3zNQeEn5ZxyoU7R1+YEk8Dvx6ZbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe5KpuVGL/ALq6rz8wtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmriMd0v7qb/WJ/y1m/57N/s/hzznkfNkVkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U0JmlWk7vTt1XZeZ454n58S6sSCP9Lm4JJI+c9zz+fNFJ4kJbxFqhbbuN1KTskMi/fPRiAWHuRzRXG9z9Dw/wDCj6L8j2u+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCK95a341awBv9XLHUCAStruB+yvyPkxux+GD60sFveRvZu2p6oirDEd2LUYASXkZTGMZ69s55xXWnvofnEow5FrH4fPu/IitZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6V5V8JdXN38YfiiUlEYa+gUs0yhWMUroWztwckbs4HH5H0+whupbotDqOpshtLAiRBakMPNk24+Xpkcd8k7uMV5J8IrRo/it4xeK8v0n1OSS9jeNIC0iLqU0RZt3AO5V4C9fQDkT8jDFqHtoWa3X5LyPYdPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KrxJPb6TeXF1quoWttF/aDSyyfZQiKJ23sx2cDjLe/3eK8K1weJr6xufik82rRaaJwttaSyIHm0lmMcrFFUqGczbvugKNzDd8pBf3bWNa1anRqp6P3m9O13rsfRN9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUU8dxdWclxBqupywTMZEkxalXU2+QcqnOV9ONvvTry1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1ob02KhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLS2vTfOq3+qcWlh8wW25HmybR93p6d8n5uMU29VoUow97WOy7/AM3oeafF68/4uj8LIVvEMn9qTyyYlBAAlTYxO3A5MhBweCT04Hp+nzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229K8i8bfbI/jhpsgutQnSGGxtWbzYlaKWbVcgFVXa3CFsMMbgD0AFes2VretYXB+3aqozqAI222P9edxPyZ68tjv93ikn72xzYdRcql2viX5S8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvMvGM/ifxLqmseH9C1S/0/S9KiuG1XUpTBv37RIII0RQSvzxM57jcoxyG2/h5rWo+LPANtql5f6il8ZJYLyNRblUnjiZH6pnnbuxzhW6luaaeuxcKkJS5NFa+vR7baHW31zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXO/EeZz8OfEI+1RHGiTjHnLwPs04x9zryRjryBnkEb95a341awBv9XLHUCAStruB+yvyPkxux+GD61zfxFtrtfh3rzPfXzoNDmO2ZYdhH2af+4obpnHPrnPApJ76FVVBUr3j8P8An5FfwRqkeleA9Lvby/iS1s/DmlzSssoYqkaux+URknaATgZI/wBrpXTaDrtrrmmpqWk6pb3FlcMjxyrMo3YnfsY8gg5JBAx1I/hHj00N94q0Pwr4F0u+nkhv9D0yTWcGINZ2ibWVVIUDc7SIEBJbBYuNpDDovCdjdeDPiNqfhiOW6s9J16Y6npnkLbhmmjdVnjbcp5GA4VcKBnjGcEXboc/tYuSSty+6r+dl5eXY9B0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Rf3dj0FGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmuC+Pl/5Hw71d57qOVGd0wkquSXtnQNgKuR8wGcj0x3ruNRtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvXC/tA2V03wq8Rxz3epTeZdWsapMYFBYywjnywCTgnjle+MjIbd1scdRwp0+a6+FrTzVuwfAF3t/ht4fgFxFE9u00LFpFQZWe5GeVb/JHqCOztZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6Vx3wcnvtUtNTl+1XcEq65ehltEiCljLO5IEoJH3z36Z74NP8d+Irnwrp0rW99qUutXlpZW2lW2y3Y3Nyzy+Uu0LnYGGex6gnJUUm9tAo8kaDlJr4V67+h2VlqkF1NeJa6rZTSQTokyx3cbFHEzHDYTgjO7twc4IOBHp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvK/BPhOf4f/EPTNKhv71F1rS83UqyRySXV/BdAu+HBAXbIdvfjknkn1Cytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767F0HGpTblZPm/R+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzWfrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvQnrsaqMOVax3l38vIL65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5rx39kx518FahNJOkLSay7bnlVMn7Ohzyp7N1/2h65Hrmpw3sN/aO+o6qMXzHe4tRsItHOeExnA9xt/wBqvKP2cEnWLULC2nvIGiGm3J+yiEhvN09SP9YD83yn0755xUp67HJW5VOmk1rF+nXyPVrWeQalKBeQjFpYjHnpxiWXA+526n077ulNs9esrrVb7TrbWrCXULdkea3S7jMiDzydxXZnALqc9PmHXO0c54x1y58K6XdXiXepT6g1pYQ2Frttibu4aSURRBQAxXcM/L82NxOcAVwer+Cbv4f6FovjCzku31fRZhda7L+4Z7hZnK3RU7fnIYDZvyBgnrjLT8i8VUUJtKztZv7l5b/oew6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6VW0hZ73RmurXU9Te2mW+eN1W22uhmJ3cpnB6n3Py4FS65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Rf3djsUYe2TvH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvJNb1a50/8Aah0q4aTdZ3NjFp0l0siNGs0onMI3bMBmKFR8ucbuvf0bxje/2Bomp6prGr6rBZW7kyySLa9TDtA4TliSAAOuRj5q+dLiO+k8Z3viPX7m6gkfUNL1wC+RVkghN28cKvs4GIWVjgDHTHFDZ5OMlGMYKLTfl/wyPqC2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKntLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYpt67HpKMPe1jsu/wDN6Ggk8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOBU02aV7KdVu4mLSXyhRMpJzcNwBs53dh37belTR2l9vn/4mOrf62POFtev2h+vydc59s5zxiqMRvLLSby8bUNVjS3GoythbXACzsWPK+2T7/d4ob12E1BQk7x3Xf8AlfkeU/APUEu/hR4kktmjto2udQOxpwXYNHE3zZU5bBA+XaDt7HJPp3xD8Tf8Iz4T1nWZp4roWxysSzK3myPGI0HCA4LMqkjpzxxuryb9nS1uY/hJ4gVbm8jVXu3MMaxbWVra3bLbgTggjODnAGMHNdXrdrfeNfiJJarfXdx4c8NTNLdm4SE+dqBgbYiFF2MYQAzZOVJxjOCUmckGlhoWau7rrfp5fPc5yx8Nt4BvPhtqdxepPqT61NDqEyzf6y4voAGYkggBSgXPfaeM5r2y2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXII474sebYaTYXV7dXsvk+ItNdDdR2xVHEsR3ZRQVbaCMjjBIPU11lpaX3n2G3UdWz5UW3atrnGyXGMp064zzjOecU0/IKVKMOZNq1l+Xp5EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxihPyOyrGF3rHp37LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6V5d4enLfFD4ySLfQS7rOBTKsgw/7hgUBwQSOhA28j+HpXptla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ivD/AIRztqHib4m31v8AaYRqNrc3zGPZ86m4uBht+fl6A7eeOD1qW/dMayisVTtb4n+foe6+JNWj0zSdT1C+vUa2thJPL5cqOxVbc5IGwZ4G0cjnjg/NXg/iaHVoPgNe63LK413WNXXXLmIyKxjOd6YXbnYsaIcE8HIxxXoPxWd9YvoPArPf6jc6pOl5eRTtEq21nD5bySOYVDAtsMa8hTu67hW38StEvdV8N6jpxu9Qla5M8SC4FuFVzYyYJ2KD6dONvbNOTuZKMZt6q0Yu3rbpp007HUxTstza+XeRKqpGFJuE+UBZMAnZxjOO/UdcgijazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0rG+G13da54R8L6jDquoyNNYW+4w/ZSA6xyq6jKdmDjB5GGzzitW1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMUN7aHRSUHBtuO0e/deRoJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pU8dpfb5/wDiY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93infXYtRhZ6x3Xfs/I8W+M1y938bvAVq0qSC0uILkEPvGZL8KcbQBk7c8jGMeoFe8308jLcZvIXzIx4nQ5/c4zwgzxx2546814L8S1S4+NOjySveS3VhdaXa+ZIEC4kv5pG37QBu4TG3jhvavU/iLrV94c09hb3Gq3usXt0bewsnS2InmMGPnKqNqgHLNkAJnkGknqedRcI1aknbT/Ppoc3piXXiPxz4p1W9O2znu/7FtPtLiPzI4La5SYj5QGQyO43EDBBUHrjU+BeqT33wz8KTyTRW5S2FuoaYDAiaeIH5lbH3fcDdgYBAW/4M8K3fhXQfDWjLc6jHLb3OJhC0Dr57WsjyspcEkli55OMN0BwBz3wlkkRvF1ql7e240/X7pkgt/JOyB1eWM/vFOCd0nQ44PfGUna5ryxioNtaxf5t9v8AM0/hDCNP8FaFBBdoqNo+mzEPMgIZ5JZDxs6BnJ9hgnPSu2SeTdL/AKZCMyIf9enP75jn7nrz9DnkHA4n4Ux38/g3Qi11ewkaPpigWwgK7Q8iqPnUntn/AHi2flwB2Mdpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8Ypxemx0RjBwV3HaP5R8iDT55DYXAN5CcvfjHnoc5nbI+536j17belO1h55tH1CKK5jlkktbtFRJlZmLH7oATJLHoO/bHSobK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xVuaxuZIJUur3VJLdoroSI4tgrJvG4EqoIH97BB/u0J+7sazdOFTnvHRt/n5HiP7Ol9JJdePIY7gi0+3i4RWKgbpBcqxyQSciNQB/InNe3X1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXz3+zLazWh8QWZmngmns7S7Vowm5kaK5b+IEY/eD3x0r2/wAX6nF4Zjh1XXtb1OzsIL/95PIlsShNswGAqHLHOMAEYPTdRfQ48FyeyvJraW//AAxs21y6z2Q+2wK3lR7czoMAI4/ucYzg9cbh1yCKlrPINSlAvIRi0sRjz04xLLgfc7dT6d93SvIL3TNa8Paba/EnV2uk1sXNrcTr5rb7XSpFaP7NtAUF0BVzmPG9GLKR971y2tL0X8ii/wBT4tLD5lFqQR5smMfLjGR8vfJ+bjFDeq0NaFSNTnvZbfddeRfSeTdL/pkIzIh/16c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/8THVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767GyjCz1juu/Z+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0rL+KF1IvgDxWxuo5f8AQrokJMjE5tGGeEHGOM/hjPNaGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1zPxwmu9K+GPim6uLzUpIypgZZkg25liEQzsUHPzjocYx3pX12M6ygqLs4/a/TyMP9nqZ0+FXgwLdRRAX90cNKqYOLgZ5Q8ds9O2O9epW87rLZFb2IERx9ZkGzCycZ2Hpnv03Y5yCOJ+GejS6X4d0mxsbu9jhg17UoEjthb7Yikl2uF3rnOF78YPAzirPjvWtU8L6Ba3WnXGq3esXAgtdNtfKgYTXDpKEGFTOwAMxyR8qtkglaE9yL0/YRk2vh8+78jo7aScXryfaoxGbayQEzKBlZJDt+51XcCR2BBOc4q0k8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOB4pomjXXwv8V+HALm7Frr9vb2ut3zTI+6+eWSWGZd+c7ikiDcAAOWwTk+zR2l9vn/4mOrf62POFtev2h+vydc59s5zximn5BCaqpuaUXdaP5W6HiviclvEurMWDk3cxLAgg/OecgDP5CijxOGXxLqyyNIzi7lDNJt3E7zydvGfpx6UVxPc/TMP/Cj6L8jtLj4PeDIdStFTQtTE0t4Ymm/tObzf9Q0mc+djdlc56YJ71JH8KdEvJbKHVJvE2qWTLG4s7zVWlhyVcghC2MZQEBvQ5HQV095pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E12JPU/MnhcOoJ+X8r8/M4i3+GkdlqK/8Ivq/iHRIYILeaK0jnjuLRWnaRZCIJSy4YgEejZ6cYwE+El6njqwhstR8R2Wh2GlNAdRtb6OK6lme/kby2YdSfMc5xjIHNel22k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKtpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eooSY62FoX0bVrdH1S8+pwtl8LbO8t0/t/Ude1mwsp7ue3sr2WExeZHIU3y7QDLjBOG/vEAEM2e18Q6ZbSeGtUt5rBntjZXitEY4QpUcY+XBAA4OMEfw4FQ2Wlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0a8p0Ro0lV5e7a2fn1uca/ww1vQl8jwt4212xsIVEBi1O1ttRKbYsgISVCKE4CgEDAwc4AdffDXWtR1DTl8R+MvEVxN9pa3zpkVtpwH7l5AQqZG7gDknjPPOB3d9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3UO9jCnRpW+J7Po+3+I42w+FlxK9r9u8Y+N3kZEKm0v4rfgoxHQEk/IeSQTznHfNt/hlquh3k7eBNf1CxllW3vJ49RhgvI55Ji6Ekt83JQEZyck5xnNekW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAoadx/V6PvO72XR9/8AEeeaz8MNeu9J1lpNTuL7xDqd/p+byCKG0SzjinZd6oH+Yj5zwwyQAMY+a/afCsvbXjf8Jb47SHNxsRNUjXBikKlmwMNk5J4zzxnqe/TR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBos7ijhqKu7vddH2b7lO18JaX4X8HajYaNYXENuLa9lYyGORnccF2ZssTwMnOf7vFYut/DvUrbV9bvfDPiLUtEt765a5ltDa29xGLgw7mkG48biAzBeD69AOm1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKetzT2VJwim3o5W0fl5nGv4d8f2l1awNrmk38guysUtzosSOX8lmwwSUKBsBHAxznqM1znxI8NeNbjwNrE2o+JLKOzSwe5ktrTSI182MQs3l72kLAHy3O773zHOcKo9RvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3Vz/xBsLC1+H+vSw2VrFJ/Ys4DxWJRgWtphncB78noRz0U0lfUxq0oKlfmfw+fn5kHwn8IWHhrQbeGysJ0nutP025u5GMcjSzMXUnL5IXjCrwBzkDJzf8AHvgt/FWmxxWdzdabqNjexXVpdJFC4jlEsiDcmRuBBIxnGRz8oFWNC0rT2jt1ksLF8afp7HdpzPli8m45PUnAyf48YrUTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FEb2L9nT9mo9Pd+z5LzOFi034kmzmW2m8KrEj3J81rBw7bJSJCR5hAy2enIH3ak1S0+Jot75Xg8BmwWK4ZpZoLmNjGpw+QjOQR7EkZ+U11dlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DRry3L9hB1UueXxefd+f4nEn4Za7dabc3viDxRrMHic3JlWawlVbK2xEWCLb5AZcHJ6E465yGoaho3xH1a70Dw74k0fTGtl1a3kvNWs5oQlwsIMpTyiqsrMqK3GFzxgZOPUL7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruod7GCw1KS0k1dNvR66X6tnjXw+0zx3car4wk8K3+kLaQ67d28FjfWokjkkLOWfzOGAAOV5YEryBgZ7vwp4DltPEp1XxFqeoeINVgt7ZrWeSGGCKBZXZG2QglVLKignqec8E56620fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgUO6saU8PSimnJu1t0+/qZPjrwhqGszabqXh2SOz17R7wS2r3aKYZFeR43hl2EEI4wDgE/KQMAgjDsLb4oNazGOx8GQxB7nd5xlZsrKRKQyqNo3Z28MQMYxXepo+mbpf+JZp/+sT/AJhhP/LZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODTd7lOlBtyU2rtdPJ+Zx2o6Z8S7fTr37VceFLi2e3uJJ2+wuGhAP7xIsONyryFZsN7Co7zwb4611TbeMdWtdPs7UMyS+Gybeea4EYZWlZh91VBO1MAk55IFdrreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulLW5P1em4pSlJrXo/Lz/wCHPN9e074nafoz2s+maJ4iuWme3gltpI7Sfc0DgNJEy7G+Vt2I3GMZ4ILDnPBum+L9N+IWvaF4TXRpzBY6TBc3WpQMxRksVVTGqsFyVDNhvRc817PeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqeHTbGQ6fFJY2TxpGm1G00sq5WQnjvk8kjqef4TQkzKeHi1GTm3p22Wvn3ON8O+C9Rk8Rwaj4u1J9buLCG3msUisbe2hhMzMhZlBJlbCnaXJ2l2OB1rt5tNiuoLy3ntZXhlxDImyHlWldGU/UZXjjqD8uKzLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FNXOiVOnC6TetujfReZwOleHPH+j6d/Z+gX3h670WzE8Fq+swut0kMTlNrGIMrbQFUNweOABV3Vbb4jDTbxWsPBSRrC/myzSzuhjAInIVIlYENgjnKjIG/qOmstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehpa8oo4eKmoRnJK9tvXre5zVr4F1m81Mat481D7dPaz+da6dYQrb2dnOiF1kGH3SMABgsPlDPjJIrnvGnhkeJ/il4l8OlJFW+0m3iVWwgSQJcvGW8sgELIqPjvt6HpXqN9o+mBbjGmaeMSN00wpj9znv055x2PzdK4m1sLM/G7VLf7La/ZhBZDyPsJ8vmK7P+p69efrzSlexhKnT91JvW99H/K/P8Cx4a17xCNL01fEHgrW31VYUW4a1SxaOVgr/ADr8wGG+9jHGCOcA1LaeIpJL/VJI/B3iphZ29ssga0s1LbZJctGDJ+9DYIUoW3EY5yM9TbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCm+a5tGnZSSqPZfZ815nMWvxJ8P3t2ljpem+IL/V5ZIt2nRaUEmgVpTlpDIqxoBlFJ3Y3MByvTn/ABX440K5+Gfi22V7jT9XitryObT9QgW2uITPKRGGQLk5WQfdyPmAyBnHqSaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eorK/4RrQtRgFxf6LpdzPbNerDJLpWWjC3D7QpPQDJI7JnnmnrfUipCbg1Gd7u2sbdH6nlZv28K6Bqfh3Qlijvb7WJNPgF2qymGBNPtvNnA4BZAo2qccsuScEH17RPCtn4X0I6dYwXZWKR2knuDE8s0hhLvJI5ySzNljzgDpggY8iv9OW4+Kd4YQix6fNrM3lrCVVVNhaRjC9h8/A/hxk9MV7RfaPpgW4xpmnjEjdNMKY/c579Oecdj83SlFu5lgox5VKTel0tL9vPzMX4n+Ex4n8PXOipZu091NJHAJDHGqzC0d4iWTBGHCsQOMDkE5B57TfiNFC8MHiXwr4ksNUiRPPht9MW5jbhxvjdVIZWOMH2PJwDXb3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TQr6nRUgmoyU2vd/l835nGW/jzQYLt5tVsPEWmK8FvGPtehSjcY2kaQjER4CnOepwc5AqwPiX4GWC9ml1qOBYGRjHcQLBKVLFwVikUOwKFSNqkHOOmBXQW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjArQttPsoJJDBZWcZWVSpTTmGMzMDjHTgAY7gbeopq4VVON7Tu9N426LszmPB3i7wrrUVxDa6kiSRm6nkiuUitpFiZxIkmyRVbZ5bq24Dv8vQ14L4I1y503wvNJZLE+p6npcFjbLMoKCWfULoZPHACljkc5x2zXv8Ae+DfDmvaef7W0WwuDBJfGMnT3QricgcgjjAA54UDBryj4nQx6d8QbG3srYC0trrStttGDEnlRSXr7AP4RiPpzip6JnJjI1nV5k9eay3Wt/Pb7z1nwr4Gt/C1hdyT/adQ1ueVjeancJF5kx8ndt6nag7KpwB/tAV0d5ZhdW03bbXAI1AgYS3yP9Fc49M9/T8ar32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdVO9jtpRhGNot/C/s+XqeZ+EL+5+HM0/h/xB4f1qfR4pzcadqGm6eLmFoJd8mxsJwys4BHPfsq1u2PjrR31Jmk0jxPHFJBbxrK2gyFWdHYuoxGT0cY4553dq7O20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgUnciNNxTUajskvs9L+pyUHxY8F3U8sGly6rql15qqLez0h3k4kYngxjHy44/DGBiol+IOn6TpIvdd8N+J9K0u4kuRHfXOnw+XGzTNgShCWjIJC8jOcgYxXepo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqvpmnWKW0syWNks0cl6UkGnFWUrOdpDdiMDB/g6U/euNxk02qj3X2fJ+Z4x4g1TSpPF+tazb32n3+nnX9FtoJreaJjAkbLM7tgFdpMjICpXlGGcAg9f8L9Jvde0+Hx54kmkuNVvoHitoIYo47azgKF9qL3ZgEYvjOOByMnM/aF0fS9J+FE40rSrKyMV15kf2K0FoEfzkBcgDD/KAMdRxnOK6/wAB6VZN8N/DrXFjbSTHTrbc01iWf/jzXguR27Dtjd0oV7nFh6a9t7789ut+2h1d9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPevOvElnqvhTxFqWvaX4dudY03V7C3a98h4vPgljjkRWSMn51ZSM4G4eWScda7q80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdWX4o06wtvC9/cQafYrNHpryKy6fghhDMQc+uQPm6EgH+E0tdTtrxjOmnzPSP8AL6+ZxPgLUPFl1pGh2+keEk8gaTp6Ne6jewRxlcMI2VUV3IcnHIyNpDdcDoJbL4oebJ9nt/AwQuqlZPPkKZkYDkIo+8COMj2IxUvw30+yufCegNcWdpM39h6ScyWJlOSGBO76AA+oAXtXUpo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoojexmqacFeb2j08kcTb6T8RbixeA3HhfTov9KE15awNdShhKfMaON1jUBWOBuJPHHBrO8SW3xH0HRr+EWem+J9PaC5jW5URWV5GucNJIuDGQhIA2kHAzxya7yy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6GjXluayw8ZT5XUlq2tvXzt+B5npXw28W2Gr6ZOuojSNObRbWy1IWsFu1wJ7eFSY9zAj5gWYSjcRtK4wFz2ekfDTQdA8R6Xfw2eq3urC5e1a+1G5W5mkU2ztg7yUDe4UfLx1zXSX2j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdQ00jKlhqKXV6N6xfb1LZ0u3vY4La6snnt7iBFkieKBhIrJJkYIwQcfxehzzivNdC8M+OPDcs9hoT6NqmlQRW0lsNVdkuhAzMI4FcK6kAh1UtjggH5cKvodto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjApu9zaVOEnJ8zTSXTz9f63MC3j+ItxMZRo3ha1g3rvt57xmlBMhUDesBX7wI4GMDHTFQW1l8Qk0e4SG28JNdLPdSGbzJfK8sOfMQL5QYuHJAbIAAwB3rsU0fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1uKNNWf7yW66eTOW1jTviObKZ5T4NgtkgkaVBFNMHCribcwVGVNxyNoLKOATj5ud8e69fazoD+FPEfhHU9C1LVdQtbdpJGhezCiSOUqtzGADIVjJCAD2y3X0vW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoau3el6fFHeLFp9iiu7IwTTSmR5W7HsMgHB6EBu1LVuxnLDqUEvaS1v07Neen6nlHh7S/HOpi7t9LudK0uwPiTUI7e9a0F3dGQSzs52yME2Y3qAwJyCeDg12Xh34fi38Q6Vq+r6rrms39urfZlnaBIYlkSQArEoCl9gwWb73zHCkit+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmhJiWGpRgryb0vs+76XMfxL4Zj8SaXq2lslzC91p1mI5k2L5cpklMcnysrHa4VgMjJUbuK57S9b8ewb4da+HhndCENzp+oWhSSQOwGI3GVRnVhkngYyGwAeuttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FNXNq8IubkpNPT7PkvM8Y1KUT6jdTXel6xaXEkrvJb/AOgnymJJKZ+0rnB4+6vToOlFP8SIkXiLVI40VI1upVVUTYFAc4AX+Ee3aiuRtX2Ps6ODxbpxaxL2X2Y/5HsF5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmp752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnHWr6nx0muRaP4e67vyMm2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNGvM39han+6m/wCPS86yzev+72754P8AFg0teU0TXtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOabvYxptW2fwvqu3oQW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk0O90UnH3tHsuq7+gJe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/wA92xzjgj1/g6HmtdGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIqnp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9wTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpXIfFy8hPwy1oRQyhzp6nP2CWH+F8kuwx+P8XGOld1fO39q6d+4n/wCP88edcZ/49ZOPu5z3z1xxjHNcx8To765+HesW2mW19LeT6d5McdtHJPJJujkUqqEYwQSOM4GSueaFfUyrNex2fw915+Ro6ZdQiZWlhkZzZWAZjpMxJbzJMk4HfPXo/QdKvpe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6ipFdTrV0YoZvL+zWW3Ekw482XHAXAz2xwP4cmrCMd0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RRG9inZRSaf2eq7LyMixu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBo15m/sLU/3U3/AB6XnWWb1/3e3fPB/iwaWvKbpr2y0fxPqu78gvr21C3GLeQYkbpo86Y/c57rx647H5ulR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rQvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/4/wA8edcZ/wCPWTj7uc989ccYxzTd7GNNq2z+F9V29CC2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8ACaq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmh3uik4+9o9l1Xf0BL213S/6PJ/rE/wCYPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/AAdDzWujHdL+6m/1if8ALWb/AJ7N/s/hzznkfNkVT09m+wXH7qYfPf8A/LWb/nu3qvbvng/xYNGtwTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eaFe4Jx5Vo95dV5eRn3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Canvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44JwK+pMmuRaP4e67vyMm2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNGvM39han+6m/wCPS86yzev+72754P8AFg0teU0TXtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdK4TS7mOT43eIXMGIIvsCBBp8nzZtro58j7/Un8t3TmvR75iVuP3UwzI3WWY4/c+6/jzzjj7vNcHpFleQfGnxLfS6dexWtzPYLDM3n7ZmSzuAwWTbuJGRkAfoc0SvZHHKzcLJ7Pqv5X5f8AAOwtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJpu90dCcfe0ey6rv6Al7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/892xzjgj1/g6HmtdGO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBo1uCceV6PddV2fkeKaXPHJ8bfiAoSQxxaZdHaLWQqhdLfblMZT7h5bG3Az0r2u+vbULcYt5BiRumjzpj9znuvHrjsfm6V5D4aikPxe+L84jcxrYhGw7gqWjyM4GT90/ewPXFe1XzErcfuphmRussxx+591/HnnHH3eaUb3OXB2VJXT3l1X93yM+8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNT3zt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4avqdEmuRaP4e67vyMm2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RRas39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea8X+Il20vxwsrS3jYRzWEk5/cOhURJejGzG5R8/fpjnjmvc9PZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg1414vBP7QpYI/Hhy7JG58j/j4HJxnv3HPfHNS78pliLOrBWfx+Xd+R7LfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/wAf54864z/x6ycfdznvnrjjGOap3sXTats/hfVdvQgtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJod7opOPvaPZdV39AS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrcE48r0e66rs/I81/aMuIZPhXqAijeM+byTYy24x9oQDlhhuvQciu50u5toPDtpH5EmUhRcrpcx6Ww6MBjrz9fm6Vxv7TG4fCbUQ8cifvVPztIc5uEP8AGB+nJ74NelSr5dm0a2s8CKcLG0kmUHkcAgAqCB2z7fd5oV7nJTcfrD0e3dd/QqXl1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rE8b31sPBGsEQyA/wBkSnJ0uZefs83JYjHp83TgHoprpr52/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5rI8ZWl3qXg7VbHT7Waa8udKkggjEkvzu0EyqBkADJI77evOCxAr6nRUa9ktH8PdefkY/w4mhh8KeHxLCzN/YWkjI06Wbs38SjHQj6/d6g11CXtrul/0eT/AFif8wec/wDLZh6cccY7j5eorH8C2lxpuh6TY3VtMlxbaNpcMqiaY4dS4PRSOoOMEj+6Sa6RGO6X91N/rE/5azf89m/2fw55zyPmyKI3sJWUEmntHquy8jIsbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3p7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/3e3fPB/iwaWvKdCa9stH8T6ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzTd7GNNq2z+F9V29CC2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP8AkEzk58yTOeO+evR+g6Gta2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJod7opOPvaPZdV39AS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGtwTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/3U3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7gnHlWj3l1Xl5GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6kya5Fo/h7ru/Iyba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/wCjyf6xP+YPOf8Alsw9OOOMdx8vUUWrN/aUv7qY/wCiWP8Ay1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIoVyqrV3o+nVdl5Hh/iQq3iLVCg2qbqUgeWY8Def4Tyv0PIopfE/PiXViQR/pc3BJJHznuefz5orje5+h4f+FH0X5Hr95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR2JPXU/OpP3F7q+HvLuzItp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOatpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwBJlVXq/dXTq+yMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNE/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1r208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pQ077lJ/F7q2XV9wS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+Rn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mi1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcASZVV6v3V06vsjJsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KNenkOhamPtkJzaXgx56c5PI+536j17belKz5TRP8AfL3V8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/ALLZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60//WJ/zFpR/wAtmP8Azz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/pkIzIh/wBenP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15oSdwT91e6t5dX5GfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7IybG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3p88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pSs+U0T/fL3V8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2ILa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zPLPDKXSePfi9c7LXyJ444yxvWX5lgJIU7cycOMA43fy9Tvri8K3GItPOZGxjVpXz+5x3j59M9z8vSuUs9GvtKv/AIh391cWyxaqJZoSs6lnQQIpyNvcg4GBkcjArt76eRluM3kL5kY8Toc/ucZ4QZ447c8deaIp3McMuWjG8esur7oz7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05qS2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EanvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcggSeuppJ+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxXn17bmX4veJbydrZJovCsiJGLpyG33EnKvt+bAU8HG7IHTJHpenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229K4S5WU/E3xlcfaYwP+Ea8skyKN+6ac4B2/NnaegGfUVLT5SK2taCt9vu+7O7vri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qmnbcdN6fCvhfWXYgtri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vszzL9o+Wd/hTqIlitQpmBJhvWnIP2hMZDKMD3HJ6mvTb64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0rjvjdFFqHg22tr64hktJdTgSXL+YFRruMMSqBSQQc4zyOm2u9vp5GW4zeQvmRjxOhz+5xnhBnjjtzx15ppanLSdq0vdW3d92Z95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEJJ66nRJ+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf8ATIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTRazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Akyqr1furp1fZHh/iQlvEWqFtu43UpOyQyL989GIBYe5HNFL4nJbxLqzFg5N3MSwIIPznnIAz+Qorje5+h4f8AhR9F+R7PeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/wDH+Vx5dvn/AI9ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84rrUVqfnEprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP8AaqK+sV/tXT1+yz/8f5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFNpXKU173w7Lov5ieO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/AHat6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/wDEx1b/AFsecLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/yuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZHrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvUGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/R5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFakymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf8AR5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss//AB/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFNpXKU173w7Lov5ieO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xWgloC0v+jzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitSZTXIvh+Hsu7M+1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVbjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v8Ao8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xVPVtBS3j1vVo31Iahc6bcQXErNCRLHG8hAK4wBmQhtoB4GO5Ohp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4pWXKU3GVZJ2+J9F3ZPqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tWL6zCLcf6PMu2RhykIx+53dvz44x/tVFfWK/2rp6/ZZ/+P8AK48u3z/x6yHHpnv6Y96JJWM4TVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZneMNBbU9CmGo3msyR2hlvk2PbxsHhnWXIZVyOUwTzjOVFbGo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrkx5Vaa5bu/RdGv8AMr3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84ovrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1CU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v+jzHEiD7kPGZmH9MccZHPy4ppIqrNXfw/Z6LsjPsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1Jp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4pWXKaKa9svh+J9F3ZPqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrVi+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv8Aaunr9ln/AOP8rjy7fP8Ax6yHHpnv6Y96JJWMYTVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/wBHmOJEH3IeMzMP6Y44yOflxVPT7RRYXB+zzDD35yUh42zsO3p3xyP4eKLK4KorP4d10XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv9a2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/2qElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/j/K48u3z/x6yHHpnv6Y96ltrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xSUVqTKa5F8Pw9l3Zn2tre/bnUX2q8WlgdwW25HmybRynTPTvkndxircdpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2R4h4nDL4l1ZZGkZxdyhmk27id55O3jP049KKPE67PEurIFK7buYYIAI+c+nH5cUVxPc/RcP/Cj6L8jNooooNgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43322=[""].join("\n");
var outline_f42_19_43322=null;
var title_f42_19_43323="Dx by pleural fluid analysis";
var content_f42_19_43323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnoses established \"definitively\" by pleural fluid analysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic pleural fluid tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empyema",
"       </td>",
"       <td>",
"        Observation (pus, putrid odor); culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Positive cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus pleuritis",
"       </td>",
"       <td>",
"        LE cells present; pleural fluid serum ANA &gt;1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculous pleurisy",
"       </td>",
"       <td>",
"        Positive AFB stain, culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal rupture",
"       </td>",
"       <td>",
"        High salivary amylase, pleural fluid acidosis (often as low as 6.00)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal pleurisy",
"       </td>",
"       <td>",
"        Positive KOH stain, culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chylothorax",
"       </td>",
"       <td>",
"        Triglycerides (&gt;110 mg/dL); lipoprotein electrophoresis (chylomicrons)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemothorax",
"       </td>",
"       <td>",
"        Hematocrit (pleural fluid/blood &gt;0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinothorax",
"       </td>",
"       <td>",
"        Creatinine (pleural fluid/serum &gt;1.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal dialysis",
"       </td>",
"       <td>",
"        Protein (&lt;1 g/dL); glucose (300 to 400 mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extravascular migration of central venous catheter",
"       </td>",
"       <td>",
"        Observation (milky if lipids are infused); pleural fluid/serum glucose &gt;1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid pleurisy",
"       </td>",
"       <td>",
"        Characteristic cytology",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43323=[""].join("\n");
var outline_f42_19_43323=null;
var title_f42_19_43324="Serotonin syndrome drugs";
var content_f42_19_43324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of drugs that can precipitate serotonin syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drugs involved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increases serotonin formation",
"       </td>",
"       <td>",
"        Tryptophan",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Increases release of serotonin",
"       </td>",
"       <td>",
"        Amphetamines (including: dextroamphetamine, methamphetamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDMA (Ecstasy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphetamine derivatives (including: fenfluramine, dexfenfluramine, phentermine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levodopa, Carbidopa-levodopa (indirectly causes release serotonin)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"18\">",
"        Impairs reuptake from the synaptic cleft into the presynaptic neuron",
"       </td>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDMA (Ecstasy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meperidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tramadol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentazocine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective serotonin reuptake inhibitors (SSRIs) (including: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin-norepinephrine reuptake inhibitors (SNRIs) (including: desvenlafaxine, duloxetine, milnacipran, and venlafaxine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dopamine-norepinephrine reuptake inhibitors (including: bupropion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin modulators: (including: nefazodone, trazodone, and vilazodone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants (TCAs) (including: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. John's wort (Hypericum perforatum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-HT3 receptor antagonists (including: ondansetron, granisetron)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sibutramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextromethorphan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclobenzaprine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Inhibits serotonin metabolism (ie, inhibits monoamine oxidase activity)",
"       </td>",
"       <td>",
"        Monoamine oxidase inhibitors (MAOIs) (including: phenelzine, tranylcypromine, isocarboxazid, moclobemide, selegiline, rasagiline, linezolid, methylene blue, procarbazine, Syrian rue [Peganum harmala, harmine])",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Direct serotonin agonist",
"       </td>",
"       <td>",
"        Buspirone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triptans (including: sumatriptan, rizatriptan, others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ergot derivatives (including: ergotamine, methylergonovine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lysergic acid diethylamide (LSD)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Increases sensitivity of postsynaptic receptor",
"       </td>",
"       <td>",
"        Lithium",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data courtesy of authors with additional data from: Boyer EW and Shannon M; The serotonin syndrome; NEJM 2005;352:1112.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43324=[""].join("\n");
var outline_f42_19_43324=null;
var title_f42_19_43325="World Health Organization surgical safety checklist";
var content_f42_19_43325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization surgical safety checklist",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Sign in",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\" colspan=\"2\">",
"            Before induction of anesthesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Patient has confirmed:",
"            <ul>",
"             <li>",
"              Identity",
"             </li>",
"             <li>",
"              Site",
"             </li>",
"             <li>",
"              Procedure",
"             </li>",
"             <li>",
"              Consent",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Site marked/not applicable",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Anesthesia safety check completed",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Pulse oximeter on patient and functioning",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td colspan=\"2\">",
"            <strong>",
"             Does patient have a:",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\">",
"            Known allergy?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            No",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Yes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\">",
"            Difficult airway/aspiration risk?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            No",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Yes, and equipment/assistance available",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\">",
"            Risk of &gt;500 mL blood loss (7 mL/kg in children)?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            No",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Yes, and adequate intravenous access and fluids planned",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Time out",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\" colspan=\"2\">",
"            Before skin incision",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Confirm all team members have introduced themselves by name and role",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Surgeon, anaesthesia professional and nurse verbally confirm",
"            <ul>",
"             <li>",
"              Patient",
"             </li>",
"             <li>",
"              Site",
"             </li>",
"             <li>",
"              Procedure",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td colspan=\"2\">",
"            <strong>",
"             Anticipated critical events",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Surgeon reviews: What are the critical or unexpected steps, operative duration, anticipated blood loss?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Anesthesia team reviews: Are there any patient-specific concerns?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Nursing team reviews: Has sterility (including indicator results) been confirmed? Are there equipment issues or any concerns?",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td colspan=\"2\">",
"            Has antibiotic prophylaxis been given within the last 60 minutes?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Yes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Not applicable",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\">",
"            Is essential imaging displayed?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Yes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Not applicable",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Sign out",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\" colspan=\"2\">",
"            Before patient leaves operating room",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\">",
"            <strong>",
"             Nurse verbally confirms with the team:",
"            </strong>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            The name of the procedure recorded",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            That instrument, sponge and needle counts are correct (or not applicable)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            How the specimen is labeled (including patient name)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Whether there are any equipment problems to be addressed",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td>",
"            __",
"           </td>",
"           <td>",
"            Surgeon, anesthesia professional and nurse review the key concerns for recovery and management of this patient",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This checklist is not intended to be comprehensive. Additions and modifications to fit local practice are encouraged.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiser T, Haynes A, Dziekan G, et al. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg 2010; 251:976. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43325=[""].join("\n");
var outline_f42_19_43325=null;
var title_f42_19_43326="DN4 questionnaire";
var content_f42_19_43326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    DN4 questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 558px; background-image: url(data:image/gif;base64,R0lGODlhlQEuAsQAAP///wAAAIiIiERERLu7uyIiIjMzM2ZmZt3d3ZmZmREREczMzFVVVe7u7nd3d6qqqsDAwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACVAS4CAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjX0CA1cDAjiTdwQBOpZzCAUBlD2YUwEEOAIBqAwAkJKgJaQrm5sirECiALeVriu5saCzI8DAag6RP70korUzyyibsDcCBQCdAs1TwyLQKbK7Q8hJ4M7eJdluDOQ64iTXPc+l0dMADAesBJ4BCQAHqPkADv0WIDCA6kCJU6gWEFAQQIG+AfggNkQAIABBf5YQFljADxUCjQtGJOiXYMBFg6wA/yZk1y9SAUoIAlBkgMpAgwQMP+ErIGogKgerCniyWfGivo4YKeUrcOAeKn0jMBHciLPBKgMiSWYMaOmAAQSWLD7FhS8TS4shxfrzGcDgiJg1G0htGFJlgAUGdjFwwBblJJkiRnocgGqA1aVuRdC02AAu43moFMxVEDKqzH4H+gKQGECiAoojWJksSEJwPrX6NLuQBmCBQ1YOATxQQMJrxQcj6FGjPGLBNgWUqg6INLLUy4qUBNCe5LquKljN/6kK9isSpo+RAuAu4bsUq+MxPxLNOwCoiFuiGKhyTUAaggaxPwWtjTXs9Nizk92dp6qAPv8kdNMddQcYE1Zy0ygAVP8vvoVUIHLz6YYAbyXE9AAmpQxgkHYjOKCKhgBQJiFl0sBDXVANNJBXRdOFNp4rFrp3HiwgWraKMSMuMBwAxQFwXGiR7HhdgKDIx1qOq2F2o2MeKYfKNNK01UBZ/gQmDzWAVQQWJbeEVcp1k5gWwDSwiHnlZr/AJBMrUR5glZW0uKQmAki1RQBBAyhkligAbpZALQCWCWVO03iJZT9Z4mIWa5A8cCaaIoR55gAKfBapUqUkUEB4ipYmzz0VZToNlVC1RthTtxyAkiduzvanAfmR2k5XbgmwoYki1HmAjiSpauM+iXUKKKIlcWkWMKLNSaQ2ovpI7Gpnwlaqhf+c6ZD/biYMKAJwqyjQgCVdYlotmtGNwGG55ZhnSXjNxCZCg/MEidKaRJVADyZWpbceKYDqIyi1DhQqboil6ieCAQbBt2KA6gqg7WYOHLAppIKGmJxZ7+7HQHbNYluCbQ3kk2qwsVX6kQKqeHyjCRkVkOJx29BS7z5YhfznxJ0Ca7AAWM0TLLjH7pIslqBFal7FKkPLjnU7bfakyznZxFaiqwS0UEMPGXtpRU9meDFpHX2kZFb5rLumYVG/meuT1tUE2GJlP7mAimP2dBFQ/YbKY6FPUwyPU2PqVxNoDnhbgmDFVp1QVxsZqimPT2JMS01pNTt10Vd7ksDI8MUVLwA2U3PR/9ks/1LYYbgqRlLmGEU2ssGutXU50FsDCSmnZPf4+OVnxPxEO2SY0wNrjhTvgu9OAC/GAwGo7QNCkhkv/fTUV2/99diLQZgxZaxjburZh1/GbM4nAQ3yL3jPrPjsm6G8EejLoL7e7dcPhmN/Uu7jnJCcgnlZ+zAGgBZjE7ykAikxydDpJjO3U9HGMlMJCUj0dirDeIgdWMGQ/TbIBFbA60HgWRNPSsAtUTzIR6+ySl54RoLztcdlKhKABjWELxNgIiTqic4F+QXDvOTnQehQFPg4SEQhsOJxZNkf0a7BKRMKMAG6QgBNDOAveJDCV6toill8BRBu/UoaZgoVFm0Vsv8HlAcnlSmiGo3gQY3Jq2rYMQG3TjGfhaTQBKzhUKik8TIZbjExvsGcWRCGrj3C8DgMcIhrHqjBNTryB7VAiAFCggmxxPFwkaPGUGIDt/yNJWw0WuAfK9kWwVmEIggpZSg7YxXlqNAtjXykLKswv1naEnu1vKUud8nLXvryl8AMpjCHScxiGvOYyEymMpfJzGY685nQjKY0p0nNalrzmtjMpja3yc1uevOb4AynOMdJznKa85zoTKc618nOdoITbqpgSM0aEjJEfQJuFoFMSxpwiloFQD39iCeiHDCStj3QE0WTzUVgtS1EucIukfFNzwACFHz2bHIBfZNKSlFPh8L/0zeIegBIgcI8BjDPnml0JxQAAoqcCCBkDwQAQSpDk+2oDjc0EUBMHkgQ3LC0oWrbqeIIEJMzSSVFBCkFQ8o3gpJmbKIBqKgeDxLVqpkHH8GaaYfkI1ESgPQuTgVdQ1RahZ+GSAEFoMxYD7YfyNjUrU7DDWFEGrh/yCdEzQuQTCgV1ZEEix9Q8StemSqCsHbVrlJ9a2iq6lTmGaBSatOqCH562IwNJawwJSsVzFqpgq5Vpm3Fp1T7AYqR7OWunA1p1XAiMabETLJdzclKSGBYe1ZVtCwBCj8okdOcjkCydqXEV1HRAN/QozP/FEFmNSsFzi4nMr8N7VTdSpPEVAqh/5O961L1wxAoNiSmawtsKbd7gtpCNbEnSKV8mJRPtqaRsu3NGAOmlArlfpa5T3Au6BgSU8nWlAQ1pS9UOsK91JYvJwgQDPdmZBO6KTWv5U1ua9pLUbjisaqLnY4n4AFc+F50wqo46XSWi18nwPOsk+uvdPuBlf8yz1KVhMqJZYthfhiDIeR4wEK3Q14TmDe7o61Jbkngie0AxC3+DehwtWNc1Y34viWOspSnTOUqW/nKWM6ylrfM5S57+ctgDrOYx0zmMpv5zGhOs5rXzOY2u/nNNRCeD3JZB4ScgM5OWzCz8IwDPpNBxzVRLAwOC9wYECalFRroDbqhiXT86g8hw/8VeiSnAvKdgBR49nMJNI2C9z3aditTgWkKloKjOpgGlaXBSdt6giYaoEUzYHQROO0G32x6T5ROgfIwnesg0BqPen6BpzsN3hQANjBSGusp1lPB95zqE7J9AE3qQlq78hXWuWnrKXaBO9805m6iIw1OUOGKUY+mlKoxl1H2QRKKrRuCdGH3U3AiM8VthARswZtQHkNA510tNpOASAuxKmSnsbIimmoKPkhdQfqWUgQ7YaC904g/SVbObj+RDgaVsW+ipFLPi5GMWHiDlKxBpORkITdmNNO/0/DIpZixBz4EMO677q0FsGWMspOb1pu05ci9ae+0TwGUuf6UIYiGTGX/to3vRJFCPa2RTI7KcwJZtE2KBplQSo0EXtscaD6WydBfbVKyBOgQ1lBnj3vgc8eFbSs43jJJQiEkMQQkkI8xZNG29JGf0PTQj7eekdjPvrQJO4hj+oo6AX4YCXRw/D2K5FAzZCTEzYx9M1+hj8VAnaMSdYrqcQq9FyFGggZILOknODbk3LRzBix5kvigzGGn/V+K/rTQqkO9CLrdvD4NQFPEulNnUsro8JCqhV9aE6H8dvNf+cpJgWvUNMI4At//6Ym6ekuW9koOWNTiirW61aH6UbQxajHwOVMV9UOPRFDxGoWRSkAZz0gZZTwRic3AYvpRsvxNQH9TiTIsJFEL/6IgfHkSSQOAO7iAJyGhgLzAGA4GU/zEc5ZSAkfmG/IwdFVldPKBe0o3OdwGGHdiEGn3dMGSGz/TMESTNN9TLQAjMHqDRDOSK5nBIQGDJcdRSLmxL+3xRDxDWHMUd93nHcbAQ31EP+5yEIcEePqRL3+kg6EHLxsTKok3IIlkdpUiLE8khQtGeSPzgrdjgwniCizkM4WXM4pRDz0DG+TAgi0AaBZhZIWRXLySCnCTgPokbfuhEtxye6wmG4iiCkynfdUWblU1O3JTGk9hNnY3OgnVDyN0KkLBfDK4fwY3iftgOIrzcLsHbnnTScnAX1ljAt5XhAp0cNAAOI/ScMhAN/888UebGCyRpD/vl2+0YDgIo4UQdxRsUw6uA4uSCIOXOA1X8wmxkxmOSICZIIkLcIz24FLMSDQxgAnBlgjxU05uuAcdgW2IcI3hdCqZB2fiOI7kWI7meI7omI7quI7s2I7u+I7wGI/yOI/0WI904AA9Ay9LsGwQ52j2mAdTQgkGYB772FlK9I+AsBAB823i5lJG9BLechwWh5DaCAtTR5APCR8S4zD7cUIUiQe3QCoGqHs6wCjk1n6P8pF0cAtumI0lKQ+ewJE4VI0qGQe3gIhjQpI5QDwj8TWTVJNAGZRCOZREyTW2dZRIiQo4kJRMaVtFWQa9BgNRKZU3MJVPuQX/VtkCWamVVXmVY7CVKwCWYdmVXhkGYpkCZ4mWZIlOxZAkXSMDctYHaXlpS7mW5lQYSrMZ3Fg9c0mKdWkDfYlNw+Z3B0MJIYQAGHIa6xYW6wY4gdk7dkkDj2ku6tQOHSGLkGiYc4IJRYIgFOOZCoKGdzCZ2vCXNUCa1DSYtCAPvuEom4kxFeM4AEgRvwaVkTkDqIma06SaYNcdIOI/uRCb4vI4c6SbYpCbpimZ6YQoc5deDqUolhSczSKbkDMmxmmWtykDyKmOxIMH2wmY2Qln0DNEc/CdpxmeZZkF5qmc4JmeX7CeuIme7mkF8Kmd8jmfVNCU+qmUVbmfTYmfXVCf/zEgoACan/fJle1ZoOp5oCxAoAoaBQ56PAz6ZdtTOulDad4YoBOqAhHaTQbEiSqQSntpDpZmoS6ADBnKBR3aoBuaTQkAFPoYotNQDcJGk3GJfi1oBis6lgmKTiGjk6uZhijHmE+BP8KJbxfxIaJkiCmKlS2KAjvaTaA3ApfJDtPgGqXidUrhmayQQDcHDFO4mkgFeGHapFoQpWrZo+WkIieoa0ryf5QIJZHgpY8DDH2iM1nEJ1BhpguqpvHpp+JkR8J2JWBInd/3EMKoGNyDdy9RhXyKBWgKpU96Tdm3At05jHEaapKUqIaopKwkCgswFI96BZFKl4D6oFJQqn55qv+oCgWq+gqT2qpF8KotFKuyOgS0SpmseqtMkKuluau8qgT++Z/9OaxIGayjYKu1CqzIegS+WhHK2qw88KzPKq3J+afMyqNaVpsXCgM3aqDZqq3saU6kRJOYhBm1JA5mymffmqzhyqHRWk0TImgmUInpiprs6o/0Ga/Q+q7cFEgsYK+ZoBlswQARRwqnUQohVxouJXETmUo6QglegQB2AaRLQK38Kk0x+TGkQTYFkR5ZJyLcM2lF8kLNOaUztCsdmSfbMAknNF1VgLH+uk1TQmonILDOQhJ3Omnfo3/JwIAjg5KVSCkV2CaE9QQye57nVA+7oa9wYiMqE6aK4oTfQ3n/J3AvT+hGD1MedUcCSeiuSjuzq2pOwCdhKyAm53c5BeuK0mlw4MWMr/OwXCGxG5E2+yq2Yzuu1tqr/Fqtexu2ehu49vm3fIu3sGq4hHutg4u4v5q45mOsx1qskGtPjlu5lnu5mJu5mru5nNu5nvu5oBu6oju6pFu6pnu6qJu6qru6rNu6rvu6sBu7sju7tFu7tnu7uJu7uru7vNu7vvu7wBu8wju8xFu8xnu8yDtO3Ko9TjsOcFChwOYCnWBzM8ibaQCHDIVq7eWBLBA7ndGcGNWmv7K8Mwg/4FNL3zo0kOIGJRp6ocYCbWlDmWC91msFppZU2vthzEAJzGOunsaz/2qAvs17IuvbBteAgC4QRPL7vnOgen6VWfxYhwn4LaQVbdNmV+RmbQyxl5CDFYNoOxR8XwdLELwxQX4nT43BYnIxvx3nPChXsTVHCQ2nT7RBCo5hE03Tb/pEvW43Dw4ACeZ2ElSFFphHGumGUT+JGJbhCSiTcbaYmJ50b29xN/izezHXwvo0M6YBFkv6jFjzo177AKIhxFNDnlCQczbRej7iLX4FdE+Ve0QXV0f3h4WFY1XjDfYAYQZTeRpCeH53hFZ8ISwMeTZLM7cRDASJdyuEM/SDJYIsMypkDRMDDBcEIiQSJNWhKEXzQUFydUiSMYend/phHMSRCWknGZwZdf/OAWDrIRkHbAxr9xovsiyKDHhs+HIx1AlYuDJCIhMM0DOjegQOnGy0sWyvF6oRNXt3UXtR5YeIto0hagxdtAsArH6IEi0GsivPtjnz+0TssHxGO5Lm57OkUIcis0WIoipuAQyuwjP5ob6MKBKfAoPG9yxP636pEy6dYn23sH7w5yev7L7+UalbY372hzsy4SEH4JqCiMlE0yfBbAT3SwoSyI9p1ZwXWFcaWHTa4cwAlnEgeBALBrAzQrXAAoUrMyFQNE/cHGp3CoYjkIT0wKiSXDRXxNI19IN/HJAk9BnK0dCkF4ab7EZC7YZc2MjlSzslSAC3gNJLfcBr6IMzQ8v/S2h/m+dKrjENiZQcDh0eS50F2CuHyMVsAXWHM4EKekhtDUEJHp1tiLIAH6w4WtSxyjUVcTs2GJVcrNPSeRMMT9M5jBGNM+xAVMgQmuOKOyx/JPwjuREJoXNEi6gsi0XEjMg7k53E+Rw0nfLEGJNKwWKL1+CM3gyKBMyK3YwLovh2gIhKXS0TyLxhW0CNf1C/bkbSWgDNfEDbakZKA5y8vt2O5Au8wV3Ad4ZrYuAY4husw80CADwGMVqTMXxC5YEJTLwY+obCO8HZ1Z1xMUwkEld9XTNyEpSIIuFSN7zC232IQkyIj4EYgPMf5C2NQTml4REeGlQApYwiAcmSrczU/7CA35AT1OXgR2K3xynrx0ZjAhZy3/n9yU2HGxKGH+BVAOahHIVMkSOJJhGTM7RTCzRkFvys2QXIgN4Ni+P7R/48kubc0pDCJ/ZsKu0GC+zFEWNzp0SpG/fAG/ps1SpdQ0u945KjMpPwOpZh0qqC0igIMue8NSCbeiyNhKUyEq/kldEoU8YA5JuoCq7I2Uy+jPGNJkRe13UDi56tVzm511hu2ahtnVV0Htl9EUyxi+kJH2YMar+tBPjYArp953ze537+54Ae6II+6IRe6IZ+6Ii+UvlIx0fAjwd55zw9kE2gHLHB2HeukC6jGd0dBNLgShKpP8nLDwobsjqCkZwONf8bycm+HZLBR+Knrjg0N8+rbhYtmdwvCXHGSNTJe5OOWOVAwJNGAuqJPuzEXuyMMLlHuZTITrm9m7SCi7vOjq27G+2LO+19m7FTFtF1QO0Dqk6dYK4e2w909n6FwO1U6aN48gLt+gp17gfm/gLX+UwI45EssAkcNxRWATeYcu/8Voijee2MK007Qu/y1qb2PshspxwU4SWPl/CWsu5r8O4Sak7sBe7LoosohEUMf9oZv869HfEAD7hLa/EXb9UoRNNUyPH+gfLeGfLPTk4ErwIH79KK/ST7rvI1PyYfrwYSj6BmVrMvAPQtH/D9KvJh1hLHg5d50PMs2uwuL+26y/T/4hr1y44oyl71/Mm7Ug+vTk/0fku6W5+mWv/01R71ZN/t7gjxvoDUYPvy52704sQkzSuiDMwDai/zAxOzZ//25eSAljqjlu4Dd88NeQ+ucI/2hw9OjsHBSpiGY9yQGUyl7XZubqHvVorvWZzvnmP5FhkXmy6sew/v6+Qau1ClhImlonF1U+rkm3F1MoIsm5LwL6LTi7zwmEL7kGDqoO/12C7wc/+mrY2Yrn6LTyLUGi802JfOunL8YpTOGX6xoT/x5iQAMBo9f1948ZyG2udT9CxCgCzQdwTJOw0z7THV2g/9vE/00AQ4up9e2CzUvo6pjEg3aIX8cg6KnUT/5J/Y//EPAoA4kqV5omSQsmr7AiucyrN947m+873/A4PC4ay2Mx59SCKz6XxCo9IpcYmzXpXULbfr/YLBWNuYrA2j0+o1O1yGveHnNr1uv+NRgT2/7//3/QAOEsblHSImKgrO8RiyPC5KTlJKRuox9lxWcnZ6ujUmaX6SlpqCjobmbJ62ur6+sJbIzqrC3k4GEOCmOmb68gb3EBjswQgEMIgUCFztCq/aZvVCV8MgBBzYCCgoJAAwO1vf0I6Um0uPq4s4DNwIMCs0MGPvJhQADBTs6QcoIMQoFuDbAIHaEBgEkEDBHgELBCprdS7GL1HrLpIYwDCAAYAjDuzRNgJeAwUH6P/pUohvgLsEKcMFaMYtnzsCARAwOKhgwQAHIw3cmjiRIjWMFxk0A2BAJAt4AJDFrKcyXzObIgY0S2kTAVYA2BDs45OAWIABC3By/CYxnZmiRtUJMNBAqc8WTsHFjEFwZVUZXVM64Ov1Zs4ThUXcPSW0oo6hbz0x4DfXLj6FeaEaEGyVaow9BXZ1/YqQD1fPC6AOdLWYrZzHrl+jAuZ2GuzatqOsnk3uNu/eQ3LLtuh7OPHduo0HL658uYlCzgMpef6cOfXqRJM3Zm19u2vgwrNzD8/bO3js4s8bJR/tOPr21dTT/u4e4+bq8JHLn38IJB+mKQbsMZYV9V2V1HD3tWX/nn6IzKNWC10ROEKEyyFYhHYL1pHYg82EhU9k/thUzE6ccRQgAASE5ZgnFbamIIZ3IKDAAyXw5x9nm8HjkU2gafOXTPgo4NOE6rAYy4UvrnGAOzNAKMMBTG32JIn2FPDViSp2UmQLWiKJxgIpMdnXXDmKEGWPWVEJgAIyYckJlzQc2WUYA0QEA4ADNVDMSnsoYOaUU7kUwD6PvYkJe3LCpuFFhZ7AKKLVQNUnoXHCeeijlyLiaC2WYtqpHdJNFx2ohHhaqqmnopqqqquy2qqrr8Iaq6yz0lqrrbfimquuu/Laq6+/AhussMMSW6yxxyKbrLLLMtuss89CG62001Jb/62112Kbrbbbctutt9+CG251qO2RZwA+fVnAXA80JMKXeeHl00YxvesTuxGVVBY7fqzJhwKIbTQAQPUCcG8JpfmT1Id71OkAv2oGsC5HACw88Uh9MDCZwyk18IcACzPwLh8PEHwvu34sIC4RyNQlQowegvlhZe/iA1VdxaQs8gIGP0XaCDwXnAxiQi+ggLo6Aw3APCNG1kxkM54ANEMSA/X0CSz3XFdY/uE8gsPNfAnUCEgLrbQ/KjeBNQkugZRUSQoUM+OXDMHD0M0B5CwoRzwXU0zLQPO8j0cgJZDu3mWLwLbLglIcANQmSB1x0FU7fvW5QSvDrgHdTKYU3l7nFf82CYYbwHPH/6K9ch9i44V6z0gRzVFk/d6dd05lxV5Auj8jbvDpFzvw5e0A1gnA1yNMXbGBIkS+euN8tJw1AG03/jG8nqe8L9h+NCA8SMSL8HvqQ6g9gkvIiJSiP91z9OUBanct/DwMT+8H1ICXLbgIhMsfVvGKDwZmjytB5KjWuAFejA/NwIbzRNA17QFAdGNLxvzKJr7xBaF8XlGAMopBAJtUpmkSlB72Iii0kymDISlDxpLwFxFkKKNoRzsh/UawtJQ17YAoKODkdGgCDcJwGWB6oPFCZzF30dCCZ8NgBrnnQcsUAEB1YZfujoi1eTmkbJGBndjyBRCeoQZ13OD/x8C0iDiX3WlNIrBa1BA3tR5WjHUkFCLUHCaSB4JMZHsgmRnxtUQmAjKQghwkIQtpyEMiMpGKXCQjG+nIR0IykpKcJCUraclLYjKTmtwkJzs5iSE5oStMACUiRBkEU+IAlUAgJTQeIJDS8UCCRLRBoMqSvR+GJAWbYeUNeKlKOy3vBBEC0yF+mQMBLMmYwLQBL6/kBGQeY0nQpEKIGmCuZ+RghDs4wDdcsqSrfVOYMmimEJTJAnOWqU1bQOcMpsnO/wTzB+SEwjS7QLjEZeN3QeQJGRtwp5jM6wGRSdnG8uIwjZxxbZdDRjCh6U8+kaBDIfLHCk1DgrpxpAEMzKhV/+CxD7lkhE3t69keFsCfgdRyLGH5Bor4MIsPlmhE5uvPUwrw0c5ZJpfIRAZaMrpRkIbvc8h7QEFy+Ty57GggUNHdCDaqpIQcFaclSk1RswGOZpTkAQtpiFVGk4yfNiBCS12ATWa0FLCC0B8f8gk0q6qNWh7AqdAkAEO8kQ+oAuGBYdOn0AogD7bZcYJiGyjWAPSA46mwBO/6R88aWhPJlWCXKRnAAYpG0OKRZB4GwsYDOlqlkjiIKl9KmZK+hM2PAEWUdn3Av9Q4TJjy6AQuaUCOQCvbiMFjF3GZiwE2W7kR9BYshfsXS66EgN0qRQA2AduIHIDZZD72uCDtrQpkQv/c6N5jKj2R0AoYEM7FddYIljVe5jgYTs7uCBwtWUFboztT2krTHWpciD/dC4R7WuYAfA2ZHwywgLDsRIIDtZrDHHC8WU6wMuDclxq5m879cbMPCn5KMiv7TwFReBmhxUp2T1SADgPMM5zZ6B6s9Fo/mU8gN5nmh9em4uMu6aTZ4KeJvJaTBzBDGaG5iYwPsJlaMm4kyVwgj/vgH63cZMcIKAkxWFoMs1ilxe66MIGAXBmQzIXGA9lMkzKs5AS8eJrItFIMuEJkj8gzo9c8HW37ytgS2HF3jTvN5Qx7YKFeZUYgbGwJ6mlCNNtkLmYa7w/dEaMEHAAoHcMwizecRRz/mgVMnDXeSupiV+Sx6aUoXoa9VrwkKXM6aDBGDFCnp+jUjM1oFFOjkpH74AjKtM9ia3WpVbCLwIz4Jk/ZXAlyYhXvotZsGE71LQsWRXckWthc7ouXz1yATksXMfK1rj/PLARX7gGWRcRdDP/JgIUJ7HkC/dzG1HjnYp/ULHxOoI9pakM9+Qk1/kGNMuiqN0Z/2tEk9S9J8XYnm+ZUpSIOVDE07aR5e8bTGr5owke9RrHYex+hVVMz2AUQJT9vyzWQ9+gYoiRrLyy0fPhMrgHSsaT8m6wr8CoDIq7xPvfHJguYh48ZIvFlO7OtZ17qTYqWjbnWlSDWHoJNvnsRPxeL/5gooCtOw8Of4q0D6cRS+gkMED1PYj3rWp/CPBcBluuFdAY2oXpHjf4EqW/91adoRwlE+U4HxjPnZkcB2rcx91WcFgW/FCXVTRCWWier64pASttRHvcTSMoEZd9C3fG+g7eTQLP6gUe2BTKjkyZAKoHmrk0SMNaFkDqqaEUCZlI2VZautO2S0UsBoKQ3Du7BJ15lK1YIk22c2tsbtfRISt3qFbzWT1Czl/u+Z45nNT0Amqf/PR9O29KYeNSnfECqLgYy/bl8yCSkGSvrP/5Qf6Q0Jdn/vuvAMfHz5AgbzVASCZItJSlxl7mXta03kEtd8BJotNNzx2WA9A3WXpS65P9JVkBdekWRZVBMDPVJbu0aby3PfMmDKrlddBVGjBSb+CkgTFGY/rFfcH1Y0WRY/1GM2Chdg9XUkl3aYITX8nAWmYhASoyXc8VARGDF5hXICxKAC9pg4izFgkxTSkDTGDEOXZHZq1kZheFY8IWElg1b4lQGisQAlZCYrkEYYmgD2fkFs0nZAHhejBlZU1FhkgWT2zlbH4jcLmwhvnUYFDrXAeDYx4RgmkgZMRVhozHhZjAh/OFgTokYmHSFw7BaUuiCHhZRgxGie/ygbglM5eDaXRWgDBDa4oSDq5masonX5wBbSmRXCgagNcFE3uHcr8WQLogZ4ImAGnFDtbVdXSj/2WE0xy58mwlpIDLpH7DJ0KrJBP+lSSyaFgmYYKMl26JFyal5XpWYg9zEWhTeIBJxRV2QojGODhW+SCJ6mWdUBruA4sa52wHIw8MFiMs14dCMlCbiw/NNWD6sHhbeYFcJBO2NQMiRQO4JXQkESgIomVdJozIO3+KV3ilWnK4pX5r8l94430YIQKOB4y7ZHFVBFH8cF035oXLRVD1OFp+MnVVNj42YSuMly5egWSPFCAIpy0UeXtqZ5EmiZEqq5EqyZEu65EvCZEzK5EzSZE3a5E0uhwOIjf59QRBdFU5ehORZXRhwg12FA1CuA10FhkYlxFaBHRPAQypOYrYVG1Li/wJIwKJO8MTVPZO6mAQzcODdWeUpbIb6jMWTVeXK1ExDrOE5juUrbIYrkoBcQmVl7MOjUYxYviUpbAY+IgxTnV1lnE/x7WVhGuZhImZiKmZ3jAqpiEpj/sFiKoKmuACnSGYaUCY6WOZlxkZ+xEd5oCTkrYFoboqLJIhnPotXDUDTXY2CHSX5DBkzvUHfRRYtkGZlmqaFbCay6OQGnd8PuWZJ8oA7CafjsYDghR1oKudyfqa03EMClERaAucIMAN97VpAmIg8epiJFJTIPJVRfYhcPATDWAVctd/2UWVEecbwuUQVogZPAF+LoOZpMie0IAQ3Ql2NMFwfcMg3tNhltP9WM9DXav3Lb2UYTRiX/R0k61QZZO1hWMajDPBin7RnRvbiVdiXbuamfNbnszAAK3LldC5DLiahMtoEBIThFB7XPugXcQ4GAvQYWhgAhoGZz5hDmnhYhC5cPiRAhT4JiJUcfnQofa5HtTCAog0lZVAnVsGNIN4akFAbJyKP583azplibq3As4maCsgNJobT5vGiLmzFfV5okBJpcxbpfDaLarKmiP6k8XRjZwjKLminOeZLRvncx71oxnkexLFXw53niqXnuwlfO16FP/Tge2LcmQrpkHIoIZkSbRJHZr4gpYQLu3SOpB6IpTYKp3ImF1Dqdajpp6JBqIYqqTqBqXr/KqpKAWQOgiC4amSyah2o6m7O6hTU6obeKqiuKm6O6q5uQa7+Kifd5hdoqoYOKyT0qrAM3wskxmsKgYuK3WzmXSrF07E+KppqK6N6qDKAhUi6KbRmUGwKAbY2RrVuK7Imq6FUiwFExIc6a3BaZ1xgZ2rUaep1Z3/4XlSNZzKUp7vtD3qOFHfpicp1Xle8py7kCdRxq7o6qpFYy/MFSaAiHH+a38UCKMUphDwQaAw8jjtFl4LSq9pZhlTtAoRyFw61HLxgRZk6zv097JYwRppeiwmmwLOSaGUgGZndhB+saD656FfEaGTMaHm+mK1NRY46WE3VB4dNGKLaanPMbLpC/4tGtGmfBafSNOke4hoqcuxv1l+VvigljsRnZCm0cakJQZqOKkW7jUDLEtNAGIBeKmvUSq3dEgsD8Vu8Lik7xOnI0WnQbaeg3Kl4ehzGhRxqMBqgfkSJ9SN3ZRsCNK1I4Y3CGoApZmuj0uzmDlKkoqsiICcQCGvMog2m3mgnhO7Uai7VQiywqsHocq7regHssq7stmqs+gGs4q5L2W7v+u7vAm/wCu/wEm/xGu/xIm/yKu/yMm/zOu/zQm/0Su/0Um/1Wu/1Ym/2au/2cm/3eu/3gm/4iu/4km/5mu/5om/6qu/6sm/7uu/7wm/8Lkfq4sDYZSMicGQVfC4VmGsboP9S/m4Btu1NLFkMgsmmgcIcRi7dOKkIKMEs22ZIfI3rluwvrlawHlxwKC0PAHOdmj2RDmjTDoAFQ4CrtLWAZElB4tXmHYgZ3ZZrBkNB/7LB/7qwFOAX2+xXBN2JwHwfQI3MQG2bQZUFQzCsu1oNQ/XZkiwfdXrGRI3I84UWRsnF6NXUTfFH6+VbhHSI6d2Dj6Ue5qEAy5ln9JWaXNlURkVVRjQlTbVVfC4fFPcaRG2xVGRXd3rVQahYQYIfVeiDrTlxRZUUVujDHfPhWxlkGi/MBvtVRrFfPvhEcUWBXmXU2QSRXzUAYCmwgOFNYTkOYh1fQegQEl+UEv8I26YXZan/yf+VX2a9Jnqx12fZVUo08oeBkpaWTccGm2EY3WzVFieKGSxTqQNmxCjeEi+7Q3FtRXU9RWupcgB+JKfRMT4YaAXuBLApI6ZtrD91hMHxSJkWBEBQczFHzHaRmgOSyf8KIEoggJVAMhTccD5RcjLoUfsA2AJo8gIQ2Lmc2wTZD90pMY6+mpmoqJBdhYX56YH+5y7Mcjg2wEld4S6oqBC65Y4qRJjl2yibsPn1WHKilEWb6R5uhc9+BFM0dH9Ec03lk1nOITbxrJm9opkAqSiZZY2WGFmYRY/BHw0XNFU4gEZCQTWt2fpU8puRQJwFGWHVWSfnhQGH8lNSI5Bunp9I/6kJH1owvlyjKaNT0FU4zlbbXnMKThqulWleUie0YfVPZPSHke3b/iNYmPUxDx3X+l9r8p7k9CBVTZg3yGWYnpbXqqLBQZg3K4x/aKnFveP7lBorb7Ch2RWKyFQ7Q4EAa9vGgI+WfRsfhNuHjBtB8Ukz7LMJHDHYQcVDJ234wNvBDe6E0duJLCS+LVxKfN3mhKNXtd41myM6CkrNfBfL8ZzDgRqs/dxFw+PbKhBJCY7O7ak5NHFqq54/0LY2YIZX3p5fDuQHl4ng/pKYoraiJoVf9nbK8am5GM0G80GdzO3b1vAq6YtrcHAYGAAMP0GxXgqThcHTPUZ7G4V8P0pvyv9vf/v3fwN4gAv4gBN4gRv4gbcHf/OkF/ikuAK4UIYoFRSlfxZn/CqluhCyU1Z4D0SlPEzlwP43VlKMVpJzFJDEV+JlI/93WZqhTUtntK5lTLRlgMelT9OlWgoRXlrzisuAX4J3YOKTSO0tghN5kRv5kYfL7kKHJii5Magv7a7u+EJ5w4bvlDts+Vp55lYSfgdDlreutbDddQvKi0docb/Dl6rTIni5zF4LP2Azfx8nQJZfNMHGmtfttUzTlwhaHCSzDCaVS6RJd5JxWL3yTfVbelvCslYq3hbLNEkWmgXKhF1kPi3XYKSJgfYyowHzl8wIl6u5oosq6S5LnktOMyWc8zw4QF+SI0q3aBazV751mKdPJqifKrDUk7nJ0QKbHDPUB177Yhdq2OKZXy0i+qczumbq6rL0AUBEHJlDLsMQegJlRuHCV7C/+sJdcbHP+rEverJv3Y2Xgp1XSkveyTa/grizK/qie6c+Oa2D+vSu+92mb5M7OZM3OZLje77r+77ze7/7+78DfMAL/MATfMEb/MEjfMIr/MIXUggAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bouhassira, D, Attal, N, Alchaar, H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114:29. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43326=[""].join("\n");
var outline_f42_19_43326=null;
var title_f42_19_43327="Primary ciliary dyskinesia PA";
var content_f42_19_43327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ciliary dyskinesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 349px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFdATkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5v8P+FdZ8Q213caPZG5itXjjmbzEXazhyowxGciN+np7itBvh74oUfNpTf9/o/wD4qvSP2cY3l0PxSqckXViT9Nl1Xq5tnC8oDQB8u/8ACBeJf+gb/wCR4/8A4qj/AIQLxL/0DT/3/j/+Kr6dNnGx+aIflTG0qJj8hK+xoA+ZT4C8Sj/mG/8AkeP/AOKoPgLxL/0Df/I8f/xVfSx0eXPy7W+hqWLQrl+WhIQdT2oA+Z0+H3idwSumZA/6bxf/ABVRt4E8SK206bz0/wBfGf8A2avp+ax8mBiowFGFz1J9ayxpsigsV4PegD50/wCED8SAn/iXf+R4/wD4qnDwD4mPTTD/AN/4/wD4qvof7MF5C9O9U7u5jgyCyj8eaAPBP+EA8Tbsf2bz/wBd4v8A4qnf8K98T/8AQM/8mIv/AIqval1OJS2zH1NNfUWmOARj2oA8VPgDxMBk6bx/18Rf/FU9Ph54ocZXTAR/18xf/FV69LqgjbbuGByx7U2PW4iQIn2Eep4NAHk6/DbxYwyulAj2uYf/AIupE+GHi9/u6Rn/ALeYf/i69Xi18xSghlBJ67q6zStYhugA5CvjnB4oA8AX4U+M2OBo3P8A19Q//F1Knwi8cP8Ad0TP/b3B/wDF19PWkiuAQRzxx0Na1irMSVwcc0AfKC/Bvx63TQT/AOBcH/xdNl+DvjuL7+hY/wC3uD/4uvsdBhQc4P1qlqbNgAdaAPkAfCXxsTgaLz/19wf/ABdPT4Q+OX+7omf+3uD/AOLr6mBJbn881pWa/MoBB4oA+Rz8IPHK9dD/APJuD/4uoz8JvGwOP7F/8moP/i6+vrnKkr1Pes+5KxoWc4UD6ZoA+TZPhZ4xj+/pAH/b1D/8XUT/AA18WJ97S1H/AG9Q/wDxdfQms6mfMYQ8E/xf4VgSTMx3NKAfU0AeLj4c+Kicf2YP/AmH/wCLp3/CtvFn/QKH/gTD/wDF17IuopHxJLkfoavWmqRSZUMD6c0AeGf8K38V5/5BX/kxF/8AFUh+HXiof8wv/wAmIv8A4qvf01ALgHA+tSLeQk5OFBoA+ev+FeeKP+gX/wCTEX/xVIfh74oC7v7KO3pnz48Z/wC+q+kIxDOBgrn2NSi0yTgZz1B70AfNP/Cv/E3/AEDP/I8X/wAVQfAHib/oGH/v/F/8VX0i+nuOdvy037Ec/doA+bT4D8SDrpp/7/x//FUw+CPEI66fj/ttH/8AFV9IyWWeq1XfTt3RMn2oA+eD4F8Rjrpx9f8AXR//ABVMbwV4gT72nkf9tY//AIqvo8aXMQMRHGKa+jSsfmQA+5oA+XtU0m+0oxi/gMJkztywOcYz0PuKoV6r8dLA2T6LnHz+d09tn+NeVUAfQX7KxT7B4s8xSw82y4H+7c17cxt8/wCokHvmvE/2UQ7WniwISP3lln8riveVtppOqk+1AFPyrB/ldJY3+mcULpdvIf3FwuT2YYq79kdF3SEKo657VDLeBMrboAO7kcn6elAEsekJbLumPmHsq8UycOTjG1R/DVVJmHzIzA9Tg9amjuJV5k+ZuwPagCJ4A4zMn0WqV1Zx7CzHYAfwrSmvIY03TDBrntTvDcZ2nI7e1AGDrdwy5S3TIHfua4bU4J5mYid1PTBOK7eZT9aoXEaMcMg+tAHA3NpcwoNxZgOpBzUH2iaKJmBbIHHNdxd2alP3bYPpWJf6dmBhsO491FAHCHVbkSMN5YH1q9b3iTDDDafc1TvbJ4Jjmq+5V4/HmgDoYEcOJAquhPPPBrorEyRokkROw9u4rjNPvWjUYPy55B6V1OlXaSYCkg9wOlAHoHhu/Mke0nJB6V3FjPgBgDjGOK8x01ijh4+OeRXb6PcyZCnOCMc+lAHUCbfHkGsrVlkZA2G2kkZAq/byFSCqg54PHSm6hOHCDsMj60AYdsSHG41rWTnzVxmoEwzAeWCelWIwQ4AHAoAmuF5J965fXrkuzJGfkHGa39Um+zxszn5ieBmuK1S5C5ZzxQBgajJhyF/FqwL+4jtxiWXB7Adabr2quSyREovqOtcpcyu4JbdknPPWgDVutUhC5RCx7FjVeHXJlI2hVIxWQC7jABP4VNFYzOQSu368UAdmupSuiMNvI54q1b3jyRsMKSc9qpafYubZASN3TjmtW002ToWUDGOaAJdPv5FZcrz7Guz0i9huEWOb5W7GuTttMCAb5Q30FbliPJACKKAOwgsZCAdoKnvVgaPGepAHdRWdp2pyRhASSn909K6ezmjuCGTAb0PagDEl0uOE4ZM++OoqP7Mg4WMV1ssEUkaq5G7tWZL5cROFLc+mKAMSaBvQDHtUTWjc5rbmuj0SFf8AgVUZrqfe3yovPYUAfP37SsPlP4e4PIuP/aVeJV7j+028jyeHfMOf+PnH/kKvDqAPpj9jOISjxgCM4Nkf/R9fSptkiXc4GfSvnH9ijp4y/wC3L/2vX0pOvqQfpQBzWsxu8q8fKegHSsWWAqTgV1V+oJXPY5rJkt8sdueTgZoAzbaMAlmGeyj3pkw8vc7ke2a0SgDgKMgcCsTXpiGKDoODQBjX8xlcknPoKxruQrGSrYPtV27kCq3rWFfT7UPPzUARTakYfvsmO+44qFNRtbg4E8aOezMBXIalcuXf5s88jrWO92xOM5xQB6U5UAkEEexqu7cHqCR61ymn62VQLNIT2B9PY1orqB5IO78aAEvbfEzFlDq3qM5rGu7S1kIEkA5zynGK3pJRNCTs3Y5IzWYPLZeCVOf4qAMpNGidD9nkdWz0bpV2y0uaGT74UjnnNX7JAHKNgqcCtWABiVAH480AX9IjkKJuZSR3Wu10lzGFBx071yelRbG+X7pPSuotVYMpDLxxigDooLgK6kvhc0y/dAiHeoIzjmqscbFSTk8VWuoZNikggEn8aANK3kDqGjI461aaYRxkkDOOMGszTY2VCO5qxOjEEk4xQBm65cliDnpk1xepCSbOMk+grp9YXJGc1meWPK+VQD0oA4p9H8yRjOeP1pr6PZQhuP8Avs5rpLlFRXZug9elc7qeoxIMIBI/bHQUAUJrGJABESVPoKt2unxtKAInc4BJY8VjPqE7A4wvOcVe06S4ljDO7sGPY0AdMMxqMbEUAdwKnjYAZ82ME+rCuedlt873wR3JqC51eOGHdEBI2COeBQB1cEq4JEiEeu6rkN2i9XUn0BzXmEmqzzkeY/H90HAq3bXOzBRiOuMGgD1S11LC4Ax/vCtayvpC4ZJNp9jXnWlahMIsl96+jc10un3iOfmBRvUcigD1Swn+0WcLMR5mMEZ681O0JmwQAW9D3rk9Gvmh2BjkZzx3rs4CsiJIrZB6UAULi0DnI4I9az5rWTeSV4rqHAZQWAYHrmljiibA2YPvzigD5b/antng/wCEXZxw4ucH1x5X+NeCV9Kftkx+WfCAH3cXeP8AyBXzXQB9OfsWE7fGQHf7F/7Xr6WccYr5p/Yr/wCZy/7c/wD2vX0zJ0oAzrhCxOarNFyf54rRdQaYsfcigDLeEQozng9a4nWpBvdunOa7zV8LasOa861cszNuO0c8UAc7fzDJwa52/Z5OVBY+lbV06ozYHXuayNQuGAH680Acfq9tMWYiJwG5+6a5uZZ4/wDlm+O3FddqdyXjYbiPpXJXMpXI3mgBsDy/NlG5HpVu0u5oyQASvUg1nQXByTzV6C6bO4nPrQBvWGpbVbcGxipZZI3KhD8j/MR6e1UbGVJVYyZGOeTU94kLgFWOVPUDHYUAW4A8bfIchTxWrZXQMgDjBPcVzkUs6ngl1H51rWKySFGEbAE+lAHbaSAy5B4zmtqzRmbcOma57RS0aFW4NdRpx54PagDah3bIz+Bqa9OQMDIB4qWyUOU3DPSrM1spiU9smgDOss7mLcgLxio7slQTgjNX4Y/LOVHBqjqswCgYHtQBhap9wMax/PGx9nr1NbGuKHjVEPUZNYBVkjOVIHrigDmPEd8wZowxwByK5e4uCy8cHOa3dWtXluWaRgm49M9qx7yO2tg5Lh5B0U+lAFa2BkmUO+1W4rRudSligWKxhKovViME1l21xvuPMbAOe/Srd8fMRiRuPUYoApTPcSuJJWUn0LVXuEcqgLpn2NSvG2wOV+XHpVSQsz9CfTigCaGCQkkunA45rSt7aUjHynPvVSCGTbuMZA9cVv6ZGxYOyNsHQkEDNAGnZwSRQICmSAM45rWs3YHniobc8e1X4NrfeAb69aANzSLwqBHJ9z+Rr0PwzPx5T/Mh5FeZWsZTDDJHXNd14RnPmCNug6UAduyYJB5yKgDtx2+lW4wJIxnv09qgeMhjmgD5s/bFct/wiIJzj7Z/7Rr5ur6Q/bEGH8J/9vf/ALRr5voA+nf2Kf8Amcv+3P8A9r19NOM18zfsU/8AM5f9uX/tevpxhxmgCuVyRSEZNTgUx8IpPpzQBz/iCULGyKckDk15tq8paRsfnXbeILgIrOx715j4jvCzEKcA9s0AY2rXsNsp8xmZvRBXJal4gIH7iFV/3jnNWtYlzuGQP61xepOytk0ASXetSOCGjT8BWVdXjzZIKj2wKrzP97FZ80m1smgC013KjEDge4qxbX7jhlRvWsqObexUnPHGab5pR8d6AOwstRg8lsxlSPQ5q8bpJQCrcHB6dK4+3nHG7qRzir9vctGhxyPagDttGG8ySEDaMKDXW2QULlQP6GvN9I1VUyHz+ddpo1+s6fKw5zxQB09vAXKuo684HaujsI2VQG7Vz+nTEKpBrrLMhlXgE+9AF+0dlUMOAD+VbMoaVIuAOM8VTt0QkIFHPpW4FUKvy5IoAz0XauOTgVjajG0jjAFdUIx5Zfb+dYd+D5wDDpxQBz19DtIGKxNT2x28me/FdNq+Fb8Oa4DxfqyWuED+5xQBz+tKGXGQjZz15PtXH6jLHA58xi7HggGp9a1SS4O5CVXpXLXkxExBbOT1oAvHUmVgsSKuD1PJqeS/uJF+aYj6GsHz1VwGOSKZPcyO5GcL6CgC/d3bhdu8kVRSVncLn8qiaczFiRgbcYpY2CJkfe9aANW2wo+ZsnPr0FbmnXkyH93I6KvvXMwMcDsK2LScCMKBx1oA7ez1WXgPhhjvXRaZdRXAGPkPbPQ/jXnlpKWYAZArpdMcge+cAigD0KyBXArqdHQoVkTtgkDtXFaHdK0SJJ9A3cV3ukxtHs44OMGgDt9Nk82BWBzxmpplzg1U0gbQVHQ8j2rQcZU0AfL/AO2OMHwj/wBvn/tCvm2vpb9sof8AIoH3vP8A2hXzTQB9P/sT/wDM5/8Abl/7Xr6cYV8yfsTf8zn/ANuX/tevp09aAG9BVW8bbC3birTH86y9ZfbCQSRxQB594mumndkQEqp4rg9XiaQksQMD612euzctjgZrjrskse9AHGapZh3YtKxJ4GF/+vXJalaxqSoZ/qa7rVo5QWbB2Hk57VxmsR/NkyqQTkYP86AOau4lGAC3HvWbKiMOcg/Wte728/OpA9DWVNsJJMigUAV0hKuCp478ZpWhJUHg4o8xEYBZkNXIXRh2BPpQBSjVl+8G+taFu58oNn86cgJJOMAdau2wWVsk8k0AVon5966HQr+SFMhhx0B5rOFmwbcQpU8jHNaulQjzAhVQDwcjpQB6D4cv/tFuGYjI9P1FdzpF2OCVH4+leZ6DA8JcE7cnIweoruNLdgADQB39k3mSIwI69RW6qkkCuS0xyXiZWPB7V2NsfMZeaAJMAQHI4rndRdftfzY2jsK6e4H7k/TiuL1hiJXK54HJoA5/xPfCPCockCvFfGF873zB3+XNena6GIYsx6GvGPFmW1JvvHnuaAMm5vSAR1FZVw5chgOM1fkjVe2TTCeoA60AZ5QPIM5HSpZ4ckgMBxVtYiJlYjjFVpXDO+BzQAlrEFzkk1I0a56ZJNOVThSOBjPWol+aU5cAA96ALtrGu4AqMd62bOKMsQEBX69axIJgrfKeK1rCXdtwcCgDoLOyRiNzFB6jmuh0+yKLuDbufoayNNk3BVjw2PzNdPYRkABgVJ9etAGlpWRgY2n+Qr0bw5cBykTnpwua4myRTGqt19c810WmB4ZoiCcdiKAPS9JyHwfTFaeOCKydEfzUjfvjmtkigD5f/bOHHg8+97/7Qr5nr6a/bQ6eD/re/wDtCvmWgD6g/Yn/AOZz/wC3L/2vX08elfMH7E//ADOX/bl/7Xr6g7UAMrndfdip2/ia6KQ/KTXE+LrsxxtGn3j1PtQBwviC7jgDAne+a4LWNTn2sYmCqPTitzxFLtGB165rgtTuyXO3g9OTQBl6jqEkhZZHZgfUmubvJcrhecH1rRv5V5LAdKxJnz90HrQBUeZeSRx3rOmKM52nr61buRIrHanX2qkd3AMZoAruhUeopUkZPukipjG5HQ5+lQEMD0xQBt2V0NgEgzkYJFaViyedjOBXOWxJyelakJJAYE7x3oA63MflblKlge3atXTxGPnXiQt6fnXHafdxo7i4VtxHy49a2ReiOSJgfkJ9OlAHpWnxxKkZILEcZzXRWNuMgg9a5vTJkksopAwbdjJxXX2S/u0IPykBs0AdLoFszTorAEdfyrr7GIrIWP0rkfDc2LgkE4rsbViyDaevWgCe5T91n9K5jV7UbNxOT6V1sqlowM5rntbThlB6CgDzPXLY4bkE8ivHvF8HlXrMMc17hrS4yCB3rxr4hLIjiQABc4oA4SZgufm+tU57jA+TlqbdybupFU3f5flAPHNAGnHO81qCGw68EVnlzGrs5O/tRZykI2Ohqpdyb2PPSgCeO6dgQTnikExLbf1qvBkRuQKlijYkMuCaAL9vKWwv51q2r7E/wrKtVB3FnVSBnp1rRtslgV5oA6PTLhwuYzsHAz3rttEvyFHm5cn+8eRXA2PDA5AA7V0ulsCBuPTvmgD0awdZUUxnPqvcV1mk4JUMOCK820+6KMrxtgdq9B8N3QuWUPgSfoaAPRfDalI3QnI6g+tb/wDDWNoQKxgN1Ira/hxQB8v/ALaP3PB31vf/AG3r5kr6c/bSGF8Hf717/K3r5joA+n/2Jzj/AITL/ty/9r19QE4Wvl/9ifr4y/7cv/a9fT7dKAK15IUgY+1ec+IS7uxPQ+vSvQNScLC3QnHevONel3eYc5waAOD1uNSW8wlvT0rhtTiiQsViXOOp5rutWbKEHnBrj9W4RmKogx1Y4/KgDkbqchsYArHuHbcSCR71oapPEpID7j1yO9YU16pPf8KACeUyfeP41TkQcNnIpZLpe6/mai+0o3GOPSgBpBBByfp1FOjTcwAPBoMkYUEKetSxbd4+fHoaAD7Nn+uKsWsR3BVPJpRkdevYipY5ArjcOaALiae7so4LEcVtafYsiMrjcR29Kt+HY4rs7CMTIMp7+1aVrE0ep8gqzds+1AGnoKskSJnIB65+ldxZsXijGeOwBrG060WSIqBh+vHetuyiPy46j9aAOn8Pkx5J4ycV2OmbjHlifvVyGlRNwo52n6c12mkxlYfmHOefyoA0GyEGK53Wgx3AZA65710b42Dvisq8GSeAaAPM9bXDHk/jXknxIX/RQTwc8V7hrsK7iRGuMnFeTfEgY08IqrlnAzjoKAPF7lHLfdyKrXNqWVSvymt6WLB+eoZtoVRj8aAKFlY/uyWOTjNUxbIJGBBP1rcf5YgUGDiq8UTSZYr8woAqpFEtntKZLGrSxW8dsEVP3jdT6CknQptGAW7VNECpXzSOetABbQx54TnpWrapCvBj5B6g1SUKHJ5Pp2rS08KTlsYHrQBrW1vbvGWO9PTGDWhBbZA8qVSfQgis0XDSKQQAvQADitbToZOCQABzycUAa1hDNEimXO3PXtXb+HWbchBIx0rm7DHlouc+2K67RYR95eGxwvrQB6v4fn862iOcsOCc10B6VxXhCci5MTcbvX2rtf4eKAPmD9tT7ng363v/ALb18w19Pftqf6vwb/vXv/tvXzDQB9PfsUdfGX/bl/7Xr6gPSvl/9ijr4y/7cv8A2vX0+xoAx9YZiSo7jFec+Ipo4VO87mPOBXY+KNQa3BRCA/rivK9buGaZgxJzzk0Ac5r+qNGjbBt57D+tec6xO0jFgWOemTXX6+crz90HkVwepscnByvSgDFuXJY5rKupFBJ5q9eMRnHIqlIpkjwsYPPLAc0AVTIrKME5qSMqG560ySB16DP4VFiQHpxQBpow2kdfbFPjUSJgYGPWoLdAbdg/DetSQsF6qPrigC35TKVIGR9aDnjjnNSoWZAQeBxVxEiaEEghs+lAHQ+GpEiAY7lcdGxmuutJN7o8io21jkjoa4fS8wHKnhu1d1FH5kcUkH35MFwO59KAOw0eOBgDGuwk9K3IoAjfKeD29KwtEiZHUEHA/lXVQmNY8bck8fSgDS0ODzFB3c5PFdnapiPFc5oEQSJcAc+1dTaoBH0oAJF+Uis26UbTgnj1rWmA25/OsO4m+ZskAZ70Acp4gG1T7V458QFaSzeTnCndj26f1r1rxROSpAOM8dBXmPiS3F1FJEwJ3LjBPegDyGWVZJMScDtiptSszFY28sQ3Fs5LdqZf2DQSMGVtwOK1rGA3Om7HJyp457UAcjdTTSYUMePTilj81TjPzEVvf2ase5z1BzyKypg7TEKAv4UAY1y7ic5Y5HFHmvuDbj9DU17H8546Hmo0TA3MPpQBZgnkwMMR9a1Le6kC4V/zrFUs/YhR2q1ESM89u1AHR2GpmJlEoWQ+hHH6V0umatDMxedGRyMblOR+VcHajLYUVs2PLDngdaAPUtLImjV4WDA9x2+tdhoz7eM9PWvMtBlkgCZJDnuOuK9B0C6807ZB83Y/40Aek+GcNco/8SjOa7ccr1xXCeGcrlsY4AruYjmJT7UAfMf7an+r8Gf719/7b18w19P/ALav+r8Gf719/wC29fMFAH09+xScf8Jl/wBuX/tevpqZwkbN6V8xfsWnH/CY/wDbn/7Xr6O1uXytPYjuQKAOG8W3QNy/Nee6u5aNnGNy9a63Xy0shbOFxya5S6KoWB78E0AcVq0c04bA2J/eY4Fcpf28SM28mRuvy8V1+tyNHuxk44I9R61yV8S6lkA+lAGDc7VyUQbfpmqfOcDoewq7dLjpx6iqLOOeRmgCvcQmNVbI2sSAMjPHt1HWolCrgjB9asuUkPzEhj3qu2yMnI4oAs2m2WTYwAB6Gri2uJBGwHvWbbSqj7sZFb0Vwk6oqowfpkc5oAsNbLDEnC4IzjFXI9PiaFJIiCp5IPameSTGqvkyDg544rb0y3LNGmwqmScn8MUAVbOzXzduHUEYJGCQfpXdeGrJ4I1R23EjPrWNa2LW86yIvmvnhB612vh+F5DHJIvfpjFAGvpsO1ST1PFa0CkMMc1BAUed1wAOmR61rWduolTc2ecf/WoA6LTYcRpxjjnNdDAMJxWZYxgAEkCtaMYQUARzj5Tj0rmNW+Tp0rq5VyprntXHDZA/GgDhPEGJSu0nOOR71yN/atN0U5Brsb5A8jAjmsea3w2cHFAHnev6SXYN5QYDrxVaz04Iihl2r6Y6V3Oo2w8rPOcVmxwqRyvAoA5mfT4nDhombnuelZ40JZUDpAokzt6dR7V1OrTQ2cC4ULk96wbvxO1vIgSCN0x93PzCgDg/EWlva3ZBU88jiseWIR7Wbk+ldbrzPqF0l3K3lpjCpmsd1jzsyCOuaAMV9zjIGKljjZcZ4zWg0O1QxUHNWIYS6KNnDdMUAVYwyoF2nce9bGmxlFXPXPTvTFsTj5QGPpnkVetVEcuNrIDx8xyaAOq0gM8a7Onc+tdfouQ/PU1x2kuSqp0TGQK7XQV3sGwc5FAHqXhOTdaqjfeH613Fv/x7oD1xXnWgymKRMHjgEe1eiW5/cr9KAPmf9tX/AFfgz633/tvXzBX0/wDtq/6rwX9b7/2hXzBQB9MfsYnH/CYf9uf/ALXr6I8RnOmDcMjeOB9DXzr+xmefF4HU/Y//AGvX0L4nYLpeBjhv8aAPO9al3ITgArXGajJyW4wO+cV02qTKodpM4PQdzXmniLU2EjxdFB444oApeJNQjEPybXlU8kdMf1ribvU5CSAqKD1IFXtQugxIJzk+lYFxhWOPuHke1ADZrnfu3ksaqMyk8g4zRJ944PNMEgbAxyKAJsR46M3GevSkiCH7wB9jTTtDAjOPT0qYOAcNj64oAdHDCWOBtI7V0Phm2S5uREcAg53Zx0rBjAJyp4rc0Ntt2mGMLkjDjtQB0N5pN1c3AlgVpYieCO341sG2ubaGGAMpLZy23BXpiruhym0gKFl8xzyegb3/ACrdjkil8sGIlsHp0oAh0a3ZUSSWLdIp6g9RXXWckaxeY/XGACKyIo94DqCMcD2q4WYqFxwox9aANrT44WV3Xseme9dJpFuJXyDwOa5rQEZzIvZjxXb6XB5EeByT1oA1baPCgdhV9BhecVTg7VeXpQA1hxWJq0RZSQOQK3H6Vj6qD5L4HNAHC3kJD5yo9e9U5rcScxgED3q5fo28k8c/lVPlRnoR6UAYurReXbyEhiRzgCsZoz9nW42EDr17V0N+3nLIGHauda7IheFlwv3T9KAOL169E9wUKnYOOtcw08MN35uASOOef0rutT0cTPuVtuR0/rXCarpjw3kiujADv2+tAFLUr37VMQwQIOAFGMVVZF3fK/B71HNbmMFySefSltVjIIkPPYUAWoUy6jcMH1HStRFjjXAxnpWGgkR+AQBV6CVxhnXg80Aa9sE42nDH1HWtOAwshWVA6r3Hf86xbZg5GDtwe9a1mJBKDggDsO9AG9YQEKrRDavXb1BFdhoKlRkrhuK53TV8wrnGT29K6+wUBMD8DQB1GkMTLHgDrXpFqf8AR057V5popO9cnDA16PYNm1X24oA+b/21P9T4K+t9/wC0K+YK+nv20/8AUeCvrffzgr5hoA+lf2M/9Z4t/wC3M/8Ao+vfvFsgTS2Zvujmvn/9jc7T4vb2tP8A2tXtnj+bGkImQN74PvwaAPKtZvS8pYnA7CuB8UHlZcZB4ODx7V0GsXBR3DHBU81yt/cCZXR+h64NAHK3j5qg7bwQRwe1WL8GGZl5z/OoEhLj5vkz0JoAoMrIxVulN2At8vGe5rQNuOj5bmmLEsbfdHNAFVgydetWUTMQYAtVhVHQAYx09KmtWKH5cfQ0AU4lbPIP5VtWNzJaMHQZLDAyKWCbcSJIk/KtwW0MttG0SgMmBtJ6UAX9AvvOTLRkzRDHHO5a67SpCyx7VbaynJ9K5HQw/wBs3Rx7QvDHnB9q7zS12WzZUBuvFAF22Zoyy7j0PBqykjEgdefSskTfMUGCa0tJYGTbMCQe1AHX6CpSPd69K66x3HGRXO6FH8qKI9y54PpXYWsWxR8g6deaALcCYA45q2owKhhzjpzVhRx0oAY33eayNVwqHPFbLYxWXqQDDBGaAOT1KANGW2nI5rDkjYvyBgdK7CaLA6ZBqhLZIw3BfrigDj5oMo/rXJ38BhnJ6bq9FvY44AQFxu6c9K5bWoUMkWRwc5oA5vaXfc4+Uc81g+I7iBGBOCuMbQAc1111FEITHjgjpmuL8R2trC6iaSQBuQ3U0AcXq0xdYwI/lrJdcD5c812n9mW9zAnkzqxbIVW4JNYmq6Fc2w8xEOB94DmgDIWZ8DBHFWTO2xdx5HaoAj8B48fhUpjG8FkOB70ASQysx4YjHauh027kTGOme/P6VhRIFICpyfStqwt2Ygt0zjNAHe6DtkgSTAye2feuqsDkCuK0xwkUeQVx0Fddo0pZAGAD9QPWgDstGXdIrY4Xk13umMDakjnmuH0E4jDYzniux0o7bVx6GgD55/bQ/wCPbwR/2/fzgr5ir6b/AGzTmy8Dkd/t384K+ZKAPo/9j5tq+Lvf7H/7Wr2D4jyYsLIA8Esa8Y/ZHfZ/wlXPe0/9rV678SXJis1HoTQB4t4ok8u7DEfI47VzptmaQhmKAj+Ic12WuxoImYDdInPPb1rjZLzbM4lOCvTNAFHVII1iDLgNnGT1xWMUBYjdmt+fZcxHGOeCaxpIY4HIdskUAMRNoBOcGntBGRlm+XPpUMt0A2E4WolcMQQx6/hQBYWNFfO8kdj6VJLEu4zRZKk8nHeoY0BJYkr+FPhfyyQrHb3B6UAXbYCWb5Y2AxzxXZaJpoKKbhiUJBBx0xXK2FysikIrGUA4zV+xvrmWdFjLKeBwcc0Ad+DaW8RGxQo6EDBqZb1fJKQZyRistbN38stGWlIxvBOBRbAW14oZmYk9T2FAGxYRecf3oKkcg+tdBpsKzTqEYYFZAaRyogXKdGI9a29CgCSDDdTQB6V4fs1SzV+p7E8YFb8SEDjoKo6GubFAc+nT2rVVeMGgB6A1KOB70wAYp/agBrZxWbfr0rTI4NZ14cYoAy5Fz9RUQUHj/wDVVmVd2M8kGoWUiQHqKAMbU7cNLlx8o4GOK5bxBBHFbtIpG4HOM9q7PU0yu88n2rhPE0byRNy2CDQBy7yeYrgjkciuN8TssssQlOWxjNa8NzJHeOjNkjK4x0NYGrXSXCyBo9sp43Hkj1oAzI53s5BKRlQcqex5q9JrP2rgxtuzwM1ks+23RJCehBI69aZafPKqKxz2z1NAE9yElAwMEdKry2hfY0ZIY8MpHTn1q7NEYpgcqV4yM9DWxZWjNbrMPmQ8kdM0AYltYTKAJBtU/wAR/pW7piwWzbi28Dgc96nwXk+do8dgV4x9KV7EFQYAAfQ9KALME67suMHGRXQaPM3BJOQePauVhR4nCyD6A966bRSHAPTnJAoA9P0Jw9vGw6nr9a7GzOLQn1Oa4HwvMfM8sk/NzXeQnbYx++fegD55/bJOdP8AAv0vv5wV8zV9MftjnOm+BD/s3384K+Z6APoP9k08+KR6/ZP/AGtXr3xBH7m33dQuMV5F+yUu6fxNnoPspP8A5Gr1n4gsXAXHIwB+VAHlWqSAh8c54Iz1Fed63ItvdMv3mH8q6nxLfmCd4IyST1bP6CuK1WaN48j/AFi/qKAIxeMyErx2+lRb/OIOctWYlwEfk8Hk1ZjnBAKUAPAG8qVwf5VIrIBwMg/zojVp2JT7+OnrTGBRAOnPNAFtmQBSX+f07Co45xnIjGe2aq4dWB/hqzBEX6A5oA2tHYPdKGUY6njoK7XRLG2M73C53rxjjArkNGgZHUyq4TuRXW2KybchlRGOQB1oA1bjWI0LKVBK/KRu/lVA6jGVRijAtkDvj1oXT1ykkhy4OTkVfR4rhFBhDYPBxQBoaDIZHUE5Vvfmu60e1xKpPTPX1rjtOhWOddgHI/Ku/wDCwdmVT0xnOOlAHommReXbqo+oFXsDGD0qpZZESgk8VbQdCev1oAep5IOafTAMDipB0oAQ1QvVHcmr5HFU7tc4oAzHwCMc00Y2Enr0qSVOe9N2DFAGbegNGR3rkNbh3AbV46Gu1uISe+PrWJf2TNn5dxB5xQB49rll5N2ZFAGfWuN1lYoNS3unyyjs2K9e8Q6aWjYFcdxkdK831uwE21x1T5SMdaAOV1VUS5UKp2kZHORiqEKEzZjwu3nNbd7ZFlEqkFV4P+zzRNFb/YYmiDCQffoAmj8qW2MkgVpMZXNatm8piyTtiHXBGBXLeZst8EE5PPNNjuikZRZG2nnBNAHSyrmQoMdcjNS2kyLKwB2gdy1c0t6yFWV8DocVfgvwEJdAeeTQB12YriACQfN2I/xrV0uHyYwc5B/Sud0yYS4CsNvXPt6V1ViylAPWgDo9CmCXcTE4GQDXpS5FgmeDzx+deV2WVkjA6EivUZm/0D6AGgD59/bG/wCQX4C/3L3+cFfNFfS37YX/ACCPAH/XO8/9oV800AfQv7JJAfxT64tef+/1en/ECT5XQN87AY/KvKv2T2xc+I1zgH7Nn/yNXeeMb0T3k7AnG7A9gKAPIPFgZnMiEHvgc4rjZW5bcM11Hia7aKaVF4RmPauSlOXw+dxPAoAzbmMgHbwD0HtT9OX5trcipLiIlW29R0FGmW7PMAzFM8dM0AbOnfI7qnUin3EDSpuAw+fzqxBbRxKdrEtjBOOaknt5PKifO0Hge/vQBlhQEIIyeuK0dPYsAscfzHgVLBaRsPnYeYeKdPJ9kTC7QvTI5NAGlHcLbRlWAkmzjA6CtPTNRaO6h807VbBOa5E3YKfulbdnljWvodtJfXSN8xEZ3e1AHb39/At4EO3A6UWF1bSEKsu7cc5C4xzWPFbQbZJLmQl5G2g4zWrpsAVsFeM7sDrQB1uiQp5wYEt1GSOPSvRvC1qVZScYA7VwOntsiVehPAAr0Twicwqx+9jHPegDsoAFUYHHarC5qGHlBgirC0APHNP7U1QKdQAVVnBJxirXaq89AFGRMdetRlQBnNWXXNRNHg8E4oArPGCeCCaqtGFkYkcVcdSDVS63bsqaAOX8QwAtkr1rzfxBYoshO0BHOefWvVdVfegDDnqK4rXoFlhZeM444oA8vexBneEkqXH4HmsWSGa2nmgkXIHr0FdJqLOD0IkTII6f59azLpftto8yHoduM8/WgDEaBRE4J+Y8gd6y50KkBeRityO1L8SFVAHXPNZt+JLZgoCyoOc4xQBWtULHaTk56VYhmG8xkEc9Krx3TqQ0CqhHXjNTQqqEOTlj6igDp9JvRaxLGo2r/F3JNdlpk6GFXU5U9DXm0NygG/DNkc54xXR6HqI+Tk7M/doA9L0kiRtxPK85969KnbbYgHqIwf0rzTQ8F4kHJfFekakdsB7fJ6e1AHgn7X5zovw+PrDdn/0RXzXX0p+1/wD8gP4d/wDXC6/lb1810Ae7/suv5f8AwlL8ZEcGP/ItdT4guFE7lsYJrjv2a22w+KRnGY7f/wBqVp+KL1UlcE5IJ4oA5LxXaeYhmiYYzyD2rieWuAGbOK6jUpHulIGdhPU1zTx+U5UdfegC0uIjv4YnsR0p1tG0s++PAYe1U4ZyZCpKkgdatQXnksRkcmgCRr4h9p4+gqxDeDy9xy2G6fnVKYiZy+0Aj0qJJWCumOcZFAFx7xixbHPOKId5di43YHQ1kq8m8Ek9a1LUMUb+8aALNnbtO4EYO4npXoPh+0S0sJnVtshTlu9cdprPCQkR/eOfxrstIYR27mRysYGzHGSe5oArmR7u23hOEcBX6Fq1NLDecMEYU4JHpgVHIyG12IBtXIVAOp65qXT/AD4YcHALNmgDqIJiGQLgg9K9I8KTtmNGACmvONJgaZowxJIINek6DGUdeACOuKAO7tz8oqyMelVbQYjWrYFAD1p1NXoadQAGoJhU/aopaAK5IqMjPTtUhGaay8UAVpFyagnjycj9atMOaY65IoA5nUYsqTj7px1rk9ZhO8sBx1ru76PLMccEVyus2/mI20nd1FAHknidBHeMT8ufmU46GuTnnkik81eA5wcdq7vxjAuxJnBwuVOOwNcJeW5t3BEmYX55H60ARRswnLMAW9BTNQiAmQqCVIyMfWppLKRbUOkoDZ6A9vWrKR/aLJVGCwB5z3FAGOttFncn3jwfQ1BdRSImyVMYOR71eUrG2GXJHXNSS7Xj8plJQnIyeRQBiwzbH2sCR6V1Ph9Q7rMuFVOcep9K5+WykguFARmVuhxXUaYgigjijIZRyx7570AeleDn866ijOcg5AzXpur58oY4Gz+leU+DH8q9ikIxtOa9R1VwbAsCcbQfzoA8N/bA/wCQF8Ov+ve5/wDQbevmqvpb9sLjRPh1n/n2uP8A0C2r5poA9p/ZyYBPEoJ6pB/KWpPEIMt8xOfL6fU1T/Z/fZb+JMdStv8A+1KveKXEVy69t35980Ac5cj5uSoA/hHaud1CNjKWHWtq7ul3qWXjOD71j3Ey5ZxyvQCgDIkVkOQMN60kQaQs5JAFRSSvvzyOehro9N0eXUbSP7LE7SMfmAFAGVDOzny4wTk4FdloOhPcRhpkAkYcAjt610HhjwZBp4Wa4UTXRGdvZP8AGusj0sRf6vGe+aAPOJ/CIILpMqkdFK9fbNINDvVDOtsSo/ujOTXqCaa0gA2/KD1xV+LTAFVQPunPSgDx2G0niZjJC6sTtxt5rstI0uWaBFlTBBDEnOcdh/Ou3ewUkBV6+1acFiq25yOcYzQBxsGnJGQWyT2yKcygyhTgEdDXRTae6gs33R0rlLr7StxtAwMkBqAOx8LwAybickeleh6PGNykAEH9K878KyuOpIyMZzXpejM+1T/SgDp7bhB2qytQ264UcdeasLQA5QOpFOpo6cc06gApkg4p9Nf9KAK7YpvHTNLIKZjrzQA00wqD19alHHB7009D+VAGdeQ5UkHFc3qlqQxwTnjBrrZk3DHrWReR7lZf7p4GKAPJvFNrujmRlBGDwelefXNkPKAKkshAOTmvYfFFtG+7YOCv6968+ktRJEQ2A6nDUAcn5byK6EBlQ4AH3gPX3qFgLSWSDfvU/MCBjBrYvrMhyIT5bo2S2OSPSuZ1ZpZyJI8kr1wOhoAiudzMWHyEfewKrW9wYpACwZe4NOhkdkkZhkd2z0qFISqiYn5M9PWgDpbJoRbJO6lyy7cH+Hrzn/PFaVtCqxo8WRHkE/59KwtKnEzFJJFDEfKTwPpXSWZPlJGQPegDqfDMoZgR0FekXE3maJFngmL+X/6q800WMQMoX7rH8vau+SQNo9uPZhQB5X+2IMaN8Ox/07XH/oFtXzRX0z+2PxpPw9Hpb3P/AKBbV8zUAewfALi18Sn0Fv8AzkrS8ZqpKycD1+orL+Ah/wBF8SL3It//AGpVvx4f9GKA/Mpzj1FAHC396C4AX2qqEWYgLmoJj83ct0rrfA3hm51KZZ5l22qnktxu9hQAnh/wVd6lKs867IBjDN3HtXq2k6Zb2FusFtGFUDGe5rQsrNUiWNBhEAUelXorNgcgD2oApQWu18gHPetSzsjK4DDjNWrOzDHLde1bFtp7JjjrzQBW+wDJWMA4qzb2O1SSgyR1rVttPZU3E4x+tSrDtYlh27UAYyWQBY7cYNNe3dmKKMKO9dFDb70JIxz6cmmfZCgbjOemaAMeG2i+zFWG4nqDXP32g+ZIdoGfeu3hsu3UZqd7H7rcE+goA4zSNPazXBXJz1xXe6MvCg8Zx2qtHp4H8PuK0bSAxkGgDoIwAB7VIKhgHyDvUooAdnnFOpgp4oAKawGOadTH+7QBDJUR5OOfrUjUwnAoAQgEUyQDjHNKT0FI/TrQBXlyrZzWbesEJHc1o3XQNnpWbe4kjyOeO3Y0Acb4kBJ+QgjGfxzXn1wzJK6OoMe49a9A1xtiIpBwRzXEapEJd6xnDEZPtQBzuqRXAUNE+4gY5HauZYKbpwQyJKOMcjd713NuA2YnwSOMiscWS2140iIGbJBUjrz1oA5aHT3ivGhlAIOCFzwc+tZ14rwzvEQdmeB6V22owRTTpJtKuFwQB1FctqCFZH3JuHZhQBkLKyNgMeOme1dZoOoGR4Y3GScDd3NcjJKjsMpsAGCPeul0QRmKOVTtZRjHPSgD0rS2DFPSuwhbGloP7u7NcHocobbkjNdrG4/s0enzCgDgv2zgBYeAQOghuh/47b18x19O/to/8efgMf8ATK6/9Bt6+YqAPXPgL/qfEJzjAtz/AOjK0vEcRvbtiMbM4JrM+BJxZeJj/sQfzkrrdP05pruUyY2hsjj1zQBzmheEYbi+UzIxt1w249/avSbW1jgjSKFFSNBgADpVmys1FuAi/d5q5bwFnGBQBNYW5ZSMHjGfatW2tunGfWpLG2CR4xycZrUt7YsevSgCK3tAoBxya1LGDcMkEjtUsNvwODV2KIKvT3oAjb5RtABNCQk53DjFWVj3NuIFWRENi989aAKsMP7s5HWlEOVIP51oRx/LgCjZ2oAppAQMgVLbx5PzDI96tLHk4xUscYUY9aAIxEm3gc0scWO1TBaci4NAEkQ2in01adQAtOHSmU4dKAFpr9KXNI3SgCu+M81Gw4p8mMUzPIoATGCB3pG5+macWyOlMdsYHegCvccqw9qx7h/KV1c8HkVqyyqARnmuY1i42RsQ2MHH0oA53WcyTsT9w8/jmuV1CEl1dCevTHWuh1OdpFxj5cZyPXNZL7rhVMZAIPIoAxWjEbrIBzUGqI3miePHlkYYe9a89v5hAcKjdMZxSS2TNbj5d23g9+KAObePz3AB2sDlWrm/FO62kSWMAZ+VlA6GuuuLc2rq6/MeSB6VjazbtdptCCTk9RQBwaRrNcjfgBj1rpoYGiSOSNkKkY49KzZNOCcD5XP8BzwKvKGiCAgjbQB1WjTBJIgO55ya9Aib/iWSD+6M15j4fLPejPc8j2r0m1fdpkp/2SP0NAHJftqDFv4GHol2P0t6+YK+n/21uIvBA/2bz+VvXzBQB618B/mt/ESd2Fv/ADkr06ytWSXJry/4Df6zWge4hH/oyvbLOISovGGFAFmziKoOPvVqWtltwV6HqaWxtjsG4e1a1tF0GPyoAWKAqApAyK0bePGMjFMhTn6dKuwRknv9aAJ4EJUcVZWIbcYp0ShVHc1Mi8cUAMSLHaplTNSBfangUANVPlpwj55qRRxS0ANCYFKBTqBQA3HPtTgKCAaPpQA/HHb8aWmg575oJoAdSg8UzOKN1ADs0h6Gm7qQmgCGUc96gbIHFWH5FRmgBinmkkVmIK8jNOJwpNMV+PxoApXdtI3zIDuHSud1DTbuQuBCz568V2UbBh05pzxjqOtAHl99oV55axx27liNxJ6VlW+kXccysYZUIHTFeuz22/FUXswGyRwKAPJ9WtnDGXYQepBGKyjdvFKAGZUcdzwRXtFxZpIrB0V19CK5PWvC9tcyHankyDpgcH8KAPNbp1jyWk3J1yeorIlvUS4XyWQwnByOefT6102raJPbb0kBePGM+grl7+zIxsG3kbTjofegDN1y2SaQywDEijge1QSSsRHFLnAHXHT/AOtVuVXmtiWbEycfKetUZopIpQ2GI7/WgDovDtsUd5iMgDANdpZSE6LKO4Jz+tcxpCslkiN3/nW/Yn/QbpSf4R/n9aAMb9tsYXwV9L3/ANoV8u19R/tvDDeDR73v/tCvlygD1P4GNtm1f/tj/wCz17tpfMo9DzXgPwVlCXWpqTjcIsf+P/4175pDZTPfjFAHXWgUxgd/UVfRAFHHH0rIs5TgZPNbFvKrfKaALMC9M8CtCFcY9u9VrcDtg1cj+ooAsIvFToMCoYyNoFTKcdaAJVFPGKYDxTt1ADweKXimZpwNADs0U3OKM8UAONNLU0tnOK8n+OHxPu/h2NL+yWVtdm7EhdZSw2hSuMYPuaAPWd4pDJXygP2n9U7+HrI/SZxTh+09qH8Xhy1/C5Yf0oA+q/MBPX6UhkHrXyyn7T9yB83hmE/S7P8A8TUq/tPtj5vDAz7Xn/2FAH1CJARnOaPMr5jX9p+P+LwzJ+F4P/iKlX9p20/i8N3I+l2v/wATQB9JM/NIGBPWvnFP2mdMP+s8P3y/7s6H+lWIv2l9Dx8+iamp9nQ/1oA+hHORUG4gkA4Ga8JX9pTw233tK1ZfwjP/ALNUiftH+FWxvsNXX/tmh/8AZqAPd4wd2c1cRsiuH+HfjbT/ABxpE2o6TFcpbxTGEidQpLYB4AJ45FdpCeKAJsZFQvECSKmzSGgCi0OCapXsGSGx1FbLgEc1BLGGGOKAOVvLGOUFGXg+3euF8RaJGjPtHB68d69UuIPQd+lc7rFjvDcZz39KAPDtRtPslwcoeCCcGgQLPMuB8vfiu21nS8nlcgfyrANv9mm2lcc9aAJI4/LCqOAoFatgP9DmP97gVWmj+RSO+KvQIVs4wMZdv60AYX7cH+s8HfW9/wDaFfLdfUv7cP8ArPB31vv/AGhXy1QB33woKpc37yXNjAq+Xzc3sNvn733fMZd3vjOOM9RXuWl65pUESiXXNDVu/wDxNbY/+1K+T6KAPsqHxToCYJ8QaEP+4nb/APxdaFt4x8Nrjf4k0IeudSg/+Lr4looA+7rfx14WX73ibQh/3EYf/iqtp488JA8+KdB/8GMP/wAVXwNRQB+gCeP/AAgBz4q0DP8A2EYf/iqkX4g+D8H/AIqvQP8AwYw//FV+fdFAH6ED4g+Dsf8AI2aB/wCDGH/4qnD4heDv+hs0D/wYw/8AxVfnrRQB+hf/AAsPwd/0Nnh//wAGUP8A8VSj4h+Df+hs8P8A/gxh/wDiq/POigD9Df8AhYfg3/obfD//AIMof/iqQ/ELwdn/AJGzw/8A+DKH/wCKr886KAP0L/4WF4Owf+Ks8P8A/gxh/wDiq+bP2q/Eel69q2hLo2p2WoRwwSb2tLhJQpLdCVJweK8HooAKKKKACiiigAooooAKKKKACiiigD6k/Zl8S6BovgG4g1fXNLsLh76R/KubuOJyu1ADhiDjg17LF8QPBwHPi3w//wCDKH/4qvz2ooA/Q7/hYPg3/obfD/8A4Mof/iqX/hYXg3/obfD3/gyh/wDiq/PCigD9Dj8QfBuP+Rt8Pf8Agyh/+KprfEDwb28W+Hv/AAZQ/wDxVfnnRQB+gk3j/wAHtnHirw/z2Gow/wDxVZl5428IuvHinQSf+whD/wDFV8HUUAfZmpeKvCztlPEeit7C+i/+Krn9R1/w053Jr2kHvxeRn/2avlOigD6lg8TaAYyH1zSh9buP/GrLeJ/DqtbINe0rAZdxF5Hx83PevlGigD6R/bF8RaJr7+E/7C1jTdT8k3nm/Y7pJvL3eTt3bScZwcZ9DXzdRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a 26-year-old man with primary ciliary dyskinesia demonstrates extensive bilateral bronchiectasis. The patient underwent underwent a lobectomy of his left lower lobe at 10 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sten-Erik Bergstr&ouml;m, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_19_43327=[""].join("\n");
var outline_f42_19_43327=null;
